



Germline and Somatic Neurofibromatosis Type 
1 Aberrations in Breast Cancer  
 





MBBS (University of Adelaide), FRACP (Medical Oncology) 
School of Medicine, Faculty of Health Sciences, University of Adelaide 
National Cancer Centre Singapore (NCCS) 




Table of Contents 
 
Table of Contents          2 
Thesis Declaration          5 
Abstract           6 
Acknowledgements          9 
List of Publications Contributed to During Candidature     10 
Abbreviations          12 
 
Chapter 1: The NF1 gene revisited – from bench to bedside   14 
1.1 Abstract          14 
1.2 Introduction          15 
1.3 NF1 syndrome         15 
1.4 Biology of NF1 and neurofibromin       17 
1.5 Roles of NF1 and neurofibromin in tumour suppression    18 
1.6 Tumours associated with NF1       23 
1.7 Somatic NF1 Aberrations in Sporadic Tumours and Effects of NF1  
Deficiency          27 
1.8 Challenges of molecular diagnosis of NF1 and detection of NF1  
somatic aberrations         35 
1.9 Downregulation of NF1 and neurofibromin via other mechanisms  36 
1.10 Therapeutic Strategies for NF1 and NF1-associated/deficient    37 
malignancies 
1.11 Conclusions          43 
1.12 References          44 
 
Chapter 2: Whole exome sequencing of multiple tumours from an NF1  
Patient           57 
2.1  Abstract          57 
2.2 Introduction          58 
2.3 Materials and Methods        58 
2.4 Results          60 
2.5 Discussion          71 
3 
 
2.6 References          74 
2.7 Supplementary data         76 
 
Chapter 3: Breast cancer in women with neurofibromatosis type 1 (NF1) – a 
comprehensive case series with molecular insights into its aggressive 
phenotype            77 
3.1  Abstract          77 
3.2 Introduction          78 
3.3 Methods          79 
3.4 Results          83 
  Clinicopathological characteristics of breast cancer in NF1 patients 
  Targeted sequencing of NF1-associated breast cancers (BCs) 
  Immunohistochemical staining of neurofibromin in NF1-associated BCs 
3.5 Discussion          98 
3.6 Conclusions                  101 
3.7 References                  102 
3.8 Supplementary data                 106 
 
Chapter 4: Immunohistochemical expression of neurofibromin in sporadic 
breast cancers                  109 
4.1  Abstract                  109 
4.2 Introduction                  110 
4.3 Methods                  111 
4.4 Results                  113 
4.5 Discussion                  136 
4.6 Conclusions                  138 
4.7 References                     139 
 
Chapter 5: Elucidating Therapeutic Molecular Targets in Premenopausal Asian 
Women with Recurrent Breast Cancers              141 
5.1  Abstract                  141 
5.2 Introduction                  142 
5.3 Methods                  143 
5.4 Results                  146 
4 
 
5.5 Discussion                157 
5.6 Conclusions                160 
5.7 References                161 
5.8  Supplementary data               164 
 
Chapter 6: Conclusion and future directions 
6.1 Summary of findings              185 
6.2 Suggestions for future work             189 
6.3 Concluding remarks               190 








I certify that this work is original, contains no material which has been accepted for the 
award of any other degree or diploma in my name in any university or other tertiary 
institution and, to the best of my knowledge and belief, contains no material previously 
published or written by another person, except where the reference has been made in 
the text. In addition, I certify that no part of this work will, in the future, be used in a 
submission in my name for any other degree or diploma in any university or tertiary 
institution without the prior approval of the University of Adelaide and where applicable, 
my partner institution responsible for the joint award of this degree.  
 
I give consent for the thesis to be made avilable for loan and photocopying after it has 
been examined and placed in the library, subject to the provisions of the Copyright Act 
1968. I also give consent for the digital version of the thesis to be made available on 
the web, via the University’s digital research repository, the library catalogue and also 





Dr. Yoon-Sim YAP 






Germline and Somatic Neurofibromatosis Type 1 Aberrations in Breast Cancer  
 
Overview 
These studies were initiated after seeing a series of women with Neurofibromatosis 
Type 1 (NF1) and breast cancer (BC) at National Cancer Centre Singapore (NCCS) 
from 2006 to 2009. Neurofibromatosis type 1 (NF1) is a relatively common tumour 
predisposition syndrome related to germline aberrations of NF1, a tumour suppressor 
gene. NF1 is usually a clinical diagnosis as individuals with NF1 typically develop 
multiple neurofibromas which can be cosmetically disfiguring, in addition to other 
features such as café-au-lait spots, skin tags and Lisch nodules. 
 
These patients under my care had aggressive HER2-positive breast cancers that did 
not seem to respond to standard systemic therapies as well as in individuals without 
NF1 syndrome. Individuals with NF1, an autosomal dominant genetic disorder, are 
known to be at increased risk of developing various tumours, such as malignant 
peripheral nerve sheath tumour (MPNST), phaeochromocytoma, glioma, and 
rhabdomyosarcoma. In 2007, the first study which reported an increased risk of breast 
cancer in women with NF1 was published. Since then, there have been a number of 
other epidemiological studies with the consistent finding that women with NF1 are 
have a three- to eight-fold increased risk of breast cancer, especially for women aged 
less than 50 years. Data on the characteristics of BC in NF1 patients is currently still 
limited. Our group was the first to discover the higher frequency of HER2-positive, 
hormone receptor negative and grade 3 breast cancers in women with NF1 compared 
to breast cancers in women without NF1. We have also performed genomic profiling 
of these NF1-associated breast cancers. 
 
Over the course of my candidature, large-scale exome or genome sequencing studies 
led by various groups such as The Cancer Genome Atlas (TCGA), International 
Cancer Genome Consortium (ICGC) and METABRIC, have revealed somatic NF1 
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aberrations in different sporadic tumours from individuals in the absence of a clinical 
diagnosis of NF1. These somatic NF1 alterations appear to be associated with 
resistance to standard therapy and adverse outcomes, similar to the breast cancers in 
women with clinical NF1 syndrome. Improved understanding of the implications of NF1 
aberrations is critical for the development of novel therapeutic strategies.  
 
In Asia, women with breast cancer are on average younger than in Western 
populations, resulting in higer rates of poor prognosis breast cancers in 
premenopausal women. Since somatic NF1 mutations in BC are associated with poor 
prognosis, we also aimed to explore the potential role of NF1 and neurofibromin in the 
sporadic BCs from patients without NF1. This included immunohistochemical staining 
of tissue micrroarrays, and targeted gene sequencing (with NF1 in the gene panel).  
 
Structure of Thesis and Research Questions 
Chapter 1: Systematic Review 
This literature review focused on the germline NF1 disorder, the biology of the NF1 
gene and neurofibromin, tumours associated with NF1 as well as sporadic tumours 
harbouring somatic NF1 aberrations in individuals without NF1 disorder. This review 
identified an important role of NF1 in carcinogenesis as well as the challenges of 
detecting NF1 aberrations and deficiency or dysfunction of the encoded protein 
neurofibromin. It also highlights the need to pursue further research, especially in the 
area of therapeutic strategies for individuals with germline NF1 syndrome and for 
sporadic tumours with somatic NF1 aberrations. 
Chapter 2: Whole exome sequencing of multiple tumours from an NF1 patient 
This paper describes the exome sequencing of BC, MPNST, and neurofibroma from 
a patient with NF1. Apart from the germline NF1 mutation, we demonstrated 
independent somatic NF1 mutations in all three tumors. Each tumor had a distinct 
genomic profile with mutually exclusive aberrations in different genes. Although 
second-hit NF1 mutation may be critical in tumorigenesis, different additional 




Chapter 3: Comprehensive case series of BCs in women with NF1 with 
molecular insights into its aggressive phenotype  
The aim was to elucidate the clinical, pathological and molecular characteristics of 
NF1-associated BCs at National Cancer Centre Singapore. There was a higher 
frequency of grade 3, oestrogen receptor (ER) negative and human epidermal growth 
factor receptor 2 (HER2) positive tumours among NF1 patients with inferior overall 
survival compared to non-NF1 BCs. Immunohistochemical expression of 
neurofibromin was seen in the nuclei and/or cytoplasm of all NF1-associated BC 
specimens, but without any discernable consistent pattern in the intensity or extent of 
staining. It appears that their aggressive features are related to germline NF1 
mutations in cooperation with somatic mutations in TP53, KMT2C and other genes. 
 
Chapter 4: Immunohistochemical expression of neurofibromin in sporadic breast 
cancers 
From the initial discovery cohort of 314 sporadic breast cancers of all subtypes, 
tumours with both nuclear and cytoplasmic expression of neurofibromin seemed to 
have better outcomes, especially in the triple negative subset. However, there was no 
correlation between expression of neurofibromin and survival outcomes in a larger 
validation cohort of triple negative breast cancers.  
 
Chapter 5: Elucidating therapeutic molecular targets in premenopausal Asian 
women with recurrent breast cancers 
Targeted sequencing was performed on a separate cohort of premenopausal poor 
prognosis BCs. The most prevalent alterations included TP53 (65%). PIK3CA (32%), 
GATA3 (29%), ERBB2 (27%), MYC (25%) and KMT2C (21%). The frequency of NF1 
mutations was 2%. Detecting changes in dosage of the NF1 gene in formalin-fixed 
paraffin-embedded specimens was not feasible.  
 
Chapter 6: Conclusion and future directions 
The final chapter summarises the findings of these studies and highlights future 
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The NF1 gene revisited – from bench to bedside 
Literature review on NF1 and cancer 
This chapter is an updated version of our paper, “The NF1 gene revisited - from bench 
to bedside” published in Oncotarget. 2014, with the addition of recent findings. 
 
1.1 Abstract 
Neurofibromatosis type 1 (NF1) is a relatively common tumour predisposition 
syndrome related to germline aberrations of NF1, a tumour suppressor gene. The 
gene product neurofibromin is a negative regulator of the Ras cellular proliferation 
pathway, and also exerts tumour suppression via other mechanisms.  
Recent next-generation sequencing projects have revealed somatic NF1 aberrations 
in various sporadic tumours. NF1 plays a critical role in a wide range of tumours. NF1 
alterations appear to be associated with resistance to therapy and adverse outcomes 
in several tumour types.  
Identification of a patient's germline or somatic NF1 aberrations can be challenging, 
as NF1 is one of the largest human genes, with a myriad of possible mutations. 
Epigenetic factors may also contribute to inadequate levels of neurofibromin in cancer 
cells. 
Clinical trials of NF1-based therapeutic approaches are currently limited.  Preclinical 
studies on neurofibromin-deficient malignancies have mainly been on malignant 
peripheral nerve sheath tumour cell lines or xenografts derived from NF1 patients. 
However, the emerging recognition of the role of NF1 in sporadic cancers may lead to 
the development of NF1-based treatments for other tumour types. Improved 
understanding of the implications of NF1 aberrations is critical for the development of 





Neurofibromatosis type 1, also known as NF1 or von Recklinghausen’s disease, is a 
tumour predisposition syndrome characterized by the development of multiple 
neurofibromas, café-au-lait spots and Lisch nodules. Initially described by Professor 
Von Recklinghausen, a German pathologist back in 1882, NF1 is one of the most 
common genetic disorders worldwide 1,2. The NF1 gene is a classic tumour suppressor 
gene on chromosome 17. Its product neurofibromin is an important negative regulator 
of Ras cellular proliferation pathways 3-7.  Individuals with NF1 are at increased risk of 
developing various tumours, including malignant peripheral nerve sheath tumour 
(MPNST), phaeochromocytoma, leukaemia, glioma, rhabdomyosarcoma and breast 
cancer 8,9. Neurofibromatosis type 1 or NF1 is distinct from neurofibromatosis type 2 
(NF2), which is less common. NF2 syndrome is related to mutations in NF2 on 
chromosome 22, with a different spectrum of tumours, notably schwannomas, 
meningiomas and ependymomas 10. 
 
More recently, somatic NF1 aberrations have been increasingly reported in various 
sporadic tumours, including brain, lung, breast, ovarian tumours and melanomas. 
Significant challenges remain in the detection of both germline and somatic 
aberrations. A better understanding of the implications of these aberrations is critical 
for the improvement of treatment outcomes of tumours with NF1 aberrations.  
 
 
1.3 NF1 syndrome 
 
NF1 is a relatively common genetic condition, with an incidence of approximately 1 in 
2,000 to 1 in 5,000 individuals worldwide 2. Although it is an autosomal dominant 
genetic disorder, approximately half of the cases have no family history, with the 
condition arising from sporadic mutations of the NF1 gene. The germline NF1 mutation 
rate is ten-fold higher than that observed in other inherited disease genes, with 
estimates from 1/7,800 to 1/23,000 gametes 2,11. 
 
The condition has 100% penetrance but its degree of expression varies considerably, 
even within the same family with the identical mutation 12.  NF1 is diagnosed clinically 
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for most patients, with genetic testing reserved for equivocal cases or in the context of 
research studies. The National Institutes of Health (NIH) diagnostic criteria stipulate 
that at least 2 of the criteria in Table 1.1 must be fulfilled to make the clinical diagnosis 
of NF1 13. 
 
Loss-of-function mutations in the NF1 gene can also lead to the development of a wide 
range of abnormalities in the cardiovascular, musculoskeletal and nervous systems, 
in addition to the predisposition to benign and malignant tumours. Hypertension, 
vasculopathy, valvular dysfunction, skeletal anomalies, dysmorphic features, 
osteoprorosis, cognitive impairment and epilepsy may occur as part of the NF1 
syndrome 14. 
 
Table 1.1: National Institutes of Health (NIH) diagnostic criteria for neurofibromatosis 
type 1 (NF1) 
 Six or more café-au-lait macules >5mm in greatest diameter in prepubertal 
individuals, and >15mm in postpubertal individuals 
 Two or more neurofibromas of any type or one plexiform neurofibroma 
 Freckling in the axillary or inguinal regions 
 Optic glioma 
 Two or more iris hamartoma (Lisch nodules) 
 Distinctive bony lesion such as sphenoid dysplasia, or thinning of the long bone 
cortex with or without pseudoarthrosis 
 A first-degree relative (parent, sibling or offspring) with NF1 based on the above 
criteria 
 
The NF1 phenotype is highly variable, ranging from a very mild manifestation of the 
disease in certain individuals, to a very severe form in some others 12. In general, there 
is no definite correlation between a particular alteration and phenotype. Exceptions 
include deletion of the entire NF1 gene which is associated with a severe form of the 
disease 15,16, a recurrently ascertained 3-bp in-frame deletion of exon 17 (c.2970-2972 
delAAT) that is associated with the typical pigmentary NF1 features but without 
cutaneous or surface plexiform neurofibromas 17, and duplication of the NF1 locus 
which usually leads to intellectual impairment and epilepsy without the other NF1 
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features 18,19. More recently, NF1 missense mutations affecting arginine at position 
1809 were reported to be associated with learning disabilities, pulmonic stenosis, and 
Noonan-like features, but no external plexiform neurofibromas or symptomatic optic 
pathway gliomas (OPGs) 20,21. In addition, missense mutations affecting one of five 
neighboring NF1 codons—Leu844, Cys845, Ala846, Leu847, and Gly848 located in 
the cysteine-serine-rich domain (CSRD). These individuals have a high prevalence of 
plexiform and symptomatic spinal neurofibromas, symptomatic optic pathway gliomas 
(OPGs), other malignant neoplasms, and bone abnormalities. These findings 
demonstrate that missense mutations outside the GAP-related domain (GRD) can be 
associated with a severe phenotype 22. There may also be intra- and interfamilial 
variation in the severity of the phenotype, suggesting that expression of the same 
genotype may be influenced by epigenetic or environmental factors 12,23. Females with 
NF1 often experience an exacerbation of the condition following pregnancy, possibly 
related to changes in the hormonal milieu 24. 
 
This overview will focus on mainly the oncological aspects of NF1 aberrations, given 
the recent discovery of somatic NF1 aberrations in various cancers in individuals 
without germline NF1. 
 
 
1.4 Biology of NF1 and neurofibromin 
 
Identified and cloned in 1990, the NF1 gene is located at chromosome 17q11.2 4,25, 
and is one of the largest genes in the human genome, with 60 exons spanning over 
350kb of genomic DNA 4,26. Another distinctive feature of the gene is the presence of 
3 genes in intron 27b on the antisense strand: OMGP (oligodendrocyte-myelin 
glycoprotein), a membrane glycoprotein, and EVI2A and EVI2B (ecotropic viral 
integration sites), which are involved in the development of mouse leukemia 27,28. 
 
NF1 encodes the protein neurofibromin, which has an estimated molecular mass of 
327kDa and consists of 2818 amino acids. Neurofibromin is ubiquitously expressed, 
but most highly in the central nervous system, especially in neurons, astrocytes, 
oligodendrocytes and Schwann cells 29. As might be expected for such a large gene, 
alternate exons, splice variants and alternate start sites have been reported.  The 
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major reported functional isoforms are derived from the insertion of extra exons that 
preserve the open reading frame and show tissue restricted expression. 
 
The two major isoforms are neurofibromin types I and II. Neurofibromin type I is 
expressed predominantly in the brain, and has significant Ras regulatory activity. 
Neurofibromin type II, also known as GRD2 (domain II-related GAP), is the product of 
the insertion of exon 23a. In contrast to neurofibromin type 1, it has limited GTPase-
activating protein (GAP) regulatory function 30,31. It is expressed mainly in Schwann 
cells, and is essential for learning and memory in mouse models. In studies on 
sporadic colon, ovarian and breast cancers as well as gastric cancer cell lines, 
expression of the type I isoform relative to type II isoform is increased in tumour 
samples compared to normal tissue 32-35. 
 
Information on other neurofibromin isoforms is limited. Neurofibromin types III and IV, 
which contain exon 48a and both exons 23a and 48a respectively, are expressed in 
mainly cardiac and skeletal muscles. They appear to be essential for normal muscle 
and cardiac development 36,37. Apart from neurofibromin types I-IV, two other isoforms 
have been described. An isoform which contains exon 9a is expressed mainly in 
neurons of the forebrain, and may be involved in memory and learning mechanisms 
38,39.  Another isoform has alternative exon 10a-2 inserted, introducing a 
transmembrane domain. The function of this variant, which is observed in a majority 




1.5 Roles of NF1 and neurofibromin in tumour suppression 
 
NF1 is considered a classical tumour suppressor gene, with both copies of the NF1 
gene reported to be inactivated in benign and malignant tumours in NF1 patients 41-43. 
The first hit is inherited or acquired as a germline mutation, and the second hit occurs 
from a somatic event. Loss of heterozygosity (LOH) due to large somatic 
rearrangements, deletions and somatic recombination may affect the wild-type NF1 
allele. This can also potentially affect other genes on chromosome 17, which include 
the tumour suppressor protein p53 at 17p13.2, human epidermal growth factor 
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receptor 2 (HER2) at 17q21.1, topoisomerase II alpha (TOP2A)(17q21.1), signal 
transducer and activator of transcription 3 (STAT3)(17q21.2) and breast cancer gene 
1 (BRCA1 )(17q21.2) 44. 
 
Various Nf1+/- mouse models show predisposition to tumour formation, including 
phaeochromocytomas, leukaemias and malignant peripheral nerve sheath tumours 
(MPNST), similar to the spectrum of NF1-associated malignancies observed in human 
counterparts 45-47. 
 
The tumour suppressor function of neurofibromin is largely attributed to a small central 
region which comprises 360 amino acids encoded by exons 20-27a. This critical region 
has marked structural and sequence similarity to ras-guanosine-
triphosphate(GTP)ase activation proteins (GAPs) and is known as the GAP-related 
domain (GRD). GAPs inactivate Ras by accelerating the conversion of active Ras-
GTP to its inactive guanosine diphosphate (GDP)-bound form. The downregulation of 
oncogene Ras by neurofibromin prevents the downstream activation of mitogen-
activated protein kinase (MAPK) and the PI3K/Akt/mTOR (mammalian target of 
rapamycin) cell proliferation and differentiation pathways, as demonstrated in Figure 





Figure 1.1: The role of NF1 and neurofibromin in the Ras pathway. 
G-protein coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs), when activated by ligand, 
promote guanine nucleotide exchange to form activated Ras-GTP complex. Neurofibromin inactivates 
Ras by accelerating the conversion of active Ras-GTP to inactive GDP-bound Ras with its Ras-GTPase 
activity. Consequently, neurofibromin suppresses activation of the downstream effectors of Ras, 
including PI3K, Akt, mTOR, S6 kinase and RAF, MEK, ERK as well as RAC1 and PAK1. 
RTKs=receptor tyrosine kinases. Grb2=growth factor receptor bound 2. SOS=mammalian homolog of 
the Drosophila son of sevenless. RAS=rat sarcoma viral oncogene homologue. GDP=guanosine 
diphosphate. GTP=guanosine triphosphate. RAF=murine sarcoma viral oncogene homologue. 
MEK=MAPK-ERK kinase. PI3K=phosphatidylinositol-3–kinase. AKT=V-akt murine thymoma viral 
oncogene homologue 1. mTOR=mammalian target of rapamycin. Rac1=Ras-related C3 botulinum toxin 
substrate 1. PAK1=P21-Activated Kinase.   
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The Ras-GAP function of neurofibromin may be enhanced by protein kinase C (PKC) 
phosphorylation of the cystein-serine rich domain (CSRD) of the neurofibromin domain 
encoded by exons 11-17. The clustering of missense mutations in these regions 
among NF1 patients indicate the importance of PKC phosphorylation in sustaining 
normal neurofibromin function 22,49,50. 
 
Neurofibromin has also been demonstrated to bind to caveolin-1 (Cav-1), a membrane 
protein which regulates signalling molecules such as p21ras, protein kinase C and 
growth factor receptors. Formation of the neurofibromin-Cav-1 complex may lead to 
inactivation of p21ras-GTP and modulation of the p21ras/MAPK, PI3K/Akt pathways, 
controlling cell proliferation and differentiation 51. The finding that missense mutations 
resulting in the classic NF1 phenotype frequently occur in exons 28 and 32, which 
encode the caveolin-binding domains of neurofibromin, supports the role of Cav-1 for 
neurofibromin function  52,53.  
 
Apart from downregulation of Ras via the homology to GAPs, there are several other 
postulated mechanisms for the tumour suppressor function of neurofibromin (Table 
1.2). 
 
Table 1.2: Mechanisms of Tumour Suppression by Neurofibromin 
Mechanisms of Tumour Suppression Reported 
 Downregulation of Ras 
 Positive regulation of adenyl cyclase (AC) 
 Pro-apoptotic effect (ras-dependent and ras-independent) 
 Regulation of cell adhesion and motility 
 Suppression of epithelial mesenchymal transition (EMT) 
 Suppression of heat shock factor (HSF) 
 
Neurofibromin is a positive regulator of the enzyme adenylyl cyclase (AC), which 
generates intracellular cyclic AMP (cAMP). cAMP-dependent signaling appears to be 
important in learning and memory, but also provides a possible mechanism for tumour 
suppressor function as it regulates Ras activity 54,55. Increased cAMP leads to 
activation of Rap1, an anti-mitogenic RAS pathway antagonist, which can result in 
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inhibition of RAF activation in astrocytes 56,57. cAMP-mediated regulation of MAPK 
may have differential effects in different tissues; the mechanisms of cAMP-mediated 
tumorigenesis in tissues outside the nervous system have not yet been elucidated. 
 
Neurofibromin has also been reported to exert tumour suppressor function via a 
proapoptotic effect by Ras-dependent and Ras-independent pathways. Nf1-/-, Nf1+/-, 
and Nf1+/+ mouse embryonic fibroblasts (MEFs) exhibited gene-dosage-related 
resistance to apoptosis. Neurofibromin-deficient MEFs and human NF1 malignant 
peripheral nerve sheath tumour (MPNST) cells were more resistant to apoptosis than 
neurofibromin-expressing MEFs and schwannoma cells. Administration of 
farnesylthiosalicyic acid (FTS), a Ras inhibitor, increased apoptosis of the 
neurofibromin-deficient SV40 MEFs and MPNST cells, indicating dependence on the 
Ras pathway. However, the resistance of neurofibromin-deficient SV40 MEFs and 
MPNST cells to staurosporine (protein kinase C inhibitor which induces apoptosis), 
UV irradiation, and vincristine was independent of Ras and cAMP, as demonstrated 
by the inability of Ras inhibitors or agents that elevate cAMP levels to overcome the 
resistance. Expression levels of key apoptotic components such as Bcl-2 family 
proteins, caspases and the X-linked inhibitor of apoptosis (XIAP) were similar in 
neurofibromin-expressing and neurofibromin-deficient MEFs. The exact mechanism of 
the Ras-independent proapoptotic effects of neurofibromin remains unclear 58.  
  
The role of neurofibromin in cell motility is important not only for the functioning in 
neurons, but may also contribute to its tumour suppressor function. Neurofibromin 
regulates the dynamics and reorganisation of actin filaments via the Rho-ROCK-
LIMK2-cofillin pathway, and may be involved in adhesion and signalling at neuronal 
synapses through its interaction (via its GRD and C-terminal domains) with the 
transmembrane heparin sulphate proteoglycan syndecan. Lack of neurofibromin 
triggers the Rho-ROCK-LIMK2-cofilin pathway to alter the organization of actin 
cytoskeleton, promoting cell motility, invasiveness, and cell-cell adhesion, resulting in 
the formation of large cell aggregates. This may lead to the formation of multiple 
neurofibromas in NF1 patients, which consist of aggregates of various cell types, 
including Schwann cells, fibroblasts, endothelial cells and mast cells on a background 




Another mechanism of tumour suppression by neurofibromin relates to its association 
with the N-terminal of focal adhesion kinase (FAK), a protein localised at contact sites 
of cells with extracellular matrix known as focal adhesions. This interaction helps to 
regulate cellular events including adhesion, proliferation, motility, cellular migration 
and survival. Nf1+/+ mouse embryonic fibroblast (MEF) cells exhibited less growth 
under serum deprivation conditions with reduced adherence on collagen and 
fibronectin-treated plates, compared to Nf1–/– cells 61.  
 
There is also data to suggest that loss of neurofibromin leads to epithelial-
mesenchymal transition (EMT). EMT is implicated in tumorigenesis and cancer 
metastasis. Immunohistochemical analysis and real-time quantitative reverse 
transcription polymerase chain reaction showed increased expression of EMT-related 
transcription factors including Snail, Slug, Twist, ZEB1 and ZEB2 in NF1-associated 
neurofibroma specimens and NF1-derived Schwann cells. Knockdown of NF1 with 
siRNA induced the expression of these transcription factors in normal human Schwann 
cells as well as epithelial-like breast cancer cell lines 62. 
 
More recently, loss of NF1 has been reported to promote carcinogenesis by activating 
heat shock factor 1 (HSF1), the master transcriptional regulator of the heat shock 
response. Knockout of NF1 in MEFs triggered activation of HSF1, increasing HSF1 
levels. This resulted in Nf1–/– cells becoming tolerant to proteotoxic stress with 
proteasome inhibitors and HSP90 inhibitor. This activation of HSF1 relied on 
dysregulated MAPK signaling. HSF1, in turn, supported MAPK signaling. In NPcis+/- 
mouse models where Trp53 and Nf1 genes are disrupted on the same chromosome 
to develop soft tissue sarcomas resembling human MPNSTs, Hsf1 knockout impeded 
NF1-associated carcinogenesis by attenuating oncogenic RAS/MAPK signaling. In 
cell lines from human malignant peripheral nerve sheath tumors (MPNSTs) driven by 
NF1 loss and in surgically excised human MPNSTs, HSF1 was also overexpressed 
and activated or phosphorylated 63.  
 
1.6 Tumours associated with NF1 
 
Individuals with NF1 are predisposed to developing both benign and malignant 
tumours throughout life. The risk of malignancy is increased 2.5 to fourfold in NF1 
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compared to the general population 8,64. Average life expectancy is reduced by 10-15 
years, with cancer being the most common cause of death 2. In a study based on the 
Finnish Cancer Registry, the 5-year survival of patients with cancer and NF1, 
excluding nervous tissue cancers, was also found to be inferior than that of 
comparable cancer patients without NF1 (54.0% v 67.5%; P = 0.01) 65. 
 
The tumour types individuals with NF1 are at increased risk of developing include both 
nervous system and non-nervous system tumours. The characteristics of the more 
common NF1-associated tumours are listed in Table 1.3. Accurate estimation of the 
relative frequencies of the various tumour types is challenging, as different studies 
based on hospital data may overestimate the frequency of specific tumours compared 
to population-based studies. This partly accounts for the wide range of prevalence or 
incidence figures reported in the literature for various tumours. 
 
Malignant peripheral nerve sheath tumours (MPNSTs), previously referred to as 
neurofibrosarcomas, are a major cause of morbidity and mortality in NF1. MPNSTs 
typically arise from malignant transformation of plexiform neurofibromas, and 
occasionally spinal nerve root or subcutaneous neurofibromas. In NF1 the lifetime risk 
of developing MPNST is 8-13%, with estimated annual incidence at 0.16%, compared 
to 0.001% in the general population 9,66,67.   
 
There is a wide range of other NF1-associated tumours including optic pathway 
gliomas (OPGs), rhabdomyosarcomas, neuroblastomas and juvenile myelomonocytic 
leukaemias (JMML) in the paediatric setting, as well as gastrointestinal stromal tumour 
(GIST), phaeochromocytomas and carcinoid tumours in adults. OPGs, like MPNSTs, 
may occur in both children and adults 9,66,67. More recently, an increased risk of breast 
cancer among women with NF1 has also been reported 68,69. Breast cancer in NF1 
patients appears to have an aggressive phenotype in reported case series with limited 
number of patients 70-72. 
 
NF1 patients are also at an increased risk of developing radiation-induced 
malignancies. In a study of NF1 patients treated with radiotherapy for optic glioma, the 
relative risk of second central nervous system (CNS) tumour was 3.04 (95% CI, 1.29 
to 7.15) 73. Hence radiotherapy should be avoided in children with NF1, unless it is 
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absolutely essential. In mouse model studies, Nf1+/-mice subjected to irradiation 
developed in-field tumours associated with NF1 such as phaeochromocytomas, as 
well as typical second malignant neoplasms such as sarcomas and breast cancers 74-
76. This may be related to upregulated, perturbed cell cycle and DNA repair pathways 
with NF1-haploinsufficiency, as observed in human lymphoblastoid cell lines from 
NF1-affected and normal individuals, as well as in lymphocytes from wildtype and 
Nf1+/- mice. Activation of DNA damage response (DDR) genes can paradoxically 
trigger oncogene-induced DNA damage and genomic instability, resulting in 
carcinogenesis 77,78. Interestingly, somatic monoallelic loss of NF1 and TP53 in the 
adjacent allele was observed in radiation-induced malignancies arising in both 
wildtype and Nf1+/- mice in one study 74.    NF1 loss appears to be a critical event in 
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1.7 Somatic NF1 Aberrations in Sporadic Tumours and Effects of NF1 
Deficiency 
 
Recent cancer genome sequencing projects have unraveled the heterogeneity of 
cancer genomes. Somatic NF1 aberrations are increasingly reported in various 
sporadic tumours, including brain, lung, breast, ovarian tumours as well melanomas 
and leukemias (Figure 1.2). This is particularly relevant with the advent of novel 
molecular therapies which can potentially be targeted at aberrations in the NF1 
pathway. Improved understanding of the mechanisms of carcinogenesis is critical for 
the optimisation of these targeted therapies. 
Brain Tumours 
 
In glioblastoma multiforme (GBM), NF1 is one of the most frequently mutated or 
deleted genes. The prevalence of NF1 somatic mutations in sporadic GBMs was 
initially estimated to be approximately 15%, with a subsequent study by The Cancer 
Genome Atlas (TCGA) network reporting aberrations in at least 23% (47 out of 206) 
of human GBM samples when both NF1 inactivating mutations and deletions 
(including heterozygous deletions) were analysed 103,104. However, when only 
mutations and homozygous deletions are considered, the frequency of alterations 
ranges from 12.1 to 17.6% 104,105.  
 
Data from mouse models support the importance of NF1 as a glioblastoma suppressor 
gene. Inactivation of TP53 and PTEN may cooperate with NF1 loss to induce 
malignant transformation 106. Haploinsufficiency for the NF1 tumour suppressor may 
have functional consequences, such as increased astrocyte proliferation and 
augmentation of angiogenesis in Nf1+/- heterozygous mouse models 107,108. Integrated 
genomic analysis of the TCGA data identified GBMs with NF1 and PTEN alterations 
to have a distinct mesenchymal-like expression profile. This mesenchymal subtype 
was characterised by the expression of mesenchymal markers such as CHI3L1 (also 
known as YKL40) and MET, as well as astrocytic markers (CD44, MERTK), reflecting 
epithelial-to-mesenchymal transition. There was also high expression of genes in the 
tumour necrosis factor (TNF) and NK-ĸB pathway, related to the greater necrosis and 











Loss of NF1 in malignant melanoma cell lines was reported soon after discovery of the 
NF1 gene in the early 1990s 111,112, but it was only recently that comprehensive 
genomic characterization of melanomas was performed. Melanomas may be 
classified into 3 major classes: 1) sun-shielded melanomas with wild type BRAF and 
NRAS which have low mutation load but high number of copy gains, 2) sun-exposed 
melanomas with BRAF or NRAS mutations and 3) sun-exposed melanomas with wild-
type BRAF and NRAS, few copy number alterations but high mutation load. The last 
subtype of melanoma is typically associated with more advanced age, and 30% of 
melanomas from this class (10/33 samples) carry deleterious NF1 mutations. TP53, 
ARID2 and PTPRK are frequently mutated in these melanomas, suggesting that 
inactivation of tumour suppressors contribute to the pathogenesis of these BRAF and 
NRAS independent tumours 113,114. The overall frequency of NF1 mutations is 
estimated at 12-14% of cutaneous melanomas in separate studies (Figure 1.2) 113,115. 
NF1 alterations are especially frequent in desmoplastic melanomas, an uncommon 
variant of melanoma with sarcomatous histology which usually occur in the chronically 
sun-exposed skin of older individuals. Up to 54.8% of desmoplastic melanomas 
harbour NF1 mutations or copy number aberrations according to one study116. 
 
Somatic NF1 mutations have also been reported in melanoma specimens harboring 
BRAF mutations 115,117. In a mouse model study, NF1 mutations cooperated with 
BRAF mutations in the pathogenesis of melanomas by preventing oncogene-induced 
senescence 117.  Loss of neurofibromin expression and NF1 loss-of-function mutations 
have been reported in melanomas from patients with de novo as well as acquired 
resistance to BRAF inhibitors 117,118. A pooled RNA interference screen 
targeting >16,500 genes in a BRAF inhibitor-sensitive melanoma cell line identified 
NF1 as the highest ranking gene whose knockdown abrogated the growth inhibitory 
effects of PLX4720, a BRAF inhibitor 118. NF1-mutant melanomas are unlikely to 
respond to standard BRAF-targeted therapies but may benefit from drugs targeting 
the MEK and PI3K pathway instead. In mice injected with BRAF/NF1-mutated 
melanoma cells, there was resistance to vemurafenib, a BRAF inhibitor. In contrast, 
there was greater sensitivity to MEK inhibitor PD0325901, PI3K inhibitor GDC-0941 
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and rapamycin, an mTOR inhibitor. Importantly, rapamycin synergized with 




Whole exome or genome sequencing of primary lung adenocarcinomas identified NF1 
as one of the most frequently mutated genes, with an estimated frequency of 10-13% 
(figure 1.2) 119,120. The clinical significance of NF1 mutations in the larger sequencing 
studies is not reported, but reduced NF1 mRNA expression was found to confer both 
intrinsic and acquired resistance to EGFR inhibitors in a separate study. However, 
somatic NF1 mutations were not found in the specimens from these patients with 
resistant tumours (more details in section on challenges of molecular diagnosis of NF1 
and NF1 somatic aberrations) 121. 
 
Up to 15% of squamous cell lung cancers have alterations in NF1 (figure 1.2). 
According to a TCGA study on squamous cell carcinomas, mRNA expression profiling 
identified 4 distinct subtypes of squamous cell lung cancers – classical, primitive, basal 
and secretory expression subtypes. The basal expression subtype of squamous cell 
lung carcinoma characteristically showed alterations in NF1 122.  
 
In a study comparing the characteristics of NF1-mutant non-small cell lung cancers 
(NSCLCs) with KRAS mutant NSCLCs,  NF1 mutant lung cancers harboured more 
oncogenic alterations such as BRAF, ERBB2, KRAS, HRAS, NRAS and TP53 
mutations than KRAS mutant cancers, though NF1 mutations and KRAS mutations 
are not mutually exclusive123. In a more recent study, loss-of-function mutations of 
RASA1, a Ras-GTPase activating protein (RasGAP), were reported to be significantly 
enriched in NF1-mutated NSCLCs. Co-mutation of RASA1/NF1 was enriched in 
adenocarcinomas or squamous cell carcinomas from smokers, and exhibited 
complete mutual exclusivity with KRAS and EGFR mutations compared with single 
mutation of either RASA1 or NF1. Importantly, targeting downstream MAPK signaling 
with MEK inhibition in vitro was significantly more potent in NSCLC cells with 
RASA1/NF1 co-mutation compared to those with single mutation of either RASA1 or 




There is less data on small cell lung cancer, but the frequency of mutations in NF1 




The importance of NF1 in ovarian cancer was first reported by Sangha et al 127. Initial 
genome-wide screen of DNA copy number alterations (CNAs) identified apparent NF1 
homozygous deletions in 2 out of 36 primary ovarian serous carcinomas. This led to 
the discovery that 6 out of 18 ovarian carcinoma-derived cell lines had markedly 
reduced or lacked expression of NF1 protein, with 5 of the 6 cell lines harbouring NF1 
mutations. Alterations in NF1, including splicing mutations and homozygous deletions, 
were identified in 22% (9/41) of the primary ovarian serous carcinomas studied. There 
was evidence of Ras pathway activation in these tumours and cell lines with NF1 
defects, in the absence of KRAS or BRAF mutations. NF1 appears to cooperate with 
TP53 mutations which are present in virtually all ovarian serous carcinomas, in 
carcinogenesis 127. 
 
In the large scale integrated genomic analyses of 489 high grade serous ovarian 
carcinomas by the TCGA cooperative group, NF1 has been recognized as one of the 
most frequently altered genes, with aberrations in 12% of the cases (8% homozygous 
deletions, 4% mutations) 128. These alterations affect signaling in the PI3K/Ras 




Although a computational biology study on gene expression datasets had previously 
reported associations between the activity levels of regulatory pathways linked with 
NF1 to clinical outcome in breast cancer 129, the importance of NF1 in the pathogenesis 
of breast cancer was not investigated further until recently. Absence of neurofibromin 
protein and lack of expression of NF1 mRNA type 1 isoform have been reported in the 
highly aggressive human breast cancer MDA-MB-231 cell line which is resistant to 
endocrine and cytotoxic agents. This was associated with accumulation of 
phosphorylated MAPK and activated Ras 130. More recently, this Claudin-low subtype 
cell line was found to harbour an NF1 mutation 131. The Cancer Genome Project led 
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by the Sanger Institute and The Cancer Genome Atlas (TCGA) projects reported NF1 
mutations in approximately 3% of the breast cancers sequenced. Proportionally more 
NF1 mutations were found in luminal or ER+HER2- subtypes, although they were also 
present in selected HER2-overexpressing and triple negative or basal tumours 132,133. 
This may have therapeutic implications, given that knockdown of NF1 in MCF7 cells 
conferred resistance to tamoxifen in a genome-wide functional study 134. More recently, 
NF1 frame-shift nonsense (FS/NS) mutations have been validated as poor outcome 
drivers in hormone receptor-positive breast cancers by Griffith et al135, while 
inactivating mutations in NF1 were associated with inferior breast cancer specific 
survival in ER negative tumours from the METABRIC study which extensively profiled 
more than 2,000 breast tumours (hazard ratio 2.7, CI1.3–5.5) 136. The recent findings 
of increased frequency of NF1 mutation in metastatic breast cancer lesions in two 
separate reports, ranging from 7% to 18% of ER positive metastatic lesions, also 
supports the role of NF1 mutations in the metastatic process 137,138.  
 
NF1 has been implicated as a breast cancer driver in a mouse model study. Chaos3 
mice, which are engineered with a point mutation in the minichromosome maintenance 
4 (Mcm4) gene, are highly unstable genomically, leading to the development of 
mammary tumours which resemble human breast cancers 139. NF1 was found to be 
deleted in nearly all the mammary tumours from these mouse models. This led to re-
examination of the TCGA data. 27.7% of human breast cancers in the TCGA project 
were subsequently found to harbour NF1 aberrations, majority of which were 
heterozygous deletions. Over 40% of HER2-overexpressing and basal subtypes 
showed these aberrations. This highlights the importance of investigating genomic 
loss in addition to somatic mutation of NF1 139.  
 
Loss of heterozygosity of NF1 has been detected in radiation-induced breast cancers 
from patients without NF1 syndrome. The monoallelic loss of NF1 is likely to increase 
the potential for cooperating with other pathways such as TP53 pathways to promote 
cellular proliferation and carcinogenesis 74. Loss of NF1 gene has also been reported 






NF1 was previously implicated as one of the important drivers in certain sporadic 
haematological malignancies. Myeloid malignanices frequently harbor mutations in the 
Ras pathway. It is likely that NRAS/KRAS/NF1 aberrations cooperate with mutations 
in transcription factors and genes that regulate the epigenome in complex events 
leading to the development of AML 141. In earlier studies, NF1 mutations were reported 
in up to 7% of acute myeloid leukemia (AML) cases, while 12% of 95 cases studied 
had copy number alterations in NF1 with mainly heterozygous deletions. Complete 
absence of NF1 expression was reported in 7% of adult AML, and this was associated 
with increased Ras-bound GTP 142. In another study on a subset of AML with CBFB–
MYH11 rearrangements, 16% of cases showed deletion of NF1 143. However, two 
recent large scale studies suggested that NF1 aberrations are not as frequent in de 
novo AML, although it may occur as a secondary event in disease progression 144,145. 
After taking into account the size of the gene in the test for significantly mutated genes, 
NF1 is not one of the significantly mutated genes in AML, with the gene altered in 2.7% 
of 187 cases 145. 
 
Limited data suggests the frequency of NF1 alterations in myelodysplastic syndrome 
(MDS) varies from 0% to 9% 146,147. Recurrent cryptic alterations or deletions of the 
NF1 locus have been detected in 3 out of 35 patients in one of the studies 146. The 
frequency of NF1 mutations in sporadic acute lymphoid leukemia (ALL) was recently 
reported as 3-8% 148,149. The prevalence of NF1 aberrations in certain paediatric 
haematological malignancies may be higher, with mutation frequency in NF1 as high 




Data on the nature and the frequency of NF1 aberrations in colorectal carcinoma vary 
widely. After the initial report by Li et al that 1 out of 22 sporadic colon 
adenocarcinomas (4.5%) harboured the amino acid substitution altering Lys-1423 in 
the NF1 GRD 150, loss of heterozygosity (LOH) involving the NF1 gene in 14-57% of 
colorectal carcinomas was reported in two small studies 151,152. In addition to NF1 
missense mutations, Ahlquist et al also found duplication of the whole NF1 gene or 
parts of it in 4 out of 24 specimens (17%) 153. Nine out of ten NF1 mutations detected 
in this study occurred in introns likely involved in exon splicing. Notably, 8 of these 10 
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carcinomas showed microsatellite instability153. In contrast, NF1 was found to be 
altered in only 3.8-5.6% of colorectal carcinomas in TCGA sequencing studies 154,155. 
 
Other Sporadic Tumours 
 
As displayed in Figure 2; there are several other tumours in which NF1 aberrations 
have been reported. 
 
MPNSTs can also be sporadic, that is, occur in individuals without NF1 disorder, or 
occur after radiotherapy as a treatment-related complication. Somatic alterations of 
NF1 occur frequently in 72% of non-NF1-associated MPNSTs, and potentially 
cooperate with CDKN2A somatic alterations (81% frequency among all MPNSTs) and 
PRC2 mutations (70% (19/27) of NF1-associated, 92% (12/13) of sporadic and 90% 
(8/9) of radiotherapy-associated MPNSTs) in the pathogenesis of MPNSTs89. 
 
Aberrations of NF1 have been reported in other sporadic soft tissue sarcomas as well. 
Up to 10.5% of myxofibrosarcomas and 8% of pleomorphic liposarcomas harbor NF1 
mutations 156,157.  In a study on embryonal rhabdomyosarcoma, loss of NF1 occurred 
in 35%(9/26) of tumours (heterozygous or homozygous deletion of NF1 or 
heterozygous chromosomal loss), and were mutually exclusive with Ras mutations, 
suggesting NF1 loss as an alternative and potentially common driver of Ras activation 
in this major subtype of soft tissue sarcoma in young children 157. 
 
A few studies reported somatic NF1 aberrations or inactivation in 26-41% of sporadic 
phaeochromocytomas from individuals without NF1. In keeping with the observation 
that NF1 individuals are at increased risk of developing phaeochromocytomas, these 
findings suggest that loss of NF1 function is a crucial event in the pathogenesis of both 
sporadic and NF1-associated phaeochromocytomas 101,158,159 .  
 
Inactivating NF1 mutations occur in approximately 11% of urothelial bladder 
carcinomas sequenced in TCGA study 160. Alterations in NF1 appear to be most 
common in the “neuronal” subtype based on mRNA expression, with a frequency of 
10% compared to 1-6% in other molecular subtypes. The neuronal showed relatively 
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high expression of neuronal differentiation and development genes, and was 
associated with the poorest survival among the different molecular subtypes161. 
 
 
1.8 Challenges of molecular diagnosis of NF1 and detection of NF1 somatic 
aberrations 
 
The diagnosis of NF1 syndrome is usually established clinically in individuals with 
constitutional features of the syndrome. Germline NF1 testing is reserved mainly for 
equivocal cases, for prenatal diagnosis and in the research setting. Detection of NF1 
mutations or deletions can be highly challenging due to several factors. NF1 is one of 
the largest genes, with 60 exons spanning over 350kb of DNA. The gene also has one 
of the highest mutation rates, with up to half of the mutations being novel mutations. 
In addition to the myriad of possible lesions with more than 2,800 different germline 
mutations reported so far22 and the lack of mutation hotspots, the presence of several 
pseudogenes can further complicate the molecular diagnosis 11,162-166. A multi-step 
protocol involving analysis of genomic DNA and mRNA with RT-PCR, direct 
sequencing, multiplex ligation-dependent probe amplification (MLPA), and previously 
using also microsatellite marker analysis and FISH, was required to identify up to 95% 
of pathogenic mutations in individuals fulfilling the clinical NIH diagnostic criteria 167-
169. Analysis of RNA is essential as splicing mutations may be present in more than 
20% of individuals with NF1 syndrome 163,168,169, and may be located deep in introns 
which may be missed when only exons are studied. 
Given the potential difficulties of detecting the pathogenic mutation in individuals with 
clinical features of NF1, the identification of somatic NF1 aberrations in sporadic 
tumours can also pose a significant challenge. While it is possible that the frequency 
of somatic NF1 alterations in various tumours is higher than what is currently 
recognized, the functional significance of the extensive range of missense mutations 
remains unclear.  
 
Although next generation sequencing (NGS) may be less laborious than direct 
sequencing, there are also limitations with NGS techniques. Decreased specificity of 
the capture probes may lead to the capture and enrichment of off-target sequences, 
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including those from pseudogenes and closely related genes 162. Exome sequencing 
alone may not detect splicing mutations or gene rearrangements. Whole genome 
sequencing combined with transcriptome analysis may be superior, but there are 
limitations to its applicability in the clinical setting currently due to the general 
requirement for fresh frozen tissue, complexity of data analysis and cost. 
 
 
1.9 Downregulation of NF1 and neurofibromin via other mechanisms 
 
Epigenetic factors, such as gene silencing by microRNAs and DNA methylation, may 
also influence the expression of NF1 and neurofibromin, as described below.  
 
microRNAs are endogenous, small noncoding RNAs which can influence their target 
gene expression post-transcription. Downregulation of NF1 by microRNA-193b, which 
is overexpressed in sporadic head and neck squamous cell carcinomas (HNSCC), led 
to activation of ERK and resulted in tumour progression. Survival outcomes in HNSCC 
patients whose tumours expressed high levels of miR-193b were inferior compared to 
patients with low miR-193b expression. Knockdown of miR-193b in HNSCC cells 
increased NF1 transcript and protein expression levels, decreased ERK 
phosphorylation with reduction in cell viability, migration, invasion and tumour 
formation 170.  
 
There is limited data on methylation changes, but methylation of NF1 has been found 
to be the cause of a somatic second-hit inactivation in pilocytic astrocytoma from a 
patient with NF1 171. 
 
Excessive proteasomal degradation of neurofibromin can also result in deficiency of 
this critical tumour suppressor protein 172. The ubiquitin ligase complex which controls 
both the regulated destruction and pathogenic destabilisation of neurofibromin was 
recently identified in glioblastomas as a Cullin 3(Cul3)/kelch repeat and BTB domain-
containing 7 complex. Inhibition of Cul3 with Cul3-specific shRNAs suppressed 
Ras/ERK signaling; agents aimed at blocking neurofibromin destruction may be a 




Given that the expression of NF1 may be influenced by epigenetic factors, microRNAs 
174 and proteasomal degradation 172,173,  a proteomics-based approach may help to 
detect deficiency of neurofibromin. The utility of immunohistochemical staining of 
neurofibromin has not been fully explored. Complete absence of neurofibromin 
staining on immunohistochemistry was found in 15-18% of melanomas 117. However, 
quantitation of protein expression correlating with treatment outcomes has not been 
well studied. This is also complicated by the fact that current antibodies available may 
not be able to distinguish between the normal and mutant neurofibromin protein. 
Functional studies of “mutant neurofibromin” will be challenging with the huge protein 
size and myriad abnormalities possible. 
 
The challenges of elucidating the mechanisms of NF1 deficiency are demonstrated in 
the recent study on reduced NF1 expression as a driver of resistance to EGFR inhibitor 
in lung cancer. NF1 mRNA expression was reduced in EGFR TKI-resistant lung 
cancer specimens, but somatic mutations and methylation changes involving NF1 
were not detected. To account for the downregulation of NF1 mRNA, 
immunohistochemistry using multiple antibodies was performed, but none of them 
demonstrated adequate specificity to detect neurofibromin in human lung tissue 121. 
 
 
1.10 Therapeutic Strategies for NF1 and NF1-associated/deficient 
malignancies 
 
Management Options for NF1 syndrome and neurofibromas 
 
The management of individuals with NF1 consists mainly of surgical resection of 
neurofibromas when they cause discomfort or impingement of neighbouring structures 
such as nerves or spinal cord. There is an unmet need for novel molecular therapies 
to treat the systemic manifestations in NF1. Although several early phase trials on 
NF1-associated plexiform neurofibromas have been listed on the clinicaltrials.gov 
website, many have been terminated or suspended, with very few studies having 




Early clinical trials using thalidomide, 13-cisretinoic acid (CRA) or interferon α-2a to 
target angiogenesis and differentiation in NF1 patients with plexiform neurofibromas 
induced at best a minor response in a minority of patients 175,176. Early phase  trials 
using pirfenidone, an antifibrotic agent drug which targets the stromal contributions, 
showed similar limited activity in plexiform neurofibromas in adults and children 177,178. 
 
Since Ras is overactivated with dysfunction of NF1, subsequent NF1 trials focused on 
inhibition of Ras. Farnesylation and geranylgeranylation of Ras proteins is essential 
for translocation to the cell membrane with subsequent activation of the Ras pathway. 
The activity of tipifarnib, a farnesyl transferase inhibitor, was reported in a phase 1 trial 
on children with solid tumours or NF1 and plexiform neurofibromas. Stable disease 
was the best response; no significant regressions were observed 179. More recently, 
in a phase 2 placebo-controlled study on children and young adults with NF1 and 
progressive plexiform neurofibromas, tipifarnib did not prolong the time to progression 
compared to placebo 180. Similarly, results from a phase 2 study using sirolimus 
(rapamycin), an mTOR inhibitor, in NF1 patients with plexiform neurofibroma, did not 
report any regression of the lesions 181. Clinical trials using everolimus, a newer 
generation mTOR inhibitor and other therapies have also been conducted, but with no 
reports of the trial findings to date. The MEK inhibitor PD0325901 was effective in 
shrinking plexiform neurofibromas in more than 80% of genetically engineered mice, 
but data on clinical activity in human subjects is awaited 182. A number of preclinical 
studies also suggest the efficacy of MEK inhibitors in NF1-associated MPNSTs or 
plexiform neurofibromas may be enhanced in combination with photothermal 
therapy183, all-trans retinoic acid (ATRA)184, and inhibition of BMP2 (Bone 
Morphogenetic Protein 2)185 or MNK (MAPK-interacting kinase)186. 
 
Pegylated interferon-α-2b, which has antiproliferative, antiangiogenic and 
immunomodulatory properties, induced minor response in 29% of young patients with 
plexiform neurofibromas in a phase I trial 187. Tumour stabilization or prevention of new 
lesions may be a more realistic endpoint as dramatic regression of established “benign” 
tumours is less likely. Although neurofibromas may show LOH in a subset of Schwann 
cells, the mode of pathogenesis is different from that of malignant tumours 188. 
However, imatinib mesylate, an oral kinase inhibitor targeting c-kit and PDGFRβ, was 
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recently reported to decrease plexiform neurofibromas by 20% or more in 6 out of 36 
NF1 patients in a phase 2 trial. This effect may partially be related to targeting cellular 
phosphor-signalling cascades189-191. In contrast, sorafenib which targets c-kit and 
PDGFRβ as well as RAF, VEGFR2, was poorly tolerated and did not show any tumour 
response in a phase 1 trial on children with NF1 and plexiform neurofibromas 192. 
Based on the preclinical activity of nilotinib (tyrosine kinase inhibitor with activity 
against BCR-ABL and c-kit among other tyrosine kinases) in NF1-associated MPNST 
and plexiform neurofibromas193, a phase 1 trial on adults with NF1-associated 
plexiform neurofibromas was initiated, with results awaited. The clinical efficacy of 
these compounds in treating neurofibromas remains to be tested in larger clinical trials. 
 
A novel approach to the treatment of NF1 may potentially involve STX3451 (2-(3-
Bromo-4,5-dimethoxybenzyl)-7-methoxy-6-sulfamoyloxy-1,2,3,4-
tetrahydroisoquinoline), a small molecule hormone-like agent resembling the natural 
anticancer metabolite, 2-methoxyoestradiol (2ME2). It may provide a novel approach 
for lowering the tumour burden in NF1 and other endocrine sensitive cancers with 
limited treatment options194. The number and size of tumours in NF1 patients are 
known to increase in response to the rise in steroid hormones during puberty and 
pregnancy, with regression after delivery 24. This hormonal dependency can potentially 
be exploited in the treatment of NF1. STX3451 was reported to induce apoptosis in 
human MPNST cell lines, with inhibition of PI3K-mTOR signaling pathways, as well as 
disruption of actin- and microtubule-based cytoskeletal structures in MPNST and 
plexiform neurofibroma cell lines194. 
  
Potential therapeutic strategies for NF1-deficient malignancies 
 
Data on the efficacy of molecular therapies in NF1-deficient malignancies is currently 
limited to results from preclinical studies (Figure 1.3). Much of this research has been 
conducted on models of MPNST derived from NF1 patients. This is set to change with 
emerging clinical trials where the molecular therapy is matched to the genomic profile 
of each individual’s tumour. A one-size-fits-all approach may not always deliver an 
optimal outcome. For instance, although imatinib is standard-of-care for most patients 
with sporadic GIST, KIT/PDGFRA mutations are uncommon in GISTs arising in NF1 
individuals, so response to imatinib is poor in these patients98. With the increasing 
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personalization of treatment in cancer, there is now an ongoing phase 2 trial using 
selumetinib in NF1-mutated (germline or somatic) GIST (ClinicalTrials.gov Identifier: 
NCT03109301). 
 
Figure 1.3: Potential therapeutic strategies for NF1-deficient malignancies 
The molecular therapies above have been tested in the preclinical setting, largely for MPNSTs. There 
is also data on some of the inhibitors for neurofibromin-deficient breast cancer, glioblastoma, AML, soft 
tissue sarcoma, lung cancer and melanoma. Combination therapy targeting more than one checkpoint 
may be required for optimal inhibition.  
 
 
There is preclinical data to support the activity of MEK inhibitors, Ras inhibitor 
farnesylthiosalicylic acid, sirolimus, everolimus and PI3K/Akt/mTOR inhibitors, in 
MPNST cell lines or xenografts derived from NF1 patients 182,195-199 (Figure 3). The 
addition of erlotinib, an epithelial growth factor receptor (EGFR) inhibitor to everolimus, 
inhibited growth and induced apoptosis further in 4 NF1-derived and 1 sporadic 
MPNST cell lines as well as the STS26T sporadic MPNST xenograft 197. EGFR 
expression is present in most MPNST cell lines, and the EGFR signaling pathways 
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were found to be associated with tumorigenesis in the Nf1:p53 mouse tumor model 
197,200. 
 
Signal transducer and activator of transcription-3 (STAT3) is a potential target for 
treating NF1-associated or NF1-deficient cancers, as STAT3 is activated downstream 
in the PI3K/mTOR pathway. The natural product cucurbitacin-I, a potent STAT3 
inhibitor, was found to inhibit the growth of NF1-deficient MPNST cells in vitro and in 
vivo in xenografts  201 . 
 
Since heat shock factor is activated with loss of NF1, it is not surprising that the 
addition of HSP90 inhibitor IPI-504, to rapamycin, led to synergistic activity with 
damage of endoplasmic reticulum and mitochondria in NF1-deficient MPNST mouse 
models 202. 
 
More recently, integrative transcriptome analyses have identified Aurorakinase 
A(AURKA) as a potential therapeutic target. AURKA was overexpressed and amplified 
in NF1-related MPNST, but not neurofibromas. MLN8237, an AURKA selective 
inhibitor, was effective in stabilizing tumour volume and prolonged survival of mice 
with MPNST xenografts 203.  
 
Inhibitors of PAK1, a downstream effector in the Ras pathway, have also been 
reported to suppress the growth of NF1-deficient MPNST cells as well as 
neurofibromin-deficient human breast cancer (MDA-MB-231) xenografts in mice. 
There is evidence that many tumours, including breast cancers, are addicted to 
abnormal activation of PAK1, a Ser/Thr kinase which in turn stimulates cyclin D1, for 
their growth 204,205.  
 
In sporadic tumours harbouring NF1 aberrations, MEK inhibitors have been found to 
be effective in treating neurofibromin-deficient sporadic glioblastoma cell lines, NF1-
deficient AMLs and NF1-deleted soft tissue sarcomas in mouse models 206-208. 
Following the discovery that NF1 deficiency confers intrinsic and acquired resistance 
to EGFR inhibitor in lung cancer, treatment of neurofibromin-deficient lung cancers in 
vitro and in xenografts with MEK inhibitory drugs (AZD-6244, CI-1040 and PD0325901) 
restored sensitivity to erlotinib when given in combination 121. An ongoing trial is 
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investigating the efficacy of trametinib, an inhibitor of MEK1 and MEK2 in NF1-mutant 
non-small cell lung cancer (ClinicalTrials.gov Identifier: NCT03232892), while another 
trial involves the use of selumetinib in young adults with recurrent or refractory low 
grade gliomas with activation of the MEK pathway (ClinicalTrials.gov Identifier: 
NCT01089101). 
 
Combination therapies targeting more than one checkpoint in the cell proliferation 
pathway, such as blocking both the PI3K/mTOR and MEK pathways in the allografts 
of NF1/BRAF-mutated melanomas and dual EGFR, MEK inhibition concurrently in 
TKI-resistant NF1-deficient lung adenocarcinomas, may be superior to monotherapy 
117,121. Inhibiting a single checkpoint may lead to activation of compensatory negative 
feedback pathways209, though cumulative toxicities from blockade of multiple targets 
can be challenging in clinical practice. 
 
Future strategies may include inhibition of excessive destruction of neurofibromin and 
other epigenetic therapies. In Nf2-mutant Schwann cells, inhibition of SIRT2, a class 
III histone deacetylase, triggered necrosis 210. The role of HDAC inhibitors, which may 
decrease Akt phosphorylation, has not been fully explored for Nf1-mutant cells. 
Inhibition of LIM kinase in the Rho-ROCK-LIMK-cofilin pathway regulated by 
neurofibromin is another potential strategy. In Nf1–/– MEFs, novel LIMK inhibitors 
blocked the phosphorylation of cofilin, resulting in actin severance and inhibition of cell 
migration and growth 211. The utility of these drugs in NF1-deficient tumours may be 
worth investigating, especially in combination with Ras or AURKA inhibitors, which 
may have synergistic effects 211,212.   
 
With the recent breakthroughs in immunotherapy for the treatment of several tumour 
types, immune checkpoint blockade may be promising in the treatment of NF1-mutant 
or deficient tumours, which may also be associated with higher mutation burden. An 
impressive response rate of 70% was reported recently in 60 patients with 
desmoplastic melanomas treated with antibodies blocking PD-1 or PD-L1 (PD-1 
ligand), with 32% complete response rate. Whole-exome sequencing of 17 cases in 
this cohort revealed frequent NF1 mutations (14/17), with high mutational load213 . 
While this observation is encouraging, it is unclear if the efficacy is directly related to 
the NF1 mutation, or the association with sun damage which may induce more 
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immunogenic mutations, or a superior adaptive immune response intrinsically with this 
subtype of melanoma. Improved understanding of the biology of NF1 and 
neurofibromin in normal cells and cancer is critical for the development of novel 
treatment strategies.  
 
 
1.11 Conclusions  
 
NF1 and neurofibromin play critical roles in tumour suppression. The frequency of 
somatic NF1 aberrations in sporadic tumours is increasingly recognized. These 
alterations are associated with distinct subtypes in certain cancers, and may be 
associated with poorer treatment outcomes. Significant challenges remain in 
unravelling the complexity of the large NF1 gene and its product neurofibromin. 
Improved molecular diagnosis techniques are essential for detecting these aberrations. 
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Whole exome sequencing of multiple tumours from 
an NF1 patient 
 
2.1 Abstract 
Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the 
development of multiple neurofibromas, cafe-au-lait spots and Lisch nodules. 
Individuals with NF1 are at increased risk of developing various tumors, such as 
malignant peripheral nerve sheath tumour (MPNST), phaeochromocytoma, leukaemia, 
glioma, rhabdomyosarcoma and breast cancer. Here, we describe the exome 
sequencing of breast cancer, MPNST and neurofibroma from a patient with NF1. We 
identified a germline mutation in NF1 gene which resulted in conversion of leucine to 
proline at amino acid position 847. In addition, we showed independent somatic NF1 
mutations in all the 3 tumors (frameshift insertion in breast cancer (p.A985fs), 
missense mutation in MPNST (p.G23R), and inframe deletion in dermal neurofibroma 
(p.L1876del-Inf)), indicating that a second hit in NF1 gene resulting in the loss of 
function could be important for tumor formation. Each tumor had a distinct genomic 
profile with mutually exclusive mutations in different genes. Copy number analysis 
revealed multiple copy number alterations in the breast cancer and the MPNST, but 
not the benign neurofibroma. Germline loss of chromosome 6q22.33, which harbors 2 
potential tumor suppressor genes, PTPRK and LAMA2, was also identified; this may 
increase tumour predisposition further. In the background of NF1 syndrome, although 
second-hit NF1 mutation is critical in tumorigenesis, different additional mutations are 






NF1 is a relatively common genetic disorder characterized by the development of 
multiple neurofibromas, cafe-au-lait spots and Lisch nodules, with estimated incidence 
of 1 in 2,000 to 1 in 5,000 individuals worldwide 1. The NF1 gene on chromosome 
17q11.2 is a classic tumour suppressor gene. Its product neurofibromin is an important 
negative regulator of the Ras cellular proliferation pathway 2,3. Individuals with NF1 
are at increased risk of developing various tumours, including MPNST, 
phaeochromocytoma, leukaemia, glioma and rhabdomyosarcoma 4. More recently, an 
increased risk of breast cancer has also been reported 5,6.  
The mechanism of pathogenesis of NF1-associated breast cancer is unknown; limited 
data suggest an aggressive biology of breast cancer in NF1 patients 7-9, with a higher 
proportion of estrogen receptor negative and HER2-posiitve tumours 9,10. Previously, 
studies on genetic aberrations in MPNST focused on only a limited set of genes, 
reporting mutations in TP53 and second hit NF1, multiple copy number alterations, 
and deletion of CDKN2A 4,11-13. Recently published studies now report frequent 
somatic aberrations in EED and SUZ12 as well, both of which are chromatin-modifying 
genes 14-16. 
 
In this study, we sequenced the exomes of breast cancer, MPNST, dermal 
neurofibroma and matched whole-blood from a single NF1 patient. The objectives 
were to unravel the genomic complexity of different neoplastic manifestations of NF1 
and to identify somatic mutations that potentially drive these tumours. 
 
2.3 Materials and Methods  
Patient 
The subject of this study fulfilled NIH Consensus Development Conference diagnostic 
criteria for NF1; family history was also positive for NF1. At the age of 39 years, she 
was diagnosed with right breast cancer. Histopathological examination revealed a 
40mm grade 3 invasive ductal carcinoma with metastasis to 1 of 17 lymph nodes. 
Estrogen- and progesterone- receptor status were positive. HER2 was 2+ in 30% of 
the cells by immunohistochemistry, and borderline positive on fluorescent in-situ 
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hybridization (FISH) testing with a ratio of HER2 to chromosome 17 signals from 60 
nuclei scored as 2.2, and an average of 4.7 HER2 signals per nucleus. Adjuvant 
chemotherapy as well as trastuzumab and tamoxifen were administered 
postoperatively, in addition to radiotherapy. 
 
Three years later, she presented with a rapidly growing soft tissue mass beneath the 
right buttock. Excision of this mass and a separate dermal neurofibroma on the right 
buttock was performed; the pathological diagnosis for the mass was malignant 
peripheral nerve sheath tumour arising from a plexiform neurofibroma. Sections 
showed a hypercellular spindle cell tumour with large areas of necrosis and 
hemorrhage and high mitotic activity.    
 
Blood and fresh frozen tumour specimens (breast cancer, MPNST, dermal 
neurofibroma) were obtained from this patient who was referred to the candidate YSY 
for the study. The design of the study was conceived by the candidate YSY who 
secured grant funding, with approval from the local Institutional Review Board. All the 
tumour specimens contained at least 70% tumour by routine histologic review with 
haematoxylin and eosin staining at Singapore General Hospital Pathology Laboratory. 
 
Exome capture and high throughput sequencing 
DNA extraction, library preparation and sequencing of DNA were performed by 
collaborators at the Laboratory of Cancer Epigenome, Division of Medical Sciences, 
National Cancer Centre Singapore, with bioinformatic analyses by collaborators from 
the Division of Neuroscience and Behavioral Disorders, Duke-National University of 
Singapore Graduate Medical School. Three micrograms of DNA per sample were 
sheared using a Covaris S1 Ultrasonicator (Covaris, MA). Adaptor-ligated libraries 
were constructed using Paired-End DNA kits (Illumina, CA). Exome capture was 
performed using SureSelect Human All Exon Kit v3 (Agilent Technology, CA). Each 
sample was sequenced on two lanes of an Illumina GA-IIx sequencer using 76-bp 
paired-end reads. The image analysis and base calling were performed using the 
Illumina pipeline (v1.6) with default settings.  
Sequence mapping and coverage computation 
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Alignment of the sequenced reads was to human reference genome hg19, using the 
Burrows-Wheeler Aligner software. PCR duplicates were removed using SAMTools. 
Variants were called using a pipeline based on the Genome Analysis Toolkit (GATK) 
software. Base quality scores were recalibrated and the sequences near microindels 
were realigned. Consensus calling for SNVs and microindels was done with the GATK 
Unified Genotyper. Only well-mapped reads and reads with fewer than 4 mismatches 
in a 40 base-pair window were considered. 
 
The putative SNVs and microindels were annotated against dbSNP 135 and 1000 
Genomes to remove common polymorphisms, excluding cancer-associated positions 
(based on presence in the COSMIC database). Using transcripts from the CCDS, 
RefSeq, Ensembl and UCSC databases, we identified non-synonymous mutations 
and classified them as tumour-somatic if the matched normal sample had sufficient 
coverage to show that the variant was not present in the germline. Putative mutations 
were validated by Sanger sequencing. 
 
Copy number variation analysis 
Analysis of copy number and regions of loss-of-heterozygosity was performed on the 
exome sequencing data using the ASCAT algorithm 2.0 (Allele-Specific Copy number 
Analysis of Tumors) (http://heim.ifi.uio.no/bioinf/Projects/ASCAT/)17. For higher 
resolution, the blood, dermal neurofibroma and primary breast tumour samples were 
assayed using the Affymetrix CytoScan HD platform. There was insufficient DNA from 
the frozen specimen of MPNST for the Cytoscan copy number analysis. Analysis of 
the array data was performed with the Chromosome Analysis Suite software (version 
2.0.1) from Affymetrix. 
 
2.4 Results 
Whole exome sequencing of breast cancer, MPNST and dermal neurofibroma in NF1 
patient identified independent NF1 mutations. 
Our target enrichment and sequencing achieved a mean coverage of 75, with an 
average of 83% of bases covered by at least 20 reads in each sample (Table 2.1). 
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Targeted Bases with 
Depth at Least 1X 
(%) 
Targeted Bases with 





Normal Blood 51,756,093 81,654,655 90 95.7 85 NA 
Breast 
Cancer 
51,756,093 69,567,784 76 95.7 84 15 
MPNST 51,756,093 71,616,111 77 95.5 83 6 
Neurofibroma 51,756,093 53,446,781 57 95.2 79 1 
Average 51,756,093 69,071,333 75 96 83 7 
 
To identify the possible NF1 germline mutations in this patient, we inspected all 
variants detected in the patient’s blood DNA, and identified a heterozygous missense 
mutation of thymidine to cytosine (g.chr17:29,556,173). This mutation resulted in a 
conversion of leucine to proline at amino acid position 847, which is also present in all 
the tumour samples confirmed by Sanger sequencing, indicating germline mutation 
(Figure 2.1).  
All reported mutations were validated by Sanger sequencing in the 4 samples (blood, 
breast cancer, MPNST and dermal neurofibroma) (Figure 2.2, Table 2.2), except the 
insertion of cytosine in the NF1 gene (g.chr17:29,553,477) in the breast cancer, most 
probably due to repetitive sequences in that region leading to slippages in Sanger 
sequencing. However, close inspection using the Integrated Genome Viewer software 
suggests a true insertion event (Figure 2.3). The somatic mutations identified in each 
sample were unique to the tumor, suggesting that each different type of tumor arose 




Figure 2.1: Sanger sequencing confirms germline NF1 variant present in all samples. 
The top panel shows the wild type and mutant nucleotide and the altered amino acid sequence at amino 
acid position 847. The bottom 5 panels are the electropherograms from Sanger sequencing of the same 
region from a reference control (commercial genomic human DNA), patient’s blood, breast cancer, 
MPNST and dermal neurofibroma. Note that the germline mutation was detected in all samples except 









Table 2.2: Mutation detected in normal, breast cancer, MPNST and dermal neurofibroma tissues from the same patient 





















CCDS42292.1 + chr17 29,556,173 g.chr17:29,556,173 T>C  c.2540 T>C  p.L847P Missense Germline  N.A. 





CCDS42292.1 + chr17 29,556,173 g.chr17:29,556,173 T>C  c.2540 T>C  p.L847P Missense Germline  N.A. 
NF1 
breast 
cancer CCDS42292.1 + 




frameshift Somatic* yes Neg 




neurofibroma CCDS42292.1 + 
chr17 29,657,329 g.chr17:29,657,329 -TCT c.5625 -TCT 
p.L1876del 









frameshift Somatic  Neg 
CCBL2 
breast 
cancer CCDS30767.1 - 












frameshift Somatic  Neg 
MAGI3 breast 
cancer 
CCDS44196.1 + chr1 114,191,856 g.chr1:114,191,856 C>G  c.2156-3 C>G  - 
possible 3’ 
splice site 
















CCDS5733.1 - chr7 103,061,951 g.chr7:103,061,951 G>A  c.11 C>T p.A4V Missense Somatic  Neg 
TP53 
breast 
cancer CCDS11118.1 - 


























CCDS42475.1 + chr19 5,456,555 g.chr19:5,456,555 C>A  c.1053 C>A  p.C351X Nonsense Somatic  Neg 
BTBD9 MPNST CCDS47418.1 - chr6 38,565,849 g.chr6:38,565,849 G>A  c.22 C>T p.R8C Missense Somatic 
 N.A. 
EHBP1 MPNST CCDS1872.1 + chr2 63,101,527 g.chr2:63,101,527 T>G  c.1150 T>G  p.L384V Missense Somatic 
 N.A. 
OR10H3 MPNST CCDS12334.1 + chr19 15,852,420 g.chr19:15,852,420 T>C  c.218 T>C  p.L73P Missense Somatic 
 N.A. 
SAMD4A MPNST CCDS32084.2 + chr14 55,168,905 g.chr14:55,168,905 A>T  c.322 A>T  p.I107F Missense Somatic 
 N.A. 






Figure 2.3: The sequencing reads as shown in the Integrated Genome Viewer 
software shows an insertion present (denoted with magenta ‡ mark) in the breast 
cancer that is not present in the germline (blood) sample. 
 
Consistent with the fact that malignant tumors harbor more somatic mutations, the 
breast cancer and MPNST harbored 15 and 6 somatic mutations, respectively (Figure 
2.2, Table 2.2). In contrast, only one somatic mutation was detected in the dermal 
neurofibroma, a benign tumor (Figure 2.2). Interestingly, this in-frame deletion of 3 
nucleotides resulted in a loss of leucine at amino acid position 1876 in the NF1 gene 
(Table 2.2). Different somatic NF1 mutations (frameshift insertion in breast cancer 
(p.A985fs), missense mutation in MPNST (p.G23R), and inframe deletion in dermal 
neurofibroma (p.L1876del-Inf)) were detected in all three tumors investigated; 
suggesting the importance of second-hit aberration in NF1 for tumorigenesis. 
Several important and interesting mutations were identified in the 2 malignant tumors. 
The breast tumor harbored somatic mutations in TP53, GATA3 and ARID1A, which 
are commonly mutated or lost in breast cancer (Figure 2.2). Mutations in other cancer-
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associated genes such as MAGI3, TSC1, PTPN4, RAB3IP and RYR1 were also 
identified. Aberrant protein degradation may be important in this cancer, as 3 of the 
14 mutated genes (USP4, USP31 and ZNRF4) in the breast cancer are involved in 
the ubiquitin-proteasome pathway. In the MPNST, apart from the NF1 mutation, other 
mutations in cancer-associated genes such as EHBP1 and WNK3 were identified.  
Extensive copy number alterations detected in breast cancer and MPNST 
To determine the extent of chromosomal aberrations in the breast cancer, the MPNST 
and the dermal neurofibroma, we subjected the sequence data to our in-house 
modified ASCAT analysis. Extensive chromosomal aberrations were observed in the 
breast cancer and the MPNST samples. Unlike the profiles seen in the breast cancer 
and MPNST, the benign dermal neurofibroma genome is “silent”, indicating that the 
neurofibroma genome is highly stable (Figure 2.4).  
Gains and losses in several cancer-related genes were identified in the breast cancer 
and MPNST samples through ASCAT analysis (Supplementary Table S2.1). 
Consistent with a previous report on chromosomal aberrations in MPNST, losses were 
more common than gains in the MPNST on ASCAT analysis 18. Homozygous losses 
were found in CDKN2A and CDKN2B, which play important roles in cell cycle control, 
and in ARID4B, a chromatin remodeling gene. Heterozygous losses were observed in 
TP53 and EED, a component of the Polycomb repressive complex 2 (PRC2), which is 
reported to be frequently altered in a recent exome sequencing study on MPNSTs 14. 
Potential oncogenes amplified in the breast cancer include GREB1, NRXN1, MGAT5, 
PKP4, DAPL1, ITGB6 and RBMS1, which may be implicated in carcinogenesis, 
proliferation and invasion. A focal amplification of around 3 Mb in chromosome 2, 
containing the FXBO11 and MSH6 genes, was estimated to contain over 20 copies of 
the affected genes. We observed heterozygous loss of several cancer-associated 
genes, including the CTNNA1 (catenin (cadherin-associated protein), alpha 1) and 
APC tumour suppressor genes in the breast cancer. With the available DNA, we 
further confirmed our findings in the breast cancer and dermal neurofibroma using the 
Cytoscan platform from Affymetrix.  
 
68 
Figure 2.4: Analysis of copy number alterations in breast cancer (A), malignant 
peripheral nerve sheath tumor (MPNST) (B) and dermal neurofibroma (C), based on 
paired tumor and nontumor DNA analysis of exome sequencing data.  
Each red dot represents a genomic coordinate that was heterozygous in the germline sample. The 
breast cancer shows the most chromosomal rearrangements while the dermal neurofibroma shows 
none. Regions of allelic imbalance that also show a decrease in Log R typically represent Loss-of-
Heterozygosity (LOH); regions of allelic imbalance with no change in Log R show Copy-Number Neutral 
LOH, and regions of allelic imbalance that correspond with increased Log R correspond to either focal 
amplifications (for example, several loci in chromosome 2 of the breast cancer) or large-scale 
amplifications. The changes in Log R and allele frequency observed across multiple chromosomes in 
breast cancer and MPNST indicate allelic imbalance or copy number alterations in these samples, but 
not in the dermal neurofibroma. 
 
Using Cytoscan, copies gained were observed in a large region of chromosome 2 
(p25.1, p24.2, p21, q14.2, q21.2, q23.3, q24.3, q33.1, q36.1, q36.2, q36.3 and q37.2), 
chromosome 4 (p15.2), chromosome 15 (q22.2 and q24.2) and chromosome 17 (q12 
and q21.32), while loss of heterozygosity was observed in chromosomes 2, 4, 5, 10, 





Figure 2.5: both exome sequencing and Cytoscan HD SNP Array show LOH in chr17p 
for the breast cancer (both platforms) and the MPNST (only exome sequencing 
available). LOH is indicated by a drop in copy number coinciding with allelic imbalance. 
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Interestingly, we have identified loss of chromosome 6q22.33 (Figure 2.6) and gain of 
chromosome 14q32.33 in the DNA from the patient’s blood, breast cancer and dermal 
neurofibroma suggesting germline chromosomal aberrations. Two putative tumor 
suppressor genes, PTPRK and LAMA2, are among the 10 genes identified in the loss 
region of chromosome 6; these germline chromosomal alterations might predispose 




Figure 2.6: Cytoscan HD SNP Array analysis reveals a germline Loss-of-
heterozygosity event of around 3.3 Mbases at chr6q22.33 (indicated by dottedline) 





Whole exome sequencing of the blood, breast cancer, MPNST and dermal 
neurofibroma from this patient has provided invaluable insight into the somatic 
anomalies in this tumour predisposition syndrome. A striking feature is the finding of 
second-hit NF1 mutation at different sites of this gene in all the tumours sequenced, 
indicating that second-hit mutation of this tumour suppressor gene may be a critical 
event in pathogenesis. NF1 aberrations can potentially lead to activation of the Ras, 
MAP kinase and PI3K-mTOR pathways, resulting in proliferation of tumour cells 3,19. 
This is consistent with the findings of a previous study which reported different somatic 
NF1 alterations in multiple benign neurofibromas and a MPNST obtained post-mortem 
from an NF1 patient 20.  Denaturing High Performance Liquid Chromatography 
(dHPLC), microsatellite analysis using RFLP markers and multiplex ligation probe 
amplification (MLPA) for the NF1 gene were performed in that study 20. With whole 
exome sequencing, we have found that each tumour from the same individual also 
has a distinct set of genes mutated. The different clonal origins indicate that each 
tumour arises from independent somatic events in the background of a heterozygous 
germline NF1 mutation. 
Incidentally, we have also discovered germline loss, resulting in loss-of-heterozygosity 
of two potential tumour suppressor genes, PTPRK and LAMA2, both located at 
chromosome 6q22.33. PTPRK appears to be a negative regulator of adhesion, 
invasion, migration, and proliferation in various tumour types, including breast and 
colorectal cancers, gliomas, lymphoma and melanoma cells. It may play a role in 
inhibition of Akt, EGFR and beta-catenin signaling 21-25. LAMA2 encodes an 
extracellular matrix protein. Reduced LAMA2 expression in hepatocellular carcinomas 
has been linked to a proliferative signature with poorer survival outcomes; 
hypermethylation of LAMA2 has also been reported in colorectal carcinomas 26,27.  
While germline loss of PTPRK and LAMA2 may have been reported in the Database 
of Genomic Variants (http://dgv.tcag.ca/dgv/app/home) in a small number of 
individuals, the context in which they occur are not clear. We hypothesise that 
heterozygous loss of this region of chromosome 6q may increase tumour 
predisposition further in this NF1 patient. 
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The mutation landscape of breast cancer is highly heterogeneous. In this case of NF1-
associated breast cancer, mutations in the TP53, TSC1 and MAGI3 (PI3K/Akt/mTOR 
pathway) tumour suppressors are likely to cooperate with NF1 in carcinogenesis. In 
addition, alterations of genes critical in other pathways, such as ARID1A (SWI/SNF 
chromatin remodeling), GATA3 (differentiation of luminal breast cells), PTPN4 (anti-
apoptosis), RYR1 (control of cellular proliferation) and USP4, USP31, ZNRF4 
(ubiquitin-proteasome pathway) may be implicated in pathogenesis. The multiple copy 
number alterations detected also result in genomic instability. Gains in some of the 
genes involved in invasive/migratory properties (MGAT5, PKP4, ITGB6), cell cycle 
progression and regulation of apoptosis (RBMS1), and angiogenesis (NRXN1) may 
be involved in tumor development and progression. Amplification of GREB1, an early 
response gene in the estrogen receptor-regulated pathway, may play a role in this 
estrogen receptor positive tumour. 
The mechanism of pathogenesis for the MPNST is likely related to second-hit 
inactivation of NF1, together with mutations in other genes, such as WNK3 which plays 
a role in the increase of cell survival in a caspase-3-dependent pathway, and EHBP1 
which has been implicated in endocytic trafficking. A single nucleotide polymorphism 
in EHBP1 has been associated with an aggressive form of prostate cancer; it may be 
implicated in carcinogenesis or cell survival 28. Somatic loss of critical tumour 
suppressors including CDKN2A, CDKN2B, TP53 and EED are also likely to contribute 
to tumorigenesis. Aberrations in EED and SUZ12 occur frequently in sporadic, NF1-
associated and radiotherapy-associated MPNSTs 14-16. EED and SUZ12 are core 
subunits of PRC2; the resulting PRC2 inactivation can lead to loss of trimethylation at 
lysine 27 of histone H3 (H3K27me3), and increased H3K27 acetylation which recruits 
bromodomain proteins and transcription factors to promote tumour growth 14,16.  
 
The low mutation burden and lack of copy number changes in the dermal neurofibroma 
is consistent with the benign nature of this tumour. Each neurofibroma consists of a 
heterogeneous collection of hyperproliferative Schwann cells, as well as fibroblasts, 
perineural cells and mast cells 20. Although the second-hit somatic NF1 mutation in 
the Schwann cells may trigger the formation of a neurofibroma in an NF1-
haploinsufficient microenvironment, the precise molecular interactions among the 
different cells in the development of neurofibromas remain poorly understood.  
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Challenges remain in the detection of aberrations in NF1 gene. NF1 is one of the 
largest human genes, with 60 exons and 350kB of genomic DNA. While next 
generation sequencing platforms may facilitate the simultaneous sequencing of the 
various exons, it may not capture intronic splicing mutations; analysis to detect 
aberrations and validation of mutations can pose a major challenge. Design of primers 
to validate the mutations detected with next generation sequencing can be 
complicated and not feasible at certain sites along the large gene, due to the presence 
of multiple pseudogenes in the human genome8. 
In summary, second-hit inactivation of NF1 appears to be a common feature of various 
tumours in NF1 syndrome. However, the complexity of the pathogenesis of various 
tumours remains to be elucidated. Besides loss of NF1 function, additional aberrations 
in other important cancer related genes involving various pathways lead to the 
development of specific tumours. Further investigations on additional tumour 
specimens from more NF1 patients will improve our understanding of the mechanisms 
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2.7 Supplementary data 
 
Supplementary Table S2.1: the estimated copy number for various 
 cancer-related genes, based on comparing the read-depth coverage of the tumour 
 sample to the matched non-malignant sample. Segmentation and copy-number 






Supplementary Table S2.2: the estimated copy number for genes with gains or 
losses as detected by the Chromosome Analysis Suite software from Affymetrix for 









Breast cancer in women with neurofibromatosis type 
1 (NF1) – a comprehensive case series with 
molecular insights into its aggressive phenotype  
 
3.1 Abstract 
This study aimed to improve the understanding of NF1-associated breast cancer, 
given the increased risk of breast cancer in this tumour predisposition syndrome and 
the limited data. We identified 18 women with NF1 and breast cancer at our institution. 
Clinical and pathologic characteristics of NF1-associated breast cancers were 
compared with 7132 breast cancers in patients without NF1 from our institutional 
database.  
Next generation sequencing was performed on DNA from the blood and breast cancer 
specimens available from the 18 NF1 patients. When this did not detect germ-line NF1 
mutations, multiplex ligation-dependent probe amplification (MLPA) was used to 
identify if there were complete/partial deletions or duplications of the NF1 gene. 
Expression of neurofibromin in the NF1-associated breast cancers was evaluated 
using immunohistochemistry.  
There was a higher frequency of grade 3 (83.3% vs 45.4%, p=0.005), oestrogen 
receptor (ER) negative (66.7% vs 26.3%, p<0.001) and human epidermal growth 
factor receptor 2 (HER2) positive (66.7% vs 23.4%, p<0.001) tumours among NF1 
patients compared to non-NF1 breast cancers. Overall survival was inferior in NF1 
patients in multivariable analysis (hazard ratio 2.25, 95% CI, 1.11 to 4.60; p = 0.025).  
Apart from germline NF1 mutations (11/16 detected; 69%), somatic mutations in TP53 
(8/10; 80%), second-hit NF1 (2/10; 20%), KMT2C (4/10; 40%), KMT2D (2/10; 20%), 
and PIK3CA (2/10; 20%) were observed. Immunohistochemical expression of 
neurofibromin was seen in the nuclei and/or cytoplasm of all specimens, but without 
any consistent pattern in its intensity or extent. This comprehensive series of NF1-
associated breast cancers suggests that their aggressive features are related to 




3.2 Introduction  
 
Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a 
relatively common genetic disorder with a prevalence of 1 in 2,500 to 3,000 individuals 
worldwide. While the condition is inherited in an autosomal dominant fashion, about 
half of the cases are sporadic, that is, without any family history 1,2. Characterized by 
the development of multiple neurofibromas, café-au-lait spots and Lisch nodules, 
individuals with NF1 are at increased risk of developing benign and malignant tumours 
in addition to a range of abnormalities in the neurological, cardiovascular and 
musculoskeletal systems 3. The average life expectancy among individuals with NF1 
is reduced by 10-15 years, with cancer being the most common cause of death 4.  
 
This tumour predisposition disorder is related to germline aberrations in the NF1 gene 
on the long arm of chromosome 17. Its product neurofibromin has a central region 
which has marked structural and sequence similarity to ras-guanosine-
triphosphate(GTP)ase activation  proteins (GAPs). GAPs inactivate Ras by 
accelerating the conversion of active Ras- guanosine triphosphate (GTP) to its inactive 
guanosine diphosphate (GDP)-bound form 5,6.  The downregulation of Ras by 
neurofibromin prevents the downstream activation of the mitogen-activated protein 
kinase (MAPK) and PI3K/Akt/mTOR (mammalian target of rapamycin) cell 
proliferation and differentiation pathways. In addition, other mechanisms of tumour 
suppression include promotion of apoptosis, regulation of cell adhesion and motility 
as well as suppression of heat shock protein and epithelial mesenchymal transition 3.  
 
The classic NF1-associated tumours include malignant peripheral nerve sheath 
tumours (MPNSTs), optic  pathway  gliomas, rhabdomyosarcomas,  neuroblastomas,  
juvenile myelomonocytic  leukaemias,  gastrointestinal  stromal  tumour (GIST) and 
phaeochromocytomas 7. More recently, an increased risk of breast cancer has also 
been reported. In the first such study reported by Sharif et al in 2007, within a cohort 
of 304 women with NF1 in north-western region of England, there were 14 cases of 
breast cancers over the follow-up period from 1975-2005. The overall standardized 
incidence ratio (SIR) was 3.5 (95% CI 1.9-5.9), but the SIR was as high as 4.9 (95% 
CI 2.4-8.8) for women aged <50 years 8. In a subsequent study from the metropolitan 
Detroit area, 9 out of 76 women with NF1 developed breast cancer over the period 
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from 1990 to 2009.  The overall SIR was 5.2 (95% CI 2.4-9.8), but this relative increase 
was even higher for women with NF1 under the age of 50 years, with SIR 8.8 (95% CI 
3.2-19.2) 9. Subsequent studies by various groups have generally supported these 
findings, namely an increased risk of breast cancer among women with NF1 compared 
to the general population, with an even higher risk among younger women 10-12. The 
largest study identified 58 cases of breast cancer among 3672 women with diagnosis 
of NF1 admitted to National Health Service hospitals in England over the period 1999-
2011. The relative risk compared to the control cohort decreased with increasing age: 
6.5 among women aged 30-39 years, to 4.4 in the 40-49 year age group, 2.6 in the 
50-59 age group, 1.9 in the 60-69 year age group, and 0.8 in the 70-79 year age group 
11. Breast cancer is now recognized as one of the NF1-related malignancies, hence 
NF1-associated breast cancer is not just a random set of sporadic breast cancers. 
NF1 has been unequivocally identified as a breast cancer susceptibility gene which 
confers moderate risk of breast cancer 13.  
 
The clinical and molecular data on NF1-associated breast cancer is currently limited. 
We previously presented our preliminary findings on the aggressive nature and high 
frequency of HER2 overexpression of breast cancers in women with NF1 14.  We 
hypothesized that compared to sporadic breast cancers, NF1-associated breast 
cancers are more aggressive with a higher risk of poor prognostic features as well as 
inferior outcomes. In this study, we aimed to further characterise the molecular profile 
of NF1-associated breast cancers. Clinical and pathologic characteristics of NF1-
associated breast cancers were compared with non-NF1 breast cancers at our 
institution. Next generation sequencing was performed on DNA from blood and breast 
cancer specimens available, and the expression of neurofibromin in the breast 






Patients with both NF1 and breast cancer were identified retrospectively from hospital 
records as well as prospectively by the candidate YSY when managed at National 
Cancer Centre Singapore (NCCS) and Singapore General Hospital (SGH). All women 
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had histologically proven breast cancer and fulfilled at least 2 of the 7 criteria 
developed by the NIH Consensus Conference for clinical diagnosis of NF1. Each 
patient, with the exception of deceased patients, provided written informed consent 
prior to study entry. The study design was conceived by the candidate, who also 
obtained funding for the study. The study protocol was approved by the Singapore 
Health Services (SingHealth) institutional review board. 
 
Details on patient demographics, tumour grade, stage, receptor status and clinical 
outcome were evaluated by the candidate from medical records; majority of the 
patients were managed by the candidate. The pathological characteristics of NF1-
associated breast cancers were compared to 7132 breast cancers in patients without 
NF1 captured in our breast cancer tumour board database over a similar period from 
2001-2016, with a focus on grade and HER2 positivity rate. For patients with 
metachronous bilateral breast cancer, only the first cancer was included. For patients 
with synchronous bilateral breast cancer, the tumour with the higher stage was 
included. If both tumours were the same stage, the patient was excluded from the 
analysis.  
 
Oestrogen receptor (ER) and progesterone receptor (PR) status was considered 
positive with a minimum of 1% of cells staining positive 15. Human epidermal growth 
factor receptor 2 (HER2) positivity was defined as 3+ immunohistochemical staining 
in more than 10% of cells, or HER2 positivity on fluorescence in situ hybridization 
(FISH) testing as per latest guidelines 16. 
 
Statistical Analyses 
Tumour characteristics were compared between NF1 and non-NF1 (control) breast 
cancers using Fisher’s exact test (for categorical variables) and Mann-Whitney U test 
(for continuous variables). Overall survival (OS) was defined as time from diagnosis 
to death from any cause. Survival curves were estimated using the Kaplan-Meier 
method and compared using the log-rank test. Median follow-up time was estimated 
using the reverse Kaplan-Meier method. Univariable and multivariable analyses were 
performed using the Cox regression model. The proportional hazards assumption was 
assessed graphically by plotting the log-log survival curves. All analyses were 
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performed in Stata (version 14, StataCorp, Texas, USA). Two-sided p-values less than 
0.05 were considered statistically significant. 
 
Targeted sequencing 
Germline DNA was extracted from peripheral blood while tumour DNA was obtained 
from fresh, frozen samples or formalin-fixed paraffin-embedded (FFPE) blocks 
containing at least 60% of tumour nuclei using QiaAmp DNA mini kit (Qiagen, 
Valencia, CA, USA), according to the manufacturer’s instructions. DNA was extracted 
from the blood and the fresh frozen specimens by the candidate and the team at 
Laboratory of Molecular Oncology, Division of Medical Sciences, National Cancer 
Centre Singapore while DNA from FFPE tumour specimens was extracted by the 
Singapore General Hospital Pathology Department, who also assisted with 
assessment of tumour content and marking of the tumour specimens.  
 
Sequencing libraries were prepared from genomic DNA using the Kapa Hyper Prep 
kit, and captured using the IDT Xgen 127-gene Pan-cancer panel, or using the 
SureSelect XT2 target enrichment kit (Agilent, Santa Clara, CA, USA) for a customised 
panel of 338 genes as previously reported 17 (Supplementary Table S1 for gene 
panels), all following manufacturers' instructions. Quality control and library 
preparation were performed by collaborators at the Laboratory of Molecular Oncology, 
Division of Medical Sciences, National Cancer Centre Singapore for the specimens 
captured with the SureSelect XT2 panel, and by collaborators at Genome Institute of 
Singapore, A*STAR, Singapore, for the IDT Xgen 127-gene Pan-cancer panel. 
Libraries were pooled and sequenced at sequencing facilities in A*STAR, Singapore 
with a 150bp paired-end run on an Illumina Miseq for the samples captured with the 
IDT Xgen panel, and on the Illumina Hiseq 4000, with 100bp paired end reads for the 
samples captured with the SureSelect XT2 panel. Whole exome sequencing was 
performed on one of the matched tumour-blood specimens as published previously 18. 
 
MLPA 
Blood specimens which tested negative for NF1 mutations were subjected to multiplex 
ligation-dependent amplification (MLPA) to detect single and multi-exon NF1 gene 
copy number variations, using the test kits (SALSA MLPA P122 NF1-area probemix) 
and SALSA MLPA P082 NF1-mix2 probemix (MRC Holland, Amsterdam, Netherlands) 
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19 .  MLPA was performed by the candidate and the collaborators at the Laboratory of 
Molecular Oncology, Division of Medical Sciences, National Cancer Centre Singapore 
As previously described 17, DNA fragment analysis was performed on the ABI 3130 
Genetic Analyzer (ABI-Life Technologies, Thermo Fisher Scientific Corporation, MA, 
USA), and analysed with the Coffalyser freeware v.131123.1303 (MRC-Holland).  
 
Sequencing Data Analysis 
Sequencing reads were aligned to the human reference genome hg19 using BWA 
tool, and PCR duplicates were removed using Picard tool 
(http://broadinstitute.github.io/picard/). SNPs and indels were called using the 
Genome Analysis Toolkit (GATK) HaplotypeCaller algorithm 20. After examining the 
sequencing coverage, samples with mean read depth coverage of < 50x were 
excluded from further analysis. Manual curation using the Integrative Genomics 
Viewer (IGV) was also conducted. Variants detected were annotated using the 
ANNOVAR tool 21 and those identified with minor allele frequency (MAF) > 1% in all 
populations from publicly available databases such as the 1000 Genomes project 22 
and ExAC 23 were excluded. Variants were considered pathogenic if they were 
frameshift insertions or deletions, stop gain (nonsense) or splice site changes. For 
missense variants, pathogenicity was  predicted with the use of  the following tools: 
SIFT 24, PolyPhen-2 25, MutationTaster 26, MutationAssessor 27 and CADD 28. A 
pathogenicity score was calculated using all five functional prediction tools, and 
considered pathogenic if at least one of the five tools classified the variants as being 
deleterious.  Pipeline analysis was performed by the collaborating bioinformatician 
from the Laboratory of Molecular Oncology at the Division of Medical Sciences, with 
the candidate and the co-supervisor Associate Professor Ann Lee for the interpretation 
of the results. 
 
Immunohistochemistry 
Collaborators from the Pathology department at Singapore General Hospital were 
involved in this part of the study. The sections (4µm) were cut from tissue blocks, 
mounted on Leica BOND Plus slides (Leica Biosystems, Richmond, IL, USA) and dried 
on heating bench for 20 minutes.  Immunohistochemical procedure was performed 
using the Leica Bond Autostainer (Leica Biosystems, Mt. Waverley, VIC, Australia). 
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The sections were deparaffinised and pretreated using bond dewax reagents and 
Bond Epitope Retrieval Solution 2 (Leica Biosystems, Newcastle Upon Tyne, UK) of 
pH 8.9 to 9.1. Endogenous peroxidase activity was blocked using hydrogen peroxide 
for 5 minutes followed by NF1 primary antibody (ab30325, 1:300 dilution; Abcam, 
Cambridge, UK) incubation for 20 minutes.  The sections were then treated with post 
primary and polymer reagents followed by mixed DAB refine reagent. The detection 
system used was Bond Polymer Refine (Leica Biosystems, Newcastle Upon Tyne, 
UK).  The sections were counterstained with haematoxylin and the slides were 
unloaded from the system, then dehydrated and mounted in DPX (CellPath, Newtown, 
UK). For immunoscoring, the staining intensity (nil, weak (1+), moderate (2+), strong 
(3+)) and the proportion of tumour cells stained in the nuclei as well as the cytoplasm 
were recorded. Tonsillar tissue, which is known to express low neurofibromin protein 
within the germinal centres (https://www.proteinatlas.org/ENSG00000196712-





Clinicopathological characteristics of NF1-associated breast cancers 
We identified 18 patients with NF1 and breast cancer managed at our institutions from 
2000 to 2016 (Table 3.1). Median age of breast cancer diagnosis was 49.5 years 
(range 30-75 years). All 18 women had invasive ductal carcinoma but one of them was 
also diagnosed with an incidental synchronous contralateral invasive lobular 
carcinoma. Seven of the patients (38.9%) had stage 3 or 4 breast cancer at diagnosis. 
Fifteen out of 18 tumours or 83.3% were grade 3, compared to 45.4% among our non-
NF1 controls (p=0.005) (Table 3.2). The majority (12 of 18, 66.7%) of the NF1-
associated breast cancers were HER2 positive, compared to 23.4% in controls 
(p<0.001). Of the remaining NFI-associated tumours, four were triple negative, and 
two were hormone receptor positive and HER2 negative. NF1-associated cancers 
were also more likely to be oestrogen receptor (ER) negative (66.7% versus 26.3%; 
p<0.001) and progesterone receptor (PR) negative (66.7% versus 37.8%; p=0.015) 
than controls.  
 
To date, 6 out of 16 patients with stage 1-3 breast cancer (37.5%) have relapsed, all 
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of whom had HER2+ tumours. Five-year overall survival (OS) was 69.6% (95% CI, 
41.0 to 86.4%) in the NF1 group, and 84.5% (95% CI, 83.4 to 85.5%) in the control 
group of non-NF1 breast cancers (p = 0.017). As tumour grade, stage and subtype 
were predictive of OS in univariate analysis (Table 3.3) but did not adhere to the 
proportional hazards assumption, multivariable analysis was performed using a Cox 
model stratified on these variables. Age at diagnosis was included as a covariate in 
the model. The resulting hazard ratio for NF1 vs. controls was 2.25 (95% CI, 1.11 to 
4.60; p = 0.025) (Table 3.4).  
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2 32 Chinese 2 (T2N0M0) 3 IDC - - - TNBC ND + Nil NA 
Adjuvant doxorubicin 
and cyclophosphamide  
NA 
































5 44 Chinese 2 (T1N1M0) 3 IDC - - + HER2 p.L847P - Nil 58 
Adjuvant doxorubicin 
cyclophosphamide; 










1, PI3K inhibitor 
(clinical trial) 
125 
6 44 Indian 1 (T1N0M0) 3 IDC - - + HER2 p.Y489C - Nil 24 
Declined adjuvant 
systemic treatment 




















































+ Nil NA 
Adjuvant doxorubicin 
cyclophosphamide, 
followed by paclitaxel, 
letrozole 
NA 
12 54 Chinese 1 (T1N0M0) 3 IDC - - + HER2 ND + Nil NA Nil NA 







14 60 Chinese 3 (T3N1M0) 3 IDC - - - TNBC p.R461X - Nil NA 
Adjuvant doxorubicin 
cyclophosphamide, 
followed by paclitaxel  
NA 
15 62 Chinese 3 (T2N2M0) 3 IDC - - - TNBC ND + Nil NA 
Adjuvant doxorubicin 
cyclophosphamide, 
followed by paclitaxel  
NA 


































IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; TNBC: triple negative breast cancer; Luminal: ER/PR+HER2-; HER2: HER2+ regardless of ER/PR; NE: not evaluated; ND: not 




Table 3.2: Comparison of NF1-associated and non-NF1 (control) breast cancers. 
 Controls, n (%)a NF1-associated, n (%)a p-valueb 
    
Histological subtype    
 Ductal  6189 (86.8) 18 (100) - 
 Lobular 366 (5.1) 0  
 Other 577 (8.1) 0  
     
Age at diagnosis, years    
 Median (range) 54 (21 – 97) 49.5 (30 – 75) 0.138 
 Unknown 2 0  
    
Tumour grade    
 1 1022 (15.2) 0 0.005 
 2 2637 (39.3) 3 (16.7)  
 3 3043 (45.4) 15 (83.3)  
 Unknown 430 0  
    
T stage    
 1 3258 (45.8) 4 (22.2) 0.044 
 2 2836 (39.8) 8 (44.4)  
 3 540 (7.6) 3 (16.7)  
 4 472 (6.6) 3 (16.7)  
 X 15 (0.2) 0  
 Unknown 11 0  
    
N stage    
 0  4123 (58.0) 7 (38.9) 0.193 
 1 1730 (24.3) 8 (44.4)  
 2 711 (10.0) 2 (11.1)  
 3 506 (7.1) 1 (5.6)  
 X 44 (0.6) 0  
 Unknown 18 0  
    
M stage    
 0 6834 (95.9) 16 (88.9) 0.166 
 1 290 (4.1) 2 (11.1)  
 X 2 (0.03) 0  
 Unknown 6 0  
    
Stage    
 I 2548 (35.7) 2 (11.1) 0.054 
 II 2756 (38.6) 9 (50.0)  
 III 1538 (21.6) 5 (27.8)  
 IV 290 (4.1) 2 (11.1)  
    
ER status    
 Negative 1867 (26.3) 12 (66.7) <0.001 
 Positive 5219 (73.6) 6 (33.3)  
 Equivocal 8 (0.1) 0  
 Unknown 38 0  
    
PR status    
 Negative 2676 (37.8) 12 (66.7) 0.015 
 Positive 4395 (62.1) 6 (33.3)  
 Equivocal 6 (0.1) 0  
 Unknown 55 0  
    
HER2 status    
 Negative 4748 (68.3) 6 (33.3) <0.001 
 Positive 1623(23.4) 12 (66.7)  
 Equivocal 577 (8.3) 0  
 Unknown 184 0  
    
Triple negative    
 No 6180 (88.6) 14 (77.8) 0.141 
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 Controls, n (%)a NF1-associated, n (%)a p-valueb 
 Yes 792 (11.4) 4 (22.2)  
 Unknown 160 0  
    
Breast cancer subtype    
 ER/PR positive, HER2 
negative 
3951 (62.1) 2 (11.1) <0.001 
 HER2 positive 1623 (25.5) 12 (66.7)  
 Triple negative  792 (12.4) 4 (22.2)  
 Unknown 766 0  
    
a Unknown data were excluded from calculation of percentages. 
b Unknown / X / Equivocal data were excluded from Fisher’s exact test. 
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Table 3.3: Univariable analysis of overall survival. 
Variable No. of events / 
No. of patients 









Overall 1073 / 6759 15.9 (12.1, UD) NA NA NA 
      
NF1 status      
 Controls 1065 / 6741 15.9 (12.1, UD) 0.017 1 0.041 
 NF1 8 / 18 7.7 (4.7, UD)  2.29 (1.13, 4.61)  
      
Age at diagnosis, 
years 
1073 / 6759 NA NA 1.04 (1.03, 1.04) <0.001 
      
Tumour grade      
 1 70 / 942 15.9 (UD) <0.001 1 <0.001 
 2 296 / 2477 13.5 (12.1, UD)  1.83 (1.41, 2.38)  
 3 569 / 2933 Not reached  3.16 (2.46, 4.06)  
       
T stage      
 1 210 / 3027 15.9 (13.5, UD) <0.001 1 <0.001 
 2 435 / 2721 Not reached  2.50 (2.12, 2.95)  
 3 160 / 523 10.0 (9.7, UD)  5.37 (4.37, 6.59)  
 4 249 / 462 4.6 (4.0, 5.1)  10.98 (9.13, 13.21)  
      
N stage      
 0  331 / 3834 15.9 (13.5, UD) <0.001 1 <0.001 
 1 326 / 1669 12.1 (11.1, UD)  2.34 (2.01, 2.73)  
 2 172 / 698 10.4 (9.9, UD)  2.97 (2.47, 3.57)  
 3 194 / 496 7.2 (6.5, 8.2)  5.20 (4.36, 6.22)  
      
M stage      
 0 894 / 6468 15.9 (13.5, UD) <0.001 1 <0.001 
 1 177 / 283 3.1 (2.9, 3.6)  7.98 (6.78, 9.39)  
      
Stage      
 I 125 / 2332 15.9 (13.5, UD) <0.001 1 <0.001 
 II 312 / 2640 Not reached  2.35 (1.91, 2.90)  
 III 456 / 1504 10.0 (8.8, UD)  6.29 (5.16, 7.67)  
 IV 180 / 283 3.0 (2.7, 3.4)  22.92 (18.21, 
28.86) 
 
      
ER status      
 Negative 425 / 1799 13.5 (10.6, UD) <0.001 1 <0.001 
 Positive 636 / 4915 15.9 (12.1, UD)  0.53 (0.47, 0.60)  
      
PR status      
 Negative 552 / 2565 12.1 (10.6, UD) <0.001 1 <0.001 
 Positive 508 / 4137 Not reached  0.52 (0.46, 0.58)  
      
HER2 status      
 Negative 660 / 4475 15.9 (12.1, UD) 0.002 1 0.003 
 Positive 277 / 1557 13.5 (11.1, UD)  1.25 (1.08, 1.43)  
      
Triple negative      
 No 835 / 5838 15.9 (13.5, UD) <0.001 1 <0.001 
 Yes 203 / 766 11.2 (10.6, UD)  2.16 (1.86, 2.52)  
      
Subtype      
 ER/PR positive, 
HER2 negative 
456 / 3704 15.9 (12.1, UD) <0.001 1 <0.001 
 HER2 positive 277 / 1557 13.5 (11.1, UD)  1.53 (1.32, 1.78)  
 Triple negative 203 / 766 11.2 (10.6, UD)  2.50 (2.12, 2.95)  
      
UD, undefined. Note: Non-proportional hazards were observed for tumour grade, T, N, M stage, overall stage, ER, 
PR status and breast cancer subtype. 
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Table 3.4: Multivariable analysis of overall survival. 
 
Variable Hazard ratio (95% CI) p-value 
   
NF1 status   
 Controls 1 0.025 
 NF1 2.25 (1.11, 4.60)  
   
Age at diagnosis, 
years 
1.03 (1.03, 1.04) <0.001 
   
Model was stratified by tumour grade (2 vs. 3), breast 
cancer stage (I / II / III vs. IV) and breast cancer subtype 
(ER / PR / HER2 positive vs. triple negative). 








Next-generation sequencing (NGS) was performed on DNA extracted from peripheral 
blood with matched tumour DNA available for 16 patients (Figure 3.1, Supplementary 
Table 3.2). Ten out of 16 unique tumour samples passed quality control metrics with 
mean coverage of at least 50x, and were included in analysis of somatic mutations 
with the matched normal specimens. The pathogenicity of the variants were examined 
using in silico prediction tools, and variants predicted to be deleterious by at least one 
of the tools were identified (Supplementary Table 3.2).  
 
 
Figure 3.1: Oncoplot showing germline and somatic mutations in 10 NF1-associated 
breast cancers  
 
 
We detected 10 different NF1 germline mutations in 11 out of 16 (69%) patients. These 
comprised 3 missense variants (p.Y489C; p.L847P in 2 patients; p.Q1447H), 3 
nonsense variants (p.R461*; p.Q2245*; p.Y2285*), 3 frameshift deletions (p.S2093fs; 
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p.T2284fs; p.Q2686fs) and one in-frame deletion variant (p.1446_1451del) (Table 3.1; 
Figure 3.1; Supplementary Table 3.2). We did not identify any complete/partial 
deletions or duplications of NF1 with MLPA on the blood specimens negative for NF1 
mutation.  
 
Mutations in TP53 were observed in 8 out of 10 tumours (80%), all of which were 
pathogenic. We identified somatic “second-hit” NF1 mutations (p.P678Pfs, 
c.3974+46_3974+47insG) in 2 of 10 patients (20%).  In addition, somatic mutations 
were observed in KMT2C (40%), KMT2D (20%), and PIK3CA (20%) (Figure 3.1). 
Additional germline and somatic mutations were identified are listed in Supplementary 
Table 3.2. 
 
The publicly available METABRIC breast cancer data 29,30 was reviewed to further 
explore the role of NF1 and TP53 alterations in sporadic breast cancers (Figure 3.2). 
Of the 2369 cases in the METABRIC dataset with sequence information, the frequency 
of NF1 mutations was 4% (92/2369) overall, with no significant differences in 
frequency among the four different subtypes (hormone receptor (HR)-HER2+, triple 
negative, HR+HER2+ and HR+HER2- subtypes). However, when we included both 
NF1 mutations and deletions (homozygous or heterozygous), the frequency of 
alterations in NF1 was increased to 29% (590/2051) in unselected breast cancer 
cases, and was as high as 50% (146/292) in triple negative and 48% (62/130) in HR-
HER2+ subtypes, followed by the HR+HER2+ subtype at 39% (41/105). Notably, the 
frequency of NF1 alterations was significantly higher in HR-HER2+ and triple negative 
tumours compared to the HR+HER2- subtype at 21% (280/1344) (p<0.001) (Figure 
3.2).  
 
Remarkably, mutations of TP53 frequently co-exist with NF1 mutations in unselected 
sporadic breast cancers (p=0.041) (Figure 3.2). Co-existence of mutations in NF1 and 
KMT2C was also observed (p=0.004). Moreover, the co-occurrence of alterations in 
NF1 and TP53 (p<0.001) as well as in NF1 and KMT2C (p=0.006) remained 
statistically significant when both deletions and mutations were included.
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Figure 3.2: Frequency and co-existence of mutations and deletions in the NF1, TP53 and KMT2C genes in (a) unselected breast 
cancers, (b) ER-negative, PR-negative, HER2-positive breast cancers , (c) triple negative breast cancers, (d) hormone receptor positive 
and HER2 positive breast cancers, (e) hormone receptor positive and HER2 negative breast cancers from the METABRIC database. 
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Immunohistochemical expression of neurofibromin  
Immunohistochemical staining for neurofibromin was observed in the nuclei and/or 
cytoplasm of all 14 breast tumour specimens examined, although the percentage 
staining positive varied from 0% to 100% in either nuclei or cytoplasm (Table 3.5). We 
did not find complete loss of neurofibromin expression in any of the specimens, 
including 2 of the specimens which had somatic NF1 mutations (Figure 3.3). In 
summary there was no obvious pattern in the immunohistochemical expression of 
neurofibromin based on NF1 mutation or ER, PR, HER2 status. 
 
Table 3.5: Immunohistochemical expression of neurofibromin 
 Nuclear Staining (%) Cytoplasmic Staining (%)  
Patient 
ID 
1+ 2+ 3+ Total% 1+ 2+ 3+ Total% Subtype 
1 10 5 0 15 0 0 0 0 HER2 
2 85 10 0 95 5 0 0 5 TNBC 
3 5 0 0 5 20 0 0 20 HER2 
5 10 5 0 15 20 5 0 25 HER2 
7 60 15 0 75 10 0 0 10 Luminal 
8 20 70 0 90 0 0 0 0 HER2 
9 45 15 0 60 10 0 0 10 HER2 
10 10 0 0 10 35 0 0 35 HER2 
11 70 25 5 100 0 0 0 0 Luminal 
12 0 0 0 0 5 0 0 5 HER2 
13 5 0 0 5 5 0 0 5 HER2 
15 70 20 0 90 10 0 0 10 TNBC 
16 25 40 20 85 30 0 0 30 HER2 








Figure 3.3: Immunohistochemical expression of neurofibromin in 2 breast cancer 
specimens with somatic second-hit NF1 mutations: (a): Patient 3 (NF1 mutations: 
germline p.L847P; somatic p.P678fs); (b): Patient 15 (NF1 mutations: germline - not 





The breast tumours in individuals with genetic predisposition disorders often have 
distinctive features, related to the underlying germline genetic defect (Table 3.6) 12,31-
40. In NF1, the breast cancers appear to be more aggressive than sporadic cancers, 
with a higher frequency of high grade tumours, hormone receptor negativity and HER2 
overexpression (Table 3.6).  
 
Table 3.6: Breast cancer characteristics (ER, PR, HER2) in breast cancer 
predisposition syndromes 
Only the relative frequencies of the different subtypes from selected larger case series or studies are 
presented here, with the prominent features highlighted in bold.  
Gene 
affected 
Frequency of ER,PR, HER2 in invasive breast carcinomas References 
BRCA1 Triple negative 61%; ER+ 25%, PR+ 16%, HER2+ 7% 
Triple negative 69%; ER+ 22%, PR+ 21%, HER2+ 10% 
31 
32 
BRCA2 Triple negative 10%; ER+ 85%, PR+ 79%, HER2+ 11% 
Triple negative 16%; ER+ 77%, PR+ 64%, HER2+ 13% 
31 
32 
TP53 Triple negative 0%; ER+ 67%, PR+ 58%, HER2+ 83% 
ER-HER2- 5%; ER+ 84%, PR+ 72%, HER2+ 63% 






ER+ 79%, PR+ 68%, HER2+ 23% 
ER+ 88%, PR+ 72%, HER2+ 21% 






Triple negative 55%; ER and/or PR+HER2- 41%, HER2+ 5%  
Triple negative 30%; ER+ 74% 
39 
40 
NF1 Triple negative 22%; ER- 67%, PR- 67%, HER2+ 67% 




This is the first study to incorporate the clinical, pathological and genomic 
characteristics of NF1-associated breast cancer in a comprehensive manner. To date, 
there has been little data in the literature on breast cancer in NF1 patients. However, 
a recent publication based on data from the Finnish Cancer and NF Registry 12 
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supports our earlier finding 14. Similar to our findings, it reported a higher frequency of 
unfavourable prognostic features among 26 breast cancer cases, including HER2 
amplification, hormone receptor negativity, higher grade and larger tumour size, 
compared to matched controls in the general population (Table 3.6) 12.  Combining the 
grade, ER, PR and HER2 information from our 18 cases with the 26 cases reported 
by Uusitalo et al 12, out of total of 44 NF1-associated breast cancers, 66% (29/44) are 
grade 3, 59% (26/44) are ER negative, 66% (29/44) are PR negative, and 45% (20/44) 
are HER2 positive. Similar to our study, survival outcomes were also worse than the 
sporadic cancers 12. Although the number of patients in our comprehensive case 
series is limited, all patients who relapsed or died from breast cancer had HER2 
positive disease. Moreover, HER2-directed therapies and cytotoxic therapies appear 
to have limited efficacy in these patients from our experience (Table 3.1). Both patients 
with de novo stage 4 HER2 positive breast cancer died within 6 months of diagnosis 
in spite of taxane and trastuzumab combination treatment; two out of three stage 3 
HER2 positive tumours relapsed while on maintenance trastuzumab. These findings 
strongly suggest that haploinsufficiency of NF1, a critical tumour suppressor gene, 
contributes to treatment resistance and suboptimal tumour control with standard 
therapies, resulting in inferior cancer survival outcomes. 
 
To elucidate any other therapeutic targets for treating NF1-associated breast cancers, 
next generation sequencing was performed on matched blood and tumour specimens. 
In addition to detection of the underlying germline NF1 mutations, germline variants in 
other cancer-related genes were also detected in our series of patients. A study which 
focused on germline genomic profiling of 14 women with NF1 and breast cancer by 
Wang et al did not find deleterious mutations in other high/moderate-penetrance 
breast cancer genes (ATM, BRCA1, BRCA2, BARD1, BRIP1, CDH1, CHEK2, FANCC, 
MRE11A, NBN, PALB2, PTEN, RAD50, RAD51C, TP53, and STK11), but discovered 
25 rare or common variants in other cancer related genes 41. It is possible that these 
variants may contribute to increasing the risk of breast cancer in women with NF1.  
A striking finding from the somatic profiling in our study is the detection of deleterious 
TP53 mutations in 80% of the tumours. This is consistent with the hypothesis that 
cooperation between NF1 and TP53 can trigger carcinogenesis, and result in the 
development of aggressive biology. The co-existence of NF1 and TP53 mutations has 
100 
 
also been observed in other sporadic tumours such as glioblastomas, melanomas and 
ovarian carcinomas 3,42-45, in addition to the sporadic breast cancers from the 
METABRIC dataset (Figure 3.2).  
Apart from TP53 mutations, NF1 mutations may cooperate with mutations in other 
genes such as KMT2C, in the pathogenesis of these NF1-associated breast tumours. 
Mutations or alterations in NF1 also frequently co-exist with KMT2C mutations or 
alterations in breast cancers from the METABRIC database (Figure 3.2).   KMT2C 
(Lysine Methyltransferase 2C), also known as MLL3, is a member of the histone lysine 
methyltransferase family. It is frequently altered in various cancers, and increasing 
evidence supports its role as a tumour suppressor 46. KMT2C encodes a DNA-binding 
protein that methylates histone H3 lys4 (H3K4), leading to an open chromatin structure 
with activation of target gene expression 46. In acute myeloid leukaemia, a recent study 
demonstrated that haploinsufficiency in MLL3, together with NF1 suppression and 
TP53 deficiency, promoted leukaemogenesis in mouse and human systems. 
Interestingly, these leukaemias were refractory to conventional chemotherapy, but 
sensitive to JQ1, a BET (bromodomain and extra-terminal) inhibitor 47. A number of 
studies have also reported that somatic mutations, losses or reduced expression of 
KMT2C were associated with inferior survival outcomes in breast cancer 48-50. 
Review of the publicly available METABRIC breast cancer data 29,30(Figure 3.2) 
showed that NF1 aberrations are more frequent in HR negative HER2 positive and 
triple negative tumours compared to HR positive HER2 negative tumours.  Importantly, 
the presence of inactivating mutations in NF1 was associated with inferior breast 
cancer-specific survival among ER negative tumours in this METABRIC dataset 
(hazard ratio 2.7; CI: 1.3-5.5) 30. A recent study on the genomic evolution of breast 
cancer metastases also reported that NF1 mutations were significantly enriched in the 
metastatic specimens 51, in keeping with the important role that NF1 plays in breast 
cancer pathogenesis and progression. 
One of the limitations of our study is the inability to evaluate copy number aberrations, 
since fresh tissue specimens were not available for the majority of patients. The 
detection of mutations in NF1 can also be challenging, even with next generation 
sequencing. Apart from its large size with 60 exons spanning over 350kb, the NF1 
gene has one of the highest mutation rates with a myriad of possible mutations, and 
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the presence of several pseudogenes can further complicate the detection of NF1 
mutations. We detected germline NF1 mutations in 69% of the clinically diagnosed 
NF1 patients, and this success rate is typical of studies with DNA-based methods 
alone detecting less than 80% of germline mutations 2. The addition of MLPA testing 
may only detect approximately 4% of patients with deletion or duplication of single or 
multiple exons 19,52. Splicing mutations may be present in more than 20% of individuals 
with NF1 syndrome, hence analysis of RNA is essential to detect these intronic 
mutations 52,53. A protein-based approach may help to detect deficiency of 
neurofibromin. However, immunohistochemical expression of neurofibromin in these 
NF1-associated breast tumours did not reveal any distinctive pattern of staining. None 
of the tumours examined had total absence of neurofibromin, in contrast to a study 
using the same antibody, which reported complete absence in 15-18% of sporadic 
melanomas 54. Tumoural heterogeneity may account for the variability in neurofibromin 
expression, but current antibodies available are also unlikely able to distinguish 
between the normal and mutant neurofibromin protein, especially in the case of 





Our study confirms the aggressive nature of breast cancers in patients with NF1, with 
a high frequency of grade 3, ER negative and HER2 positive tumours. The mutation 
profile of the tumours strongly suggest that germline NF1 mutations, in cooperation 
with TP53 and other genes such as KMT2C, play a critical role in the pathogenesis of 
these tumours. This study also highlights the poor response of these tumours to 
standard cytotoxic and HER2 therapeutic approaches; hence more effective 
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3.8 Supplementary data 
 
Supplementary Table S3.1: Gene panels 
SureSelect custom gene panel (338 genes) (Gene symbol) 
 
ABCC11 CARD11 EGFR FGF4 INPP4B MSH2 PHLPP2 SDHD TRIM17 
ABL1 CASP5 EML4 FGF6 IRF4 MSH6 PIK3CA SERPINI2 TSC1 
AKT1 CASP8 EP300 FGFR1 IRS2 MTOR PIK3CG SETD2 TSC2 
AKT2 CBFB EPCAM FGFR2 JAK1 MUTYH PIK3R1 SF3B1 TSHR 
AKT3 CBL EPHA3 FGFR3 JAK2 MYC PIK3R2 SLAMF6 VHL 
ALK CCND1 EPHA5 FGFR4 JAK3 MYCL1 PMS2 SLC26A10 VPS13B 
APC CCND2 EPHB1 FH JUN MYCN POLD1 SMAD2 WISP3 
AR CCND3 EPS8L1 FHIT KDM5A MYD88 POLE SMAD3 WRN 
ARAF CCNE1 ERBB2 FILIP1 KDM5C MYH9 PPEF2 SMAD4 WT1 
ARFRP1 CD79A ERBB3 FLT1 KDM6A MYST3 PPP2R1A SMARCA4 XPO1 
ARID1A CD79B ERBB4 FLT3 KDR NBN PRDM1 SMARCB1 XRCC2 
ARID1B CDC73 ERG FLT4 KEAP1 NCOR1 PRKAR1A SMARCD1 ZFP36L1 
ARID2 CDH1 ESR1 FOXA1 KIAA1919 NF1 PRKDC SMARCD2 ZIM2 
ASXL1 CDH5 ETV1 FOXL2 KIT NF2 PRMT7 SMO ZNF217 
ATM CDK12 ETV4 FTMT KLHL6 NFE2L2 PRSS1 SOCS1 ZNF451 
ATR CDK4 ETV5 GATA1 KRAS NFKBIA PRSS7 SOSTDC1 ZNF582 
ATRX CDK6 ETV6 GATA2 LIG4 NKX2-1 PTCH1 SOX10 ZNF668 
AURKA CDK8 EWSR1 GATA3 LRP1B NOD2 PTCHD3 SOX2 ZNF703 
AURKB CDKN1A EZH2 GID4 MAGI3 NOTCH1 PTEN SPEN  
AXIN1 CDKN1B FAM123B GNA11 MAP2K1 NOTCH2 PTPN11 SPINK1  
AXL CDKN2A FAM46C GNA13 MAP2K2 NOTCH3 PTPN22 SPOP  
BAP1 CDKN2B FAM47C GNAQ MAP2K4 NOTCH4 PTPRF SRC  
BARD1 CDKN2C FAN1 GNAS MAP3K1 NPM1 RAD50 SSX9  
BCL2 CEBPA FANCA GPR124 MAP3K13 NRAS RAD51C STAG2  
BCL2L1 CFHR5 FANCB GPS2 MAPKAP1 NTRK1 RAD51D STAT3  
BCL2L2 CHEK1 FANCC GRIN2A MCAT NTRK2 RAF1 STAT4  
BCL6 CHEK2 FANCD2 GSK3B MCL1 NTRK3 RARA STK11  
BCOR CIC FANCE HEATR7B2 MDM2 NUP93 RB1 SUFU  
BCORL1 CREBBP FANCF HGF MDM4 OR2L2 RET TAOK1  
BCR CRKL FANCG HIF1A MED12 OR6A2 RICTOR TBX3  
BLM CRLF2 FANCI HRAS MEF2B PAK1 RINT1 TET2  
BMPR1A CSF1R FANCL HSP90AA1 MEN1 PAK3 RNF43 TGFBR2  
BRAF CTCF FANCM IDH1 MET PALB2 ROS1 TLR4  
BRCA1 CTNNA1 FBXW7 IDH2 MITF PALLD RPTOR TMPRSS2  
BRCA2 CTNNB1 FETUB IGF1R MLH1 PAX5 RUNX1 TNFAIP3  
BRIP1 CXCL6 FGF10 IGSF22 MLL PBRM1 RUNX1T1 TNFAIP6  
BRIX1 DAXX FGF14 IKBKE MLL2 PDGFRA SDHA TNFRSF14 
BTK DDR2 FGF19 IKZF1 MLL3 PDGFRB SDHAF2 TNK2  
C11ORF30 DNMT3A FGF23 IL7R MPL PDK1 SDHB TOP1  






xGen® Pan-Cancer Panel (127 genes) (Gene Symbol) 
 
ACVR1B EPPK1 NPM1 TSHZ2 
ACVR2A ERBB4 NRAS TSHZ3 
AJUBA ERCC2 NSD1 U2AF1 
AKT1 EZH2 PBRM1 USP9X 
APC FBXW7 PCBP1 VEZF1 
AR FGFR2 PDGFRA VHL 
ARHGAP35 FGFR3 PHF6 WT1 
ARID1A FLT3 PIK3CA  
ARID5B FOXA1 PIK3CG  
ASXL1 FOXA2 PIK3R1  
ATM GATA3 POLQ  
ATR H3F3C PPP2R1A  
ATRX HGF PRX  
AXIN2 HIST1H1C PTEN  
B4GALT3 HIST1H2BD PTPN11  
BAP1 IDH1 RAD21  
BRAF IDH2 RB1  
BRCA1 KDM5C RPL22  
BRCA2 KDM6A RPL5  
CBFB KEAP1 RUNX1  
CCND1 KIT SETBP1  
CDH1 KRAS SETD2  
CDK12 LIFR SF3B1  
CDKN1A LRRK2 SIN3A  
CDKN1B MALAT1 SMAD2  
CDKN2A MAP2K4 SMAD4  
CDKN2C MAP3K1 SMC1A  
CEBPA MAPK8IP1 SMC3  
CHEK2 MECOM SOX17  
CRIPAK MIR142 SOX9  
CTCF KMT2B SPOP  
CTNNB1 KMT2C STAG2  
DNMT3A KMT2D STK11  
EGFR MTOR TAF1  
EGR3 NAV3 TBL1XR1  
EIF4A2 NCOR1 TBX3  
ELF3 NF1 TET2  
EP300 NFE2L2 TGFBR2  
EPHA3 NFE2L3 TLR4  
EPHB6 NOTCH1 TP53  
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Immunohistochemical expression of neurofibromin in 
sporadic breast cancers 
 
4.1 Abstract 
NF1 (Neurofibromatosis type 1) is one of the significantly mutated genes in many 
cancers, including breast cancer. However, the clinical relevance of neurofibromin 
deficiency in sporadic breast cancer is unclear. We hypothesised that loss of expression 
neurofibromin, a tumour suppressor, will be associated with overexpression of pAkt and 
pMAPK downstream in the PI3K-MAPK pathway, resulting in worse outcomes. The 
expression of neurofibromin was initially evaluated through immunohistochemistry on 
microarrayed cores obtained from 314 stage 1-3 breast cancer specimens diagnosed 
between 2000 and 2002. “Positive” expression of neurofibromin was defined as nuclear 
and cytoplasmic staining in 10% or more of tumour cells. Positive expression of 
neurofibromin, as defined above, was seen in 44.6% (140/314) of tumours. Staining for 
neurofibromin was observed in a median of 5% (0-95%) of cells for nuclear staining, 
and 40% (0-95%) of cells for cytoplasmic staining. “Negative” expression of 
neurofibromin was associated with high tumour grade (p<0.001), hormone receptor 
negativity (p<0.001), lymph node positivity (p=0.041) and larger tumour size (p=0.031). 
“Negative” expression of neurofibromin was also associated with increased risk of 
relapse (5-year relapse rate 29.2% vs 17.0%; hazard ratio 1.56, p=0.029) and death (5-
year death rate 21.7% vs 12.7%; hazard ratio 1.64, p=0.029) on univariate analysis. On 
multivariate analysis, lack of neurofibromin was an independent predictor of relapse and 
death for triple negative cancers (hazard ratios 3.33, p=0.011 and 2.94, p=0.026 
respectively), but not in the luminal and HER2 positive immunohistochemical subtypes. 
To validate this finding, the expression of neurofibromin was subsequently evaluated in 
tissue microarrays with a total of 594 triple negative breast cancers diagnosed from 
1993 to 2011. No association between neurofibromin expression and survival outcomes 
was found in the validation set. Immunohistochemistry may be suboptimal for assessing 
deficiency or dysfunction of neurofibromin. Novel methods such as mass-spectrometry-





NF1 (Neurofibromatosis type 1) is one of the significantly mutated genes in many 
cancers, including breast cancer 1-3. However, given the large size of the gene with 
lack of mutational hotspots, there are challenges with detecting NF1 mutations and 
interpreting the functional significance of the variants detected 1. Loss of NF1, 
especially heterozygous loss, is more common, and may potentially lead to activation 
of the downstream PI3K-Akt-MAP kinase pathway, since its product neurofibromin is 
an important negative regulator of Ras cellular proliferation pathways1,4. Loss of NF1 
was implicated as a critical breast cancer driver in a study looking at the mammary 
tumours generated in Chaos3 mice models, which exhibit high levels of genomic 
instability 5. The role of NF1 in breast cancer pathogenesis and progression is 
increasingly recognized. A recent study has also reported inferior survival outcomes 
in hormone-receptor positive tumours harbouring NF1 nonsense or frameshift 
mutations 6.  
 
Given the potential role of NF1 and neurofibromin in breast cancer, as well as the 
limitations in evaluation of its deficiency from DNA-based studies, we sought to 
investigate the immunohistochemical expression of neurofibromin in sporadic breast 
cancers. In addition, there may be downregulation of the neurofibromin tumour 
suppressor protein via epigenetic mechanisms1, hence the immunohistochemical 
staining of neurofibromin may serve as a useful surrogate of the downstream protein 
expression. To our knowledge, the immunohistochemical expression of neurofibromin 
has only been evaluated in a study on tissue microarrays (TMAs) containing 22 
sporadic breast cancers, 18 benign lesions and 6 normal breast tissue specimens. 
There were no differences in expression of neurofibromin in the various tissues7.  
 
We hypothesise that loss of expression of neurofibromin, a tumour suppressor, will be 
associated with overexpression of pAkt and pMAPK downstream in the PI3K-MAPK 
pathway, resulting in worse outcomes. The objectives of the study were to evaluate 
the immunohistochemical expression of neurofibromin in breast cancer, and its 
association with clinocopathological features and survival outcomes. We also aimed 
to evaluate the association of neurofibromin expression with immunohistochemical 
expression of pAkt and pMAPK. 
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4.3 Methods  
 
This study used TMAs constructed from 347 sporadic breast cancers diagnosed 
between April 2000 and Dec 2002 at the Department of Anatomical Pathology, 
Singapore General Hospital for the discovery set, and from 681 triple negative breast 
cancers diagnosed over the period 1993 to 2011 for the validation set. The tumours 
used for the discovery and validation sets were independent, that is, no overlap. Using 
a Beecher microarrayer with 1mm punch, at least two representative areas of the 
tumour in each FFPE tissue block were constructed into the TMAs. This study was 
approved by SingHealth Centralised Institutional Review Board.  
 
The TMA sections (4µm) were subjected to immunohistochemical staining with 
antibodies to neurofibromin (ab30325, 1:300 dilution; Abcam, Cambridge, UK), 
phospho-Akt (pAkt) (#3787, clone 736E11, 1:50 dilution; Cell Signaling Technology 
Danvers, MA, USA) and pMAPK (Phospho-Thr202/Tyr204, #4370, 1:400 dilution; Cell 
Signaling Technology, Danvers, MA, USA), according to manufacturers’ instructions. 
These experiments were undertaken in the pathology department at the Singapore 
General Hospital, a diagnostic laboratory which also conducts academic research, 
including immunohistochemical studies using various antibodies. These antibodies 
were chosen based on various references in the literature7-10, including the study by 
Maertens et al which implicated loss of NF1 with activation of Akt and ERK signaling 
in melanomas as a mechanism of resistance to BRAF inhibitors8. Tonsillar tissue, 
which is known to express low neurofibromin protein within the germinal centres 
(https://www.proteinatlas.org/ENSG00000196712-NF1/tissue/tonsil), was used as 
positive control. The immunohistochemical assessment was performed independently 
by two observers (including the candidate) blinded to the clinicopathological 
characteristics and survival outcomes. For immunoscoring, the staining intensity (nil, 
weak (1+), moderate (2+), strong (3+)) and the proportion of tumour cells stained in 
the nuclei as well as the cytoplasm were recorded separately.  
 
“Positive” expression of neurofibromin was defined as nuclear and cytoplasmic 
staining in 10% or more of tumour cells, considering that tumour suppressor proteins 
including neurofibromin may shuttle between the nucleus and the cytoplasm for 
112 
 
regulation of various cellular functions 11. Tumours which did not fulfil this criterion 
were classified as “negative” for expression of neurofibromin. Expression of 
neurofibromin, pAkt and pMAPK in nuclei and cytoplasm was scored separately. 
 
Details on clinicopathologic status, including tumour grade, size, nodal and 
lymphovascular invasion status  as well as survival outcomes (relapse status and 
overall survival status) were obtained from medical records. Tumours that were stage 
4 at diagnosis were excluded from the analyses. The definitions of estrogen receptor 
(ER) and progesterone receptor (PR) in this study were based on the latest 
recommendations by the American Society of Clinical Oncology and the College of 
American Pathologists 12, but human epidermal growth factor receptor 2 (HER2) 
positivity definitions were based on the earlier definitions by the American Society of 
Clinical Oncology and the College of American Pathologists in 2007 13. 
 
Continuous variables were summarised using median and range, while categorical 
variables were summarised by the number and the percentage of patients in each 
category. Relapse-free survival (RFS) was calculated as the time from diagnosis to 
disease relapse or death from any cause. Overall survival (OS) was defined as time 
from diagnosis to death from any cause. OS, rather than breast cancer-specific 
survival (BCSS), was used as an endpoint of survival outcome in this analysis. OS is 
often regarded as one of the most robust endpoints and frequently adopted in 
epidemiological studies and clinical trials. Unlike OS, which can be easily and 
accurately determined from medical records or death registry, BCSS may be subject 
to bias and inaccuracies as cause of death may not be attributed correctly to the 
contributing cause. Patients who were alive and relapse-free at last follow-up were 
censored at date of last follow-up. The Kaplan-Meier method was used to estimate the 
failure function, from which 5-year relapse rates were derived. The log-rank test was 
used to determine if there was a difference in RFS and OS between different groups 
of patients. The Cox proportional hazards model was used to estimate the hazard 
ratios between groups. A 2-sided p-value of less than 0.05 was taken as statistically 





4.4 Results  
 
Discovery Set 
Out of the 347 stage 1-3 sporadic breast cancers used in the TMAs, 175 (50.4%) were 
“luminal” (defined as hormone receptor positive and HER2 negative), 74 (21.3%) were 
HER2-positive (regardless of hormone receptor status), and 95 (27.4%) were triple 
negative. Other clinicopathological characteristics are displayed in Table 4.1. A total 
of 314 stage 1-3 breast cancer specimens in this series had adequate tissue for 
evaluating the expression of neurofibromin through immunohistochemistry (Table 4.1). 
Median follow-up was 132.2 months.  
 
“Positive” expression of neurofibromin, as defined above, was seen in 44.6% 
(140/314) of tumours. “Negative” expression of neurofibromin was associated with 
high tumour grade (p<0.001), hormone receptor negativity (p<0.001), lymph node 
positivity (p=0.041) and larger tumour size (p=0.031) (Table 4.1). Figure 4.1 shows 3 
different specimens with varying expression of neurofibromin (mild, moderate, strong).  
 
Staining for neurofibromin was observed in a median of 5% (0-95%) of cells for nuclear 
staining, and 40% (0-95%) of cells for cytoplasmic staining (Table 4.2). The 
percentage of cells staining positive for pMAPK and pAkt, as well as the H scores, are 
shown in Table 4.2. Examples of specimens with varying immunohistochemical 




Table 4.1: Clinicopathological parameters by neurofibromin (NF1) expression 
(Positive expression of neurofibromin was defined as both nuclear and cytoplasmic staining in 10% or 
more of tumour cells; tumours which did not fulfil this criterion were classified as “negative” for 
expression of neurofibromin.) 





Parameter Number % Number % Number % p-value 
        
Age at diagnosis, 
years 
      0.191 
 Mean 53.3 54.2 52.4  
 Median 51  53  50.5  
 Range 23 – 85 29 – 85 23 – 84  
        
Race        0.004 
 Chinese 291 83.9 136 78.2 125 89.3  
 Malay 31 8.9 26 14.9 5 3.6  
 Indian 16 4.6 9 5.2 6 4.3  
 Others 9 2.6 3 1.7 4 2.9  
        
Tumour size, mm       0.031 
 Mean 31.1 34.1 28.4  
 Median  25  29 23  
 Range 2 – 200 3 – 200 2 – 200  
        
Tumour grade       < 0.001 
 1 64 18.4 21 12.1 34 24.3  
 2 130 37.5 55 31.6 64 45.7  
 3 145 41.8 96 55.2 38 27.1  
 Unknown  8 2.3 2 1.2 4 2.9  
        
Histologic subtype       ND 
 Invasive ductal 
carcinoma (IDC) 
312 89.9 160 92.0 123 87.9  
 Invasive lobular 
carcinoma (ILC) 
12 3.5 5 2.9 7 5.0  
 IDC and ILC 1 0.3 1 0.6 0 0  
 Invasive cribriform 
carcinoma 
2 0.6 0 0 2 1.4  
 Medullary 
carcinoma 
2 0.6 2 1.1 0 0  
 Metaplastic 
carcinoma 
1 0.3 1 0.6 0 0  
 Mucinous 
carcinoma 
9 2.6 2 1.1 4 2.9  
 Papillary carcinoma 4 1.2 2 1.1 2 1.4  
 Tubular carcinoma 4 1.2 1 0.6 2 1.4  
        
Lymphovascular 
invasion 
      0.579 
 Absent 278 80.1 136 78.2 113 80.7  
 Present 69 19.9 38 21.8 27 19.3  
        
Nodal stage       0.041 
 0 175 50.4 78 44.8 78 55.7  
 1 86 24.8 45 25.9 35 25.0  
 2 43 12.4 29 16.7 10 7.1  
 3 33 9.5 19 10.9 11 7.9  
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Parameter Number % Number % Number % p-value 
 Unknown 10 2.9 3 1.7 6 4.3  
        
ER status       < 0.001 
 Negative 147 42.4 92 52.9 45 32.1  
 Positive 197 56.8 82 47.1 92 65.7  
 Unknown 3 0.9 0 0 3 2.1  
        
PR status       < 0.001 
 Negative 173 49.9 107 61.5 51 36.4  
 Positive 171 49.3 67 38.5 86 61.4  
 Unknown 3 0.9 0 0 3 2.1  
        
HER2 status       0.329 
 Negative 270 77.8 133 76.4 111 79.3  
 Positive 74 21.3 41 23.6 26 18.6  
 Unknown 3 0.9 0 0 3 2.1  
        
Molecular subtype       0.001 
 Luminal 175 50.4 70 40.2 84 60.0  
 HER2 positive 74 21.3 41 23.6 26 18.6  
 Triple negative 95 27.4 63 36.2 27 19.3  
 Unknown 3 0.9 0 0 3 2.1  
 
Note: 33 patients (9.5%) had unknown neurofibromin staining status due to lack of adequate tissue.  




Figure 4.1: Sporadic breast cancer specimens demonstrating (a) mild, (b) moderate 















Table 4.2: Immunostaining of neurofibromin (NF1), pMAPK and pAKt in nuclei and 






















 Median percentage staining positive (range) % 
NF1 (nucleus)  5 (0 – 95)  
 Unknown 33 9.3 
NF1 (cytoplasm) 40 (0 – 95)  
 Unknown 33 9.3 
pMAPK (nucleus)  5 (0 – 90)  
 Unknown 18 5.1 
pMAPK (cytoplasm) 0 (0 – 80)  
 Unknown 18 5.1 
pAKT (nucleus)  0 (0 – 80)  
 Unknown 13 3.7 
pAKT (cytoplasm) 5 (0 – 70)  
 Unknown 13 3.7 
 H-score: Median (range) % 
NF1 (nucleus)  5 (0 – 175)  
 Unknown 33 9.3 
NF1 (cytoplasm) 40 (0 – 160)  
 Unknown 33 9.3 
pMAPK (nucleus)  5 (0 – 230)  
 Unknown 18 5.1 
pMAPK (cytoplasm) 0 (0 – 155)  
 Unknown 18 5.1 
pAKT (nucleus)  0 (0 – 80)  
 Unknown 13 3.7 
pAKT (cytoplasm) 5 (0 – 85)  
 Unknown 13 3.7 
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Figure 4.2: Sporadic breast cancer specimens demonstrating (a) mild, (b) moderate 
and (c) strong expression of pMAPK, and (d) mild, (e) moderate and (f) strong 
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 “Negative” expression of neurofibromin was also associated with increased risk of 
relapse (5-year relapse rate 29.2% vs 17.0%; hazard ratio 1.56, p=0.029) (Table 4.3) 
and death (5-year death rate 21.7% vs 12.7%; hazard ratio 1.64, p=0.029) on 
univariate analysis (Table 4.4). As demonstrated in the relapse-free survival and 
overall survival curves (Figures 4.3 and 4.4), the prognostic role of neurofibromin 
seemed most prominent in the triple negative subtype. 
 
On multivariate analysis, lack of neurofibromin was an independent predictor of 
relapse and death for triple negative cancers (hazard ratios 3.33, p=0.011 and 2.94, 
p=0.026 respectively), but not in the luminal and HER2 positive immunohistochemical 
subtypes (Table 4.5 and Table 4.6). 
 
In general, there was no evidence that loss of NF1 was associated with increased 
pAKT or pMAPK expression (Table 4.7 and Table 4.8). On the contrary, there was 
evidence that NF1, pAKT and pMAPK expressions were positively correlated; 
Spearman’s correlations were all positive. The strongest association found was 






Table 4.3: Univariate analysis of relapse-free survival  












All patients 114 / 346 23.8 (19.6 – 
28.7) 
NA NA NA 
      
Tumour size, cm  114 / 346 NA NA 1.13 (1.08 – 1.18) < 0.001 
      
Tumour grade    0.001  < 0.001 
 1 10 / 63 7.9 (3.4 – 18.0)  1  
 2 44 / 130 20.1 (14.0 – 
28.3) 
 2.63 (1.32 – 5.24)  
 3 58 / 145 34.1 (26.9 – 
42.6) 
 3.43 (1.75 – 6.72)  
      
Nodal stage   < 0.001  < 0.001 
 0 37 / 175 13.5 (9.2 – 19.7)  1  
 1 29 / 85 23.7 (16.0 – 
34.3) 
 1.76 (1.08 – 2.87)  
 2 20 / 43 34.3 (21.9 – 
51.1) 
 2.83 (1.63 – 4.89)  
 3 23 / 33 60.3 (43.8 – 
77.2) 
 6.11 (3.61 – 10.35)  
      
Lymphovascular 
invasion 
  0.001  0.002 
 Absent 81 / 277  20.9 (16.5 – 
26.3) 
 1  
 Present 33 / 69 35.3 (25.2 – 
47.9) 
 1.97 (1.31 – 2.95)  
      
Molecular subtype   0.044  0.046 
 Luminal 50 / 174 17.0 (12.2 – 
23.6) 
 1  
 HER2 positive 28 / 74 31.0 (21.6 – 
43.2) 
 1.52 (0.95 – 2.41)  
 Triple negative 36 / 95 31.5 (23.0 – 
42.1) 
 1.65 (1.07 – 2.54)  
      
NF1 expression   0.030  0.029 
 Negative 64 / 174 29.2 (22.9 – 
36.7) 
 1  
 Positive 38 / 139 17.0 (11.6 – 
24.4) 
 0.64 (0.43 – 0.96)  
      
Luminal       
NF1 expression   0.346  0.348 
 Negative 21 / 70 20.8 (12.9 – 
32.6) 
 1  
 Positive 21 / 83 12.2 (6.8 – 21.5)  0.75 (0.41 – 1.37)  
      
HER2 positive      
NF1 expression   0.615  0.617 
 Negative 15 / 41 35.8 (23.0 – 
52.8) 
 1  
 Positive 12 / 26 32.2 (17.6 – 
54.3) 
 1.22 (0.57 – 2.61)  
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Triple negative      
NF1 expression   0.031  0.021 
 Negative 28 / 63 34.4 (23.9 – 
47.7) 
 1  
 Positive 5 / 27 19.4 (8.5 – 40.6)  0.36 (0.14 – 0.95)  
      
[1] Log-rank test 
[2] Likelihood ratio test (from Cox model) 








Table 4.4: Univariate analysis of overall survival  












All patients 93 / 346 17.4 (13.8 – 
22.0) 
NA NA NA 
      
Tumour size, cm  93 / 346 NA NA 1.15 (1.09 – 1.20) < 0.001 
      
Tumour grade    0.004  0.002 
 1 8 / 63 6.4 (2.4 – 16.0)  1  
 2 36 / 130 17.1 (11.5 – 
25.1) 
 2.68 (1.24 – 5.78)  
 3 47 / 145 23.1 (16.9 – 
31.1) 
 3.35 (1.58 – 7.10)  
      
Nodal stage   < 0.001  < 0.001 
 0 29 / 175 10.7 (6.9 – 16.5)  1  
 1 22 / 85 14.4 (8.4 – 24.0)  1.68 (0.97 – 2.93)  
 2 17 / 43 19.7 (10.3 – 
35.6) 
 2.93 (1.60 – 5.36)  
 3 20 / 33 51.0 (35.0 – 
69.2) 
 6.12 (3.44 – 10.89)  
      
Lymphovascular 
invasion 
  0.007  0.011 
 Absent 66 / 277 15.1 (11.3 – 
20.0) 
 1  
 Present 27 / 69 26.9 (17.8 – 
39.2) 
 1.84 (1.18 – 2.88)  
      
Molecular subtype   0.030  0.031 
 Luminal 39 / 174 11.2 (7.3 – 17.0)  1  
 HER2 positive 23 / 74 21.8 (13.7 – 
33.5) 
 1.59 (0.95 – 2.66)  
 Triple negative 31 / 95 26.5 (18.6 – 
36.9) 
 1.82 (1.14 – 2.93)  
      
NF1 expression   0.031  0.029 
 Negative 54 / 174 21.7 (16.2 – 
28.8) 
 1  
 Positive 31 / 139 12.7 (8.1 – 19.7)  0.61 (0.39 – 0.96)  
      
Luminal      
NF1 expression   0.306  0.309 
 Negative 17 / 70 13.3 (7.1 – 23.9)  1  
 Positive 16 / 83 8.6 (4.2 – 17.2)  0.70 (0.35 – 1.39)  
      
HER2 positive      
NF1 expression   0.686  0.687 
 Negative 13 / 41 21.3 (11.2 – 
38.1) 
 1  
 Positive 10 / 26 28.9 (14.9 – 
51.3) 
 1.19 (0.52 – 2.72)  
      
Triple negative      
NF1 expression   0.074  0.059 
 Negative 24 / 63 31.4 (21.3 – 
44.8) 
 1  
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 Positive 5 / 27 11.8 (3.9 – 32.3)  0.43 (0.16 – 1.12)  
      
[1] Log-rank test 
[2] Likelihood ratio test (from Cox model) 




Figure 4.3: Relapse free survival according expression of neurofibromin in a) overall 
cohort, b) luminal subtype, c) HER2-positive subtype and d) triple negative subtype. 
 
a) Kaplan-Meier plot of relapse-free 




b)  Kaplan-Meier plot of relapse-free 
survival by neurofibromin expression in 
luminal patients  
 
 
c) Kaplan-Meier plot of relapse-free survival 




d)  Kaplan-Meier plot of relapse-free 
survival by neurofibromin expression in 












































139 126 110 100 93 86 48 0NF1 positive
174 143 120 109 98 87 47 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168
Time from diagnosis, months









































83 78 72 66 60 56 31 0NF1 positive
70 63 54 49 47 42 27 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168
Time from diagnosis, months









































26 22 16 14 14 11 9 0NF1 positive
41 32 27 25 24 21 12 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168
Time from diagnosis, months









































27 23 19 17 17 17 6 0NF1 positive
63 48 39 35 27 24 8 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168
Time from diagnosis, months





Figure 4.4: Overall survival according expression of neurofibromin in a) overall cohort, 
b) luminal subtype, c) HER2-positive subtype and d) triple negative subtype. 
 
 
a) Kaplan-Meier plot of overall survival by 
NF1 expression in all patients 
 
 
b) Kaplan-Meier plot of overall survival by 
NF1 expression in luminal patients 
 
c) Kaplan-Meier plot of overall survival by 
NF1 expression in HER2 positive patients 
 
 
d) Kaplan-Meier plot of overall survival by 







































139 131 117 108 97 90 50 0NF1 positive
174 153 128 121 106 94 48 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168
Time from diagnosis, months





































83 81 75 70 63 59 33 0NF1 positive
70 63 57 56 51 47 28 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168
Time from diagnosis, months





































26 23 18 16 15 12 9 0NF1 positive
41 36 30 28 26 21 12 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168
Time from diagnosis, months





































27 24 21 19 17 17 6 0NF1 positive
63 54 41 37 29 26 8 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168
Time from diagnosis, months





Table 4.5: Multivariate models of RFS by breast cancer subtype 
 Luminal 
(Events = 39,  
Patients = 146) 
HER2 positive 
(Events = 25,  
Patients = 63) 
Triple negative 
(Events = 32, 
Patients = 87) 
 Hazard ratio  
(95% CI) 
p[1] Hazard ratio  
(95% CI) 
p[1] Hazard ratio  
(95% CI) 
p[1] 
Tumour size, cm  1.22 (1.05 – 1.42) 0.015 1.46 (1.15 – 1.84) 0.004 1.03 (0.94 – 1.13) 0.560 
       
Tumour grade   0.104  0.773 Not included[2]  
 1 1  1    
 2 – 3  2.17 (0.80 – 5.89)  1.33 (0.18 – 10.06)    
       
Nodal stage  0.003  0.230  0.033 
 0 – 1  1  1  1  
 2 – 3 3.16 (1.52 – 6.58)  1.95 (0.69 – 5.53)  2.27 (1.10 – 4.66)  
       
Lymphovascular 
invasion 
 0.879  0.331  0.014 
 Absent 1  1  1  
 Present 1.06 (0.51 – 2.22)  0.57 (0.17 – 1.87)  2.56 (1.25 – 5.24)  
       
NF1 expression  0.705  0.867  0.011 
 Negative 1  1  1  
 Positive 1.14 (0.57 – 2.28)  1.07 (0.48 – 2.41)  0.30 (0.11 – 0.87)  
       
[1] p-value from likelihood ratio test  
[2] Hazard ratio for tumour grade was inestimable as there were no events amongst the Grade 1 patients in the 
triple negative subset. Therefore, it was excluded from the model.  
 
Table 4.6: Multivariate models of OS by breast cancer subtype 
 Luminal 
(Events = 30,  
Patients = 146) 
HER2 positive 
(Events = 21,  
Patients = 63) 
Triple negative 
(Events = 28, 
Patients = 87) 
 Hazard ratio  
(95% CI) 
p[1] Hazard ratio  
(95% CI) 
p[1] Hazard ratio  
(95% CI) 
p[1] 
Tumour size, cm  1.32 (1.11 – 1.56) 0.002 1.52 (1.18 – 1.96) 0.004 1.03 (0.92 – 1.14) 0.643 
       
Tumour grade   0.327  0.991 Not included[2]  
 1 1  1    
 2 – 3  1.73 (0.55 – 5.38)  0.99 (0.13 – 7.61)    
       
Nodal stage  0.009  0.073  0.118 
 0 – 1  1  1  1  
 2 – 3 3.17 (1.35 – 7.41)  2.89 (0.96 – 8.66)  1.90 (0.88 – 4.12)  
       
Lymphovascular 
invasion 
 0.838  0.355  0.085 
 Absent 1  1  1  
 Present 0.92 (0.39 – 2.15)  0.57 (0.16 – 1.97)  2.05 (0.94 – 4.49)  
       
NF1 expression  0.947  0.834  0.026 
 Negative 1  1  1  
 Positive 0.97 (0.45 – 2.11)  1.10 (0.45 – 2.69)  0.34 (0.12 – 0.99)  
       
[1] p-value from likelihood ratio test  
[2] Hazard ratio for tumour grade was inestimable as there were no events amongst the Grade 1 patients in the 
triple negative subset. Therefore, it was excluded from the model.  
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Table 4.7: Association between pAKT, pMAPK and nuclear NF1 expression (using a 
cut-off of 10% of cells staining positive) 





Parameter Number % Number % Number % ρ p-value 
         
Cytoplasmic NF1        0.21 < 0.001 
 Negative 30 8.7 26 15.3 4 2.8   
 Positive 284 81.8 144 84.7 140 97.2   
 Unknown 33 9.5 0 0 0 0   
         
Nuclear pAKT       0.38 < 0.001 
 Negative  210 60.5 133 78.2 59 41.0   
 Positive 125 36.0 37 21.8 84 58.3   
 Unknown 12 3.5 0 0 1 0.7   
         
Cytoplasmic pAKT       0.01 0.915 
 Negative  182 52.4 89 52.4 74 51.4   
 Positive 153 44.1 81 47.6 69 47.9   
 Unknown 12 3.5 0 0 1 0.7   
         
Nuclear pMAPK       0.26 < 0.001 
 Negative  181 52.2 112 65.9 57 39.6   
 Positive 148 42.7 58 34.1 86 59.7   
 Unknown 18 5.2 0 0 1 0.7   
         
Cytoplasmic pMAPK       0.27 < 0.001 
 Negative  226 65.1 134 78.8 77 53.5   
 Positive 103 29.7 36 21.2 66 45.8   
 Unknown 18 5.2 0 0 1 0.7   
         
Note: 33 patients were missing nuclear NF1 status. 
ρ: Spearman’s correlation.  
 
Table 4.8: Association between pAKT, pMAPK and NF1 expression (cytoplasmic 
only) (using a cut-off of 10% of cells staining positive) 





Parameter Number % Number % Number % ρ p-value 
         
Cytoplasmic pAKT       0.05 0.361 
 Negative  182 52.4 18 60.0 145 51.1   
 Positive 153 44.1 12 40.0 138 48.6   
 Unknown 12 3.5 0 0 1 0.4   
         
Cytoplasmic pMAPK       0.16 0.006 
 Negative  226 65.1 27 90.0 184 64.8   
 Positive 103 29.7 3 10.0 99 34.9   
 Unknown 18 5.2 0 0 1 0.4   
         
Note: 33 patients were missing cytoplasmic NF1 status. 





To validate the preliminary finding that positive expression of neurofibromin in both 
nucleus and cytoplasm was associated with better outcomes, immunohistochemical 
staining with the same neurofibromin antibody was performed on TMAs with a total of 
681 triple negative breast cancers diagnosed over the period 1993 to 2011. The 
clinicopathological characteristics of this validation set are tabulated in Table 4.9, with 
the characteristics and neurofibromin staining of the triple negative subset from the 
discovery set side-by-side for comparison. Overall the characteristics of the 2 cohorts 
appear similar and comparable. 
 
While standard prognostic factors such as tumour grade, stage and the presence of 
lymphovascular invasion were significant predictors of relapse free survival in this 
cohort (Table 4.10), there was no correlation of neurofibromin status with relapse 
status when using the same combined expression definition as in the discovery set 
(Table 4.11). We failed to find any significant association of relapse free survival with 
neurofibromin status even when analysed via various definitions, looking at nuclear 
expression versus cytoplasmic expression individually with different cutoffs, and using 
H-scores (Table 4.11). The relapse-free survival and overall survival curves of the 
validation cohort using the same definition as the discovery cohort (staining in at least 
10% of the cells in the nucleus and at least 10% in the cytoplasm) are shown in Figures 






Table 4.9: Clinicopathological characteristics (including neurofibromin staining 
results) of triple negative validation cohort, and the triple negative subset of the 






      







Total number of patients 681 100.0 95 100.0 
     
Age at diagnosis, years     
Median  52   54  
Range 25 - 89  33-86  
     
Race      
Chinese 569 83.6 80 84.2 
Indian 38 5.6 5 5.2 
Malay 54 7.9 9 9.5 
Others 20 2.9 1 1.1 
     
Tumour size, mm     
Median  30   30  
Range 2 - 200  2-200  
Unknown  20 2.9 0  
     
Tumour grade     
1 18 2.6 6 6.3 
2 132 19.4 27 28.4 
3 529 77.7 62 65.3 
Unknown  2 0.3 0  
     
Histologic subtype     
IDC 627 92.1 88 92.6 
ILC 15 2.2 2 2.1 
IDC&ILC 1 0.2 0 0 
Metaplastic 14 2.1 1 1.1 
Medullary 18 2.6 2 2.1 
Adenoid cystic 2 0.3 0 0 
Papillary 4 0.6 0 0 
Mucinous 0 0.0 1 1.1 
     
Lymphovascular 
invasion 
    
Absent 474 69.6 70 73.7 
Present 200 29.4 25 26.3 
Unknown (blank) 7 1.0 0 0 
     
Nodal stage     
0 327 48.0 53 55.8 
1 140 20.6 16 16.8 
2 80 11.8 16 16.8 
3 47 6.9 7 7.4 
Unknown 87 12.8 3 3.2 
        









      








Nuclear NF1 Total +%  
  
  
Median 0   0  
Range 0 - 100  0-95  
Unknown 71 10.4 4 4.2 
     




Median  30   20  
Range 0 - 95  0-90  
Unknown 71 10.4 4 4.2 
     
Nuclear NF1 H-score     
Median 0   0  
Range 0 - 160  0-160  
Unknown 71 10.4 4 4.2 





Median  30   30  
Range 0 - 140  0-140  
Unknown 71 10.4 4 4.2 
 
  
Table 4.10: Univariable analysis of relapse-free survival in validation cohort - 
demographics and baseline clinical characteristics 
  
No. of events 
/ patients 
5-year relapse rate, % 
(95% CI)  
p-value[1]  
Hazard ratio  
p-value[2] 
(95% CI) 
All patients 251 / 660# 33.3 (29.7 to 37.1) NA NA NA 
      
Tumour size, cm  243 / 642 NA NA 1.14 (1.10 to 1.18) <0.001 
  
    
Tumour grade   
 0.6   
1 5 / 18 23.0 (9.3 to 50.3)  1  
2 53 / 128 31.1 (23.7 to 40.2)  1.61 (0.64 to 4.02) 0.3 
3 192 / 512 34.1 (30.0 to 38.5)  1.61 (0.66 to 3.91) 0.3 
      
Nodal stage  
 <0.001   
0 83 / 324 20.4 (16.3 to 25.4)  1  
1 54 / 135 33.0 (25.5 to 41.9)  1.76 (1.25 to 2.47) 0.001 
2 47 / 77 54.5 (43.5 to 66.2)  3.26 (2.28 to 4.66) <0.001 
3 35 / 45 77.2 (63.5 to 88.5)  6.53 (4.38 to 9.74) <0.001 
  
 




<0.001   
Absent 147 / 459 27.4 (23.5 to 31.9)  1  
Present 102 / 194 47.3 (40.3 to 54.8)  2.12 (1.65 to 2.73) <0.001 
      
[1] P-value calculated using Log-rank test    
[2] P-value calculated using Wald test (from Cox model)    
# Date of last follow up not available for 21 patients; NA: Not applicable.   
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Table 4.11: Univariable analysis of relapse-free survival in validation cohort with 
neurofibromin status 
  
No. of events 
/ patients 
5-year relapse 
rate, % (95% CI)  
p-value[1]  
Hazard ratio  
p-value[2] 
(95% CI) 
      
Total +% using cut-off of 10%         
Combined NF1 expression  1.0   
Negative 146 / 380 33.9 (29.2 to 39.0)  1  
Positive 80 / 214 32.4 (26.4 to 39.3)  1.00 (0.76 to 1.31) 1.0 
Unknown 25 / 66 32.6 (22.6 to 45.5)  0.97 (0.63 to 1.48) 0.9 
 
     
Nuclear NF1   1.0   
<10% 142 / 369 34.0 (29.3 to 39.2)  1  
≥10% 84 / 225 32.3 (26.5 to 39.1)  0.99 (0.76 to 1.30) 1.0 
Unknown 25 / 66 32.6 (22.6 to 45.5)  0.97 (0.63 to 1.48) 0.9 
      
Cytoplasmic NF1   0.2   
<10% 23 / 49 44.1 (31.0 to 59.8)  1  
≥10% 203 / 545 32.4 (28.5 to 36.6)  0.74 (0.48 to 1.15) 0.2 
Unknown 25 / 66 32.6 (22.6 to 45.5)  0.74 (0.42 to 1.31) 0.3 
      
Total +% using cut-off of 1%         
Combined NF1 expression  0.6   
Negative 133 / 338 34.6 (29.7 to 40.1)  1  
Positive 93 / 256 31.7 (26.2 to 38.0)  0.94 (0.72 to 1.23) 0.6 
Unknown 25 / 66 32.6 (22.6 to 45.5)  0.95 (0.62 to 1.45) 0.8 
      
Nuclear NF1   0.6   
≥1% 94 / 259 31.8 (26.3 to 38.0)  0.93 (0.72 to 1.22) 0.6 
Unknown 25 / 66 32.6 (22.6 to 45.5)  0.94 (0.61 to 1.45) 0.8 
      
Cytoplasmic NF1   0.7   
0% 9 / 19 42.6 (24.0 to 67.5)  1  
≥1% 217 / 575 33.0 (29.2 to 37.1)  0.87 (0.45 to 1.69) 0.7 
Unknown 25 / 66 32.6 (22.6 to 45.5)  0.85 (0.39 to 1.81) 0.7 
     
H-score categorised into 3 groups         
Nuclear NF1   0.5   
< 50 190 / 502 32.5 (28.5 to 36.9)  1  
50 – 99 27 / 70 36.8 (26.6 to 49.5)  1.14 (0.76 to 1.71) 0.5 
≥ 100 9 / 22 44.6 (23.8 to 72.3)  1.45 (0.74 to 2.83) 0.3 
Unknown 25 / 66 32.6 (22.6 to 45.5)  1.00 (0.66 to 1.51) 1.0 
      
Cytoplasmic NF1   0.6   
< 50 157 / 422 32.8 (28.4 to 37.7)  1  
50 – 99 59 / 152 33.2 (26.1 to 41.5)  1.00 (0.74 to 1.35) 1.0 
≥ 100 10 / 20 45.0 (26.5 to 68.7)  1.40 (0.74 to 2.65) 0.3 
Unknown 25 / 66 32.6 (22.6 to 45.5)  0.98 (0.64 to 1.50) 0.9 
            
[1] P-value calculated using Log-rank test, excluding the category "Unknown"   





Figure 4.5: Kaplan Meier plot of relapse-free survival according to expression of 
neurofibromin (staining in at least 10% of the cells in the nucleus and at least 10% in 




Figure 4.6: Kaplan Meier plot of overall survival according to expression of 
neurofibromin (staining in at least 10% of the cells in the nucleus and at least 10% in 
the cytoplasm to be “positive”) in triple negative validation cohort. 
  





























214 162 125 107 79 61 48 34 16 2 0NF1 positive
380 284 235 201 158 133 99 71 37 6 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168 192 216 240






























214 177 135 111 80 63 50 35 17 2 0NF1 positive
380 313 253 218 169 140 101 73 38 6 0NF1 negative
No. at risk:
0 24 48 72 96 120 144 168 192 216 240







4.5 Discussion  
 
With the increasing evidence of the critical role that NF1 plays in breast cancer and 
other tumours, we had postulated that loss of expression of neurofibromin would be 
associated with inferior survival outcomes. We sought to evaluate the deficiency of 
neurofibromin using immunohistochemistry on TMAs of sporadic breast cancers, 
given that loss of NF1 appears to be more common than mutations, and expression 
of neurofibromin may be influenced by epigenetic or proteasomal mechanisms 1. 
 
Data on the use of neurofibromin antibody is relatively limited. Apart from the study 
which reported no differences in expression of neurofibromin in 22 sporadic breast 
cancers, 18 benign lesions and 6 normal breast tissue specimens 7, the same antibody 
to neurofibromin (ab30325, 1:300 dilution; Abcam, Cambridge, UK) has also been 
used in a study on melanomas by Maertens et al 8. It reported complete absence of 
neurofibromin in 15-18% of sporadic melanomas which had developed resistance to 
BRAF inhibitors. Loss of neurofibromin was also associated with activation of pAkt and 
pERK(or pMAPK) in Western blot, usint the same antibodies that we used for this 
study. A different study assessed the expression of neurofibromin in lung cancers via 
Western Blotting with antibody to NF1 (#A300-140) from Bethyl. Protein expression 
was lower in EGFR-mutant lung carcinomas that had developed to EGFR inhibitors, 
compared to treatment-naïve tumours which remained sensitive to erlotinib 14. 
 
Taking into consideration that many tumour suppressors, including neurofibromin, 
shuttle between the nucleus and the cytoplasm 11, we adopted a definition of 
neurofibromin positivity which requires its presence in at least 10% of the cells in the 
nucleus and at least 10% in the cytoplasm as well, though the nuclear and cytoplasmic 
staining do not have to be in the same cells. Neurofibromin regulates the 
Ras/PI3K/MAPK proliferation pathway in the cytoplasm, but is also actively 
transported to the nucleus 11. Within the nucleus, it may affect the expression of other 
genes, potentially suppressing epithelial mesenchymal transition (EMT) 1,15. In 
hormone receptor positive breast cancer, a very recent study elucidated an additional 
role of neurofibromin in co-repressing the estrogen receptor (ER)16. NF1 inactivation 
was reported to enhance ligand-dependent ER transcriptional activity. NF1-silencing 
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can turn tamoxifen, a selective estrogen receptor modulator used to breast cancer, 
into an agonist instead, making the cells hypersensitive to estradiol 16. 
 
In the discovery cohort, we found that “negative” expression of neurofibromin was 
associated with adverse prognostic features such as high tumour grade (p<0.001), 
hormone receptor negativity (p<0.001), lymph node positivity (p=0.041) and larger 
tumour size (p=0.031). It was also an independent prognostic factor for triple negative 
breast cancers in multivariable analysis for both relapse-free survival, as well as 
overall survival (hazard ratios 3.33, p=0.011 and 2.94, p=0.026 respectively). However, 
validation in a larger series of triple negative breast cancers did not support this initial 
finding.  
 
This discrepancy may be due to the relatively small sample size of different subtypes 
in the discovery cohort, or due to limitations of immunohistochemical staining on 
archived TMAs. We also did not find any correlation of lack of neurofibromin with 
expression of pAkt and pMAPK as hypothesized initially. Staining with phospho-
antibodies may not be reliable in old archived FFPE specimens. Immunohistochemical 
staining with neurofibromin antibody may also be suboptimal as the current antibodies 
available are based on detection of a specific epitope, and may not be able to 
distinguish between the normal and mutant neurofibromin proteins, especially in the 
case of missense mutations for such a large protein.  Deletions and frameshift 
changes downstream to the region of the epitope for the antibody resulting in truncated 
neurofibromin will also not be detected. For example, the antibody for neurofibromin 
(ab30325, 1:300 dilution; Abcam, Cambridge, UK) in this study only detects a small 
epitope (amino acids 27-41) close to the N-terminus in the neurofibromin protein which 
contains 2,818 amino acids 17; this antibody is no longer in production.  
 
Correlation with NF1 genomic status was not performed in this study, due to 
challenges with DNA from FFPE specimens, as well as limitation with time and 
resources. Another possibility is that with the heterogeneity of the genomic landscape 
of breast cancers, the tumours are likely to harbor aberrations in other cancer-related 
genes, which may have similar effect to the presence of inactivating NF1 mutations or 
losses, confounding the outcome associations. Other possible reasons for the 
discrepancy in findings include the different time period of the discovery (2000-2002) 
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and validation (1993-2011) cohorts. Adjuvant treatment details could not be retrieved 
for all patients due to issues with access to old clinical records, but treatment changes 
over the time period include possibly the use of more chemotherapy and incorporation 
of taxanes in addition to anthracyclines since early 2000s. The treatment variables are 
unlikely to affect the results to any significant extent as the standard prognostic 
variables of tumour size, grade and stage have remained robust in predicting survival 
outcomes in both cohorts. 
 
4.6 Conclusions  
 
While the final results of this TMA study did not support our initial hypothesis that loss 
of expression of neurofibromin in sporadic breast cancers would be associated with 
overexpression of pAkt and pMAPK, leading to worse outcomes, this may be related 
to the limitations of using immunohistochemistry to evaluate the function of complex 
proteins. It may be worth repeating the study with the use of imaging analysis software 
and a different neurofibromin polyclonal antibody raised against a peptide at the C-
terminus, if there is one available. However, novel proteomic platforms such as mass 
spectrometry18 may potentially be more promising for elucidating the effects of 
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Elucidating Therapeutic Molecular Targets in 
Premenopausal Asian Women with Recurrent Breast 
Cancers 
5.1 Abstract 
Breast cancer is an increasing problem in Asia, with a higher proportion of 
premenopausal patients who are at higher risk of recurrence. Targeted sequencing 
was performed on DNA extracted from primary tumour specimens of 63 
premenopausal Asian patients who relapsed after initial diagnosis of non-metastatic 
breast cancer. The most prevalent alterations included: TP53 (65%); PIK3CA (32%); 
GATA3 (29%); ERBB2 (27%); MYC (25%); KMT2C (21%); MCL1 (17%); PRKDC, 
TPR, BRIP1 (14%); MDM4, PCDH15, PRKAR1A, CDKN1B (13%); CCND1, KMT2D, 
STK11 and MLH1 (11%).  NF1 was mutated in 2% of the tumours; there were 
limitations with detecting loss of NF1 in FFPE specimens. Sixty of the 63 patients (95%) 
had at least one genetic alteration in a signaling pathway related to cell cycle or p53 
signaling. The presence of MCL1 amplification, HIF-1-alpha transcription factor 
network pathway alterations and direct p53 effectors pathway alterations were 
independent predictors of inferior overall survival from initial diagnosis. Comparison 
with non-Asian premenopausal tumours in The Cancer Genome Atlas (TCGA) 
revealed a higher prevalence of TP53 mutations among HER2-positive cancers, and 
more frequent TP53, TET2 and CDK12 mutations among hormone receptor positive 
HER2-negative cancers in our cohort. Given the limited number of non-Asian 
premenopausal breast cancers that had relapsed in TCGA, we compared the 
frequency of mutations in our cohort with 43 premenopausal specimens from both 
TCGA and International Cancer Genome Consortium (ICGC) that had relapsed. There 
was a trend towards higher prevalence of TP53 mutations in our cohort. Certain 
genomic aberrations may be enriched in tumours of poor-prognosis premenopausal 
Asian breast cancers. The development of novel therapies targeting these aberrations 




Breast cancer is an increasing health problem in East Asia where the incidence of 
breast cancer has been rising dramatically over the past few decades. In contrast to 
the trends in the United States which report stable or decreasing breast cancer 
incidence rates among Chinese Americans and non-Hispanic whites over the period 
1990-2008, the breast cancer rates have been increasing in several Asian countries, 
with net drift at 2.67% per year for women in Singapore, and as high as 5.64% per 
year for women from rural China 1.  For the younger age groups, the incidence of 
breast cancer in several Asian countries, such as Singapore and South Korea, has 
even surpassed that in the United States 1,2.  
 
The recent increase in breast cancer rates cannot be solely attributed to the effects of 
screening and improved data capture. The adoption of a Westernised lifestyle in recent 
generations has been suggested as a major cause of this trend. Hormonal risk factors 
such as earlier age at menarche, low parity, delayed age at first birth, rising body mass 
index and dietary factors with increased consumption of fat and animal-source 
products, have been implicated 2-4. In addition, the progressive urbanization and 
industrialization of East Asia has been suggested to result in increasing exposure of 
women to environmental pollutants with oestrogenic effects, and this may contribute 
further to the increasing incidence of breast cancer 4. 
 
There are distinct ethnic differences in the biology of certain cancers such as lung 
adenocarcinoma, where the frequency of mutations in EGFR (epidermal growth factor 
receptor) is significantly higher in East Asians compared to Western populations 5. To 
date, such differences have not been reported in breast cancer. However compared 
with Western countries, the age of diagnosis of breast cancer is generally younger in 
East Asia 2,4,6. Over 40% of breast cancers in Asia are diagnosed in women under 50 
years of age, compared to approximately 20% in Western countries 6. Younger women 
with early breast cancer are at higher risk of relapse and death from breast cancer; 
this may be related to differences in tumour and/or host biology 7. Comparison of 
breast cancers from young and elderly women in The Cancer Genome Atlas (TCGA) 
revealed an association of GATA3 mutations and chr6q27 deletions with younger age, 
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and higher expression of gene signatures related to proliferation, stem cell features 
and endocrine resistance 8. 
 
Given the limited data on Asian breast cancers, and the higher prevalence in 
premenopausal patients, it is critical to elucidate the genomic landscape in 
premenopausal Asian patients who relapse after initial diagnosis of non-metastatic 
breast cancer. The main objective of this study is to identify actionable genomic 
aberrations in the primary breast cancers from premenopausal Asian patients who 
subsequently relapse. We also aimed to identify the genomic aberrations associated 
with inferior survival outcomes, and to compare the frequency of these genomic 
aberrations with non-Asian premenopausal tumours in publicly available databases 
such as TCGA and International Cancer Genome Consortium (ICGC). 
 
5.3 Materials and Methods  
Patients and samples 
Women who were premenopausal on initial diagnosis of breast cancer and relapsed 
subsequently were identified during outpatient clinic visits, inpatient hospital 
admissions, or from the institutional database at the National Cancer Centre 
Singapore and the Asan Medical Centre, South Korea. Demographic data, 
histopathological features, treatment details and patient outcome (time to relapse and 
overall survival) were obtained from medical records. The definitions of estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) positivity in this study were based on the latest recommendations 
by the American Society of Clinical Oncology and the College of American 
Pathologists 9,10. The study design was conceived by the candidate, and was approved 
by SingHealth Centralised Institutional Review Board and Asan Medical Center 
Institutional Review Board in the respective institutions. This research was conducted 
in accordance with all relevant guidelines and procedures, with signed informed 
consent obtained from patients over 2014-2016, and waiver of consent from deceased 
patients as granted by the local ethics committees. 
 




DNA extraction, QC, library preparation and pipeline analysis were performed by 
collaborators from Oncology Next-Generation Diagnostics, Novartis Institutes for 
Biomedical Research, Cambridge, USA. DNA was extracted from formalin-fixed 
paraffin-embedded (FFPE) sections of the initial breast cancer primary with at least 
50% tumour percentage from 110 patients, using Promega Maxwell DNA purification 
kit as per manufacturer's instructions. DNA libraries were generated using the TruSeq 
Nano Library Preparation kit (Illumina). Hybridization capture to a customised Agilent 
SureSelectXT panel was used to enrich coding regions from 567 cancer-related genes. 
The analysis cohort consisted of 63 unique samples that passed quality control metrics 
for sequencing on a HiSeq-2500 with average coverage of at least 300X. Other quality 
control requirements included a mean bait coverage > 200, and the Picard HsMetrics 
parameters of GC_DROPOUT < 20 and AT_DROPOUT < 20. The average coverage 
achieved was 630X, average on-target rate was ~ 80% and the average duplication 
rate was 26.5%. The NGDx PanCancer version 2 panel interrogates the entire coding 
sequence of 567 cancer-related genes plus select introns from 57 genes often 
rearranged or altered in solid tumor cancers (Supplementary Table S5.1).  
 
Sequencing data was processed as follows:  Sequence reads were aligned with BWA-
MEM to the reference human genome (build hg19) (https://arxiv.org/abs/1303.3997). 
Next, PCR duplicates were marked with Picard (http://broadinstitute.github.io/picard/) 
and the Genome Analysis ToolKit (GATK) was used for local realignment and base 
quality score recalibration 11,12. Single nucleotide variants (SNVs) were called using 
MuTect 13, indels using Pindel 14 and copy number was called using PureCN 15. SNVs 
and indels were annotated with dbSNP v146 16, COSMIC v70 17 and for various other 
databases using the SnpEff tool 18. 
 
SNVs and indels were filtered for germline variants and artifacts using a pool of normal 
control samples and an extensive set of filters using the dbSNP and 1000 genomes 
databases. SNV were considered as sequencing artifacts if they were observed in at 
least 2 of 50 normal samples, or occurred within simple repeats or segmental 
duplications in the UC Santa Cruz reference genome annotation.  SNV were 
considered as germline variants if they matched one of the following 3 criteria: (1) 
found in at least 2 samples in the Exome Sequencing Project database; (2) annotated 
as common by dbSNP (>5% minor allele fraction in 1 or more populations, as 
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determined by the G5 flag in dbSNP); (3) identified in the 1000 Genomes Project.  
Putative germline variants could be rescued if they were annotated in the COSMIC 
database.  Otherwise, germline variants were excluded from further analyses. Non-
silent variants with a minimum of 5 supporting reads and total read coverage  50X 
were retained. For indels, the minimum threshold was set at 4 reads. Indel length size 
was capped at 100bp. 
 
Allele-specific copy number was obtained from coverage data for probe intervals. 
Coverage was first normalized for GC-bias. The purity, ploidy and copy number were 
jointly estimated for each sample using PureCN 15. For coverage normalization, 
PureCN uses a pool of normal samples to determine a ‘best-match’ set of normals 
using Principal Component Analysis. Probe-level copy number values are averaged 
into per-gene values before reporting. We also conducted pathway level analysis of 
16 most relevant pathways in cancer development and progression (Supplementary 
Table S5.2). 
 
Genomic analysis of TCGA and ICGC samples 
TCGA data was obtained from the cBioPortal and included the most comprehensive 
set of cases from the “TCGA Provisional” dataset 
(http://www.cbioportal.org/study?id=brca_tcga).  The ICGC data included the BRCA-
EU study and was obtained from the ICGC Portal (https://dcc.icgc.org/projects/BRCA-
EU). Since this was a whole genome study, we only retained and analysed mutations 
in the 567 cancer-related genes present in the PanCancer panel. All intergenic, 
intronic, upstream, downstream and other silent mutations or others of no significance 
were discarded for comparison purposes. In addition, single nucleotide calls made 
using the CaVEMan and indels called by Pindel alone were retained in accordance 
with the reporting of genomic data 19. Clinical characteristics of the patients were 
picked up from the Supplementary Material in the publications 19,20. 
 
Statistical Analyses 
For each gene, a Fisher exact test was used to assess differences in the population 
frequencies of mutations (SNV and indels) in this cohort, versus pre-menopausal, non-
Asian breast cancer subjects from TCGA and/or ICGC.  The Benjamini-Hochberg 
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method of computing the False Discovery Rate was used to adjust for multiple 
hypothesis testing. 
 
Overall survival (OS) distributions were estimated using the Kaplan-Meier method, and 
differences in survival from initial diagnosis were assessed with log-rank tests.  
Adjusting for age at diagnosis and breast cancer subtype, two multivariable Cox 
proportional hazards regression models (one to assess the associations of genetic 
alteration status with OS, another to assess the associations of pathway alterations 
with OS) were estimated. For the model assessing genetic alteration associations, 
variable selection was performed via best subsets selection using the Akaike 
Information Criterion (AIC), constrained with the compulsory inclusion of age and 
subtype. Thirteen of the most commonly altered genes (alteration frequency of 13% 
and above) were selected for this multivariable analysis of single gene alterations. For 
the model assessing pathway alteration associations, due to high pairwise correlations 
among pathway alterations and issues of multicollinearity, variable selection was 
performed via regularized coefficient shrinkage using the LASSO (Least Absolute 
Shrinkage and Selection Operator) technique, leaving age and subtype unpenalized. 
These analyses were performed using STATA 15.0. 
 
5.4 Results 
Clinical and Pathological Characteristics 
A total of 110 patients were identified over the study period from September 2014 to 
May 2016 to have relapsed from breast cancer and had been premenopausal at initial 
diagnosis. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) sections 
of the initial breast cancer primary from these patients, of which 63 unique samples 
passed quality control. Hence the patient population with sequencing data consists of 
63 women who were premenopausal at initial diagnosis from 2008 to 2015 (Table 5.1). 
The median age at diagnosis was 42 years (range 25-49 years). Majority of the cases 
were stage 2 (41.3%) or stage 3 (52.4%) at diagnosis. The most common 
immunohistochemical subtype was “luminal” (defined as ER and/or PR+ HER2- in this 
study) at 42.9%, followed by HER2-overexpressing subtype (regardless of hormone 
receptor status) at 33.3%, while triple negative cases comprised 23.8% of patients in 
the cohort. The median time to relapse was 23 months (range 6-150 months). The 
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median OS was 59 months (95% C.I. 45-79 months) after initial diagnosis, and 25 
months (95% C.I. 20-27 months) after relapse. 
 
Prevalence of genomic alterations 
Among the 63 cases with sequencing data, a total of 406 SNVs and 52 indels were 
found (Figure 5.1, Supplementary Table S5.3).  The most prevalent mutations and 
amplifications in oncogenes included:  PIK3CA (32%); GATA3 (29%); ERBB2 (27%); 
MYC (25%); MCL1 (17%); PRKDC (14%); MDM4 (13%); and CCND1 (11%). While 
NF1 was altered in 6% (4/63) of the tumours – only one harboured a mutation 
(1/63=1.6%), with amplification detected in 3 other tumours. Detecting loss of NF1 was 
not feasible with the DNA from FFPE specimens. The most prevalent alterations in 
tumor suppressor genes included: TP53 (65%); KMT2C (21%); PCDH15 (13%); 
KMT2D (11%); STK11 (11%); and MLH1 (11%).  Sixty of the 63 patients (95%) had at 
least one genetic alteration in a signaling pathway related to cell cycle or p53 signaling 




Table 5.1: Patient and Primary Tumour Characteristics 
















Age in years, median (range)  42 (25 – 49) 
Follow-up in months from initial diagnosis, median 
(range) 
 44 (8 – 168) 
Ethnicity     
Chinese 6 (37.5) 13 (46.4) 9 (47.4) 28 (44.4) 
Korean 7 (43.8) 10 (35.7) 5 (26.3) 22 (34.9) 
Malay 0 3 (10.7) 5 (26.3) 8 (12.7) 
Indian 2 (12.5) 0 0 2 (3.2) 
Others 1 (6.3) 2 (7.1) 0 3 (4.8) 
AJCC stage     
0 0 0 1 (5.3) 1 (1.6) 
I 0 1 (3.6) 1 (5.3) 2 (3.2) 
II 5 (31.3) 11 (39.3) 10 (52.6) 26 (41.3) 
III 10 (62.5) 16 (57.1) 7 (36.8) 33 (52.4) 
Unknown (TxN1M0) 1 (6.3) 0 0 1 (1.6) 
Grade     
1 0 0 0 0 
2 6 (37.5) 11 (39.3) 6 (31.6) 23 (36.5) 
3 10 (62.5) 16 (57.1) 13 (68.4) 39 (61.9) 
Unknown 0 1 (3.6) 0 1 (1.6) 
ER status at diagnosis     
Positive 9 (56.3) 19 (67.9) 8 (42.1) 36 (57.1) 
Negative 7 (43.8) 9 (32.1) 11 (57.9) 27 (42.9) 
PR status at diagnosis     
Positive 7 (43.8) 13 (46.4) 7 (36.8) 27 (42.9) 
Negative 9 (56.3) 15 (53.6) 12 (63.2) 36 (57.1) 
HER2 status at diagnosis     
Positive 4 (25.0) 11 (39.3) 6 (31.6) 21 (33.3) 
Negative 12 (75.0) 17 (60.7) 13 (68.4) 42 (66.7) 
Immunohistochemical subtype     
“Luminal” (ER and/or PR+, HER2-) 7 (43.8) 13 (46.4) 7 (36.8) 27 (42.9) 
HER2-overexpressing (regardless of ER/PR) 4 (25.0) 11 (39.3) 6 (31.6) 21 (33.4) 
Triple negative (ER-, PR-, HER2-) 5 (31.3) 4 (14.3) 6 (31.6) 15 (23.8) 
Histology     
Ductal 15 (93.8) 25 (89.3) 15 (78.9) 55 (87.3) 
Lobular 0 0 2 (10.5) 2 (3.2) 
Others 1 (6.3) 3 (10.8) 2 (10.6) 6 (9.6) 
Adjuvant/neoadjuvant chemotherapy      
No 0 3 (10.7) 4 (21.1) 7 (11.1) 
Yes 16 (100) 25 (89.3) 15 (78.9) 56 (88.9) 
Adjuvant/neoadjuvant anti-HER2 therapy (among 
HER2+) 
    
No 0 1 (9.1) 1 (16.7) 2 (9.5) 
Yes 4 (100) 10 (90.9) 5 (83.3) 19 (90.5) 
Adjuvant/neoadjuvant endocrine therapy (among 
ER+ and/or PR+) 
    
No 0 3 (15.8) 2 (22.2) 5 (13.5) 




Figure 5.1: Genomic profile of 63 tumor samples ordered by receptor status: HER2+ 
(n = 21), hormone receptor (HR)+ and HER2- (n = 27) and Triple Negative (n = 15), 
and purity.  
The figure lists the prevalence of mutations, indels and copy number variations for recurrently 
mutated genes in breast cancer and the mutation load of each sample. Purity and mutation load are 
indicated for each sample. The darker the shade, the higher the value. 
 
Association between clinical, molecular characteristics and survival outcomes 
From multivariable analysis where the resultant model incorporated age, 
immunohistochemical subtype as well as other clinicopathologic characteristics 
including the most common gene alterations, age (HR 1.10 per year increase; 95% CI 
1.03-1.17; p=0.006) and presence of MCL1 amplification (HR 4.24; 95% CI 1.62-11.07; 
p=0.003) were found to be independent predictors of OS from initial diagnosis (Table 
5.2).  
 
Given that mutations in different genes can compromise a particular pathway and this 
may provide a better prediction of outcomes compared to alterations in individual 
genes, we also tested for associations between pathway alterations and OS (Table 
5.3). From multivariable analysis, only age (HR 1.09 per year increase; 95% CI 1.02-
1.17; p=0.008), presence of alterations in the HIF-1-alpha transcription factor network 
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pathway, which includes MCL1 among other genes (HR 2.57; 95% CI1.18-5.60; 
p=0.017), and presence of alterations in direct p53 effectors (HR 3.61; 95% CI 1.08-




Table 5.2: Multivariable analysis for patient and tumour characteristics, including 
genetic alterations (all patients, n=63) for OS from initial diagnosis. Reduced model 
is the model with lowest AIC, and inferences should be made from here. 




 Full model Reduced model 
Characteristic HR (95% CI) P[1] HR (95% CI) P[1] 
Age (hazard ratio per year increase) 1.11 (1.02 – 1.20) 0.013 1.10 (1.03 – 1.17) 0.006 
Immunohistochemical subtype  0.117[2]  0.196[2] 
“Luminal” 1 - 1 - 
HER2-overexpressing 0.28 (0.08 – 1.00) 0.049 0.52 (0.20 – 1.31) 0.166 
Triple negative 0.66 (0.20 – 2.20) 0.498 1.28 (0.51 – 3.20) 0.599 
AJCC stage     
0, I, II 1 - 1 - 
III 2.07 (0.80 – 5.37) 0.135 1.88 (0.89 – 3.95) 0.097 
Grade     
1, 2 1 - - - 
3 0.63 (0.17 – 2.36) 0.492 - - 
TP53 alteration     
No 1 - - - 
Yes 2.51 (0.47 – 13.51) 0.284 - - 
PIK3CA alteration     
No 1 - - - 
Yes 0.67 (0.25 – 1.76) 0.414 - - 
GATA3 alteration     
No 1 - - - 
Yes 1.11 (0.38 – 3.19) 0.851 - - 
MYC alteration     
No 1 - - - 
Yes 1.83 (0.63 – 5.31) 0.264 - - 
KMT2C alteration     
No 1 - - - 
Yes 1.48 (0.51 – 4.28) 0.469 - - 
MCL1 alteration     
No 1 - 1 - 
Yes 4.93 (1.29 – 18.79) 0.020 4.24 (1.62 – 11.07) 0.003 
PRKDC alteration     
No 1 - - - 
Yes 0.76 (0.20 – 2.87) 0.691 - - 
TPR alteration     
No 1 - - - 
Yes 1.60 (0.28 – 9.19) 0.598 - - 
BRIP1 alteration     
No 1 - - - 
Yes 2.08 (0.21 – 20.75) 0.533 - - 
CDKN1B alteration     
No 1 - - - 
Yes 1.89 (0.54 – 6.63) 0.319 - - 
PCDH15 alteration     
No 1 - - - 
Yes 1.56 (0.48 – 5.03) 0.455 - - 
PRKAR1A alteration     
No 1 - 1 - 
Yes 0.25 (0.02 – 2.50) 0.237 0.38 (0.11 – 1.27) 0.116 
MDM4 alteration     
No 1 - - - 
Yes 0.39 (0.06 – 2.53) 0.326 - - 
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Table 5.3: Multivariable analysis for patient and tumour characteristics, pathway 
alterations (all patients, n=63) for OS from initial diagnosis. Reduced model contains 
only the variables selected via LASSO regularization, and inferences should be made 
from here. 
 [1] Based on Wald test; [2] Based on likelihood ratio test 
 
 
 Full model Reduced model 
Characteristic HR (95% CI) P[1] HR (95% CI) P[1] 
Age (hazard ratio per year increase) 1.10 (1.01 – 1.20) 0.026 1.09 (1.02 – 1.17) 0.008 
Immunohistochemical subtype  <0.001[2]  0.165[2] 
“Luminal” 1 - 1 - 
HER2-overexpressing 0.07 (0.01 – 0.31) 0.001 0.48 (0.20 – 1.16) 0.103 
Triple negative 3.33 (0.63 – 17.76) 0.158 1.07 (0.42 – 2.72) 0.894 
AJCC stage     
0, I, II 1 - - - 
III 4.29 (1.20 – 15.31) 0.025 - - 
Grade     
1, 2 1 - - - 
3 1.36 (0.32 – 5.71) 0.675 - - 
Chromatin remodeling by hswi/snf 
atp-dependent complexes     
No 1 - - - 
Yes 0.18 (0.02 – 1.45) 0.107 - - 
Role of ERBB2 in signal 
transduction and oncology     
No 1 - - - 
Yes 0.41 (0.08 – 1.95) 0.261 - - 
P53 signaling pathway     
No 1 - - - 
Yes 1.45 (0.06 – 37.74) 0.822 - - 
Cell cycle:g2/m checkpoint     
No 1 - - - 
Yes 0.38 (0.00 – 48.26) 0.697 - - 
Mapkinase signaling pathway     
No 1 - - - 
Yes 0.10 (0.02 – 0.47) 0.003 - - 
Mtor signaling pathway     
No 1 - - - 
Yes 0.56 (0.10 – 3.29) 0.524 - - 
Cell cycle:g1/s checkpoint     
No 1 - - - 
Yes 0.04 (0.00 – 1.90) 0.104 - - 
C-MYC pathway     
No 1 - - - 
Yes 0.62 (0.11 – 3.39) 0.579 - - 
Notch signaling pathway     
No 1 - - - 
Yes 8.76 (1.97 – 38.97) 0.004 - - 
BRCA1 dependent ub ligase activity     
No 1 - - - 
Yes 0.03 (0.00 – 0.31) 0.002 - - 
PTEN dependent cell cycle arrest 
and apoptosis     
No 1 - - - 
Yes 8.39 (1.40 – 50.29) 0.020 - - 
Rb tumor suppressor/checkpoint 
signaling in response to dna 
damage     
No 1 - - - 







HIF-1-alpha transcription factor 
network     
No 1 - 1 - 
Yes 3.60 (0.80 – 16.17) 0.095 2.57 (1.18 – 5.60) 0.017 
IL6-mediated signaling events     
No 1 - - - 
Yes 0.86 (0.13 – 5.51) 0.870 - - 
E2F transcription factor network     
No 1 - - - 
Yes 1.93 (0.24 – 15.25) 0.534 - - 
Direct p53 effectors     
No 1 - 1 - 
Yes 
2358.48 (1.46 – 
3810528.00) 0.039 




Comparison with premenopausal non-Asian breast cancers in TCGA20 
The prevalence of mutations was compared between this cohort and 167 
premenopausal, non-Asian breast cancer patients from TCGA with information on 
hormone receptor and HER2 status (Figure 5.2).  The small number of Asian 
premenopausal cases in TCGA cohort, with 9 hormone receptor positive, HER2 
negative tumours, 5 HER2 positive tumours and no triple negative cancers, precludes 
any meaningful comparison with our cohort. Given the variability in copy number 
calling on a number of platforms with varying sample purity levels across different 
laboratories in TCGA, it is challenging to perform an accurate comparison of copy 
number alterations with our dataset. Hence comparisons with genomic data were 
made only for the mutations in the set of 567 genes used in our study. 
 
Comparison of the HER2-positive cases (regardless of hormone receptor status) 
revealed a significantly higher prevalence of TP53 (76%) mutations (FDR q < 0.05) 
in our cohort (Figure 5.2A).  Among the hormone receptor (HR) positive and HER2 
negative cases, there was a significantly higher prevalence of TP53 (48%), TET2 
(18%) and CDK12 (15%) mutations (FDR q < 0.05) (Figure 5.2B) than TCGA cohort.  
With the small number of triple negative breast cancer patients, no significant 






Figure 5.2: Mutation prevalence in our cohort (PABC: Premenopausal Asian Breast 
Cancers) and comparison to pre-menopausal, non-Asian breast cancer patients in 
The Cancer Genome Atlas.  
Starred genes indicate significant difference from TCGA data (FDR q < 0.05). (A) Comparison of 21 
HER2-positive samples against 58 non-Asian TCGA samples. (B) Comparison of 27 hormone 
receptor-positive samples against 81 non-Asian TCGA samples. (C) Comparison of 15 triple negative 




Comparison with premenopausal breast cancers in TCGA and ICGC that 
subsequently relapsed 
In order to compare frequently-mutated genes between Asian and non-Asian 
premenopausal breast cancers, we surveyed 43 premenopausal breast cancer 
patients who had relapsed from both TCGA and ICGC studies (25 non-Asian 
premenopausal from TCGA and 18 premenopausal from ICGC-EU) (Figure 5.3) 19,20. 
ICGC is currently the only other publicly available dataset with information on 
recurrence status. Comparison between all patients revealed a higher prevalence of 
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TP53 mutations (65% versus 35%) in our cohort (Figure 5.3A). However the limited 
number of cases in both cohorts did not result in statistical significance. 
 
 
Figure 5.3: Mutation prevalence in our cohort (PABC: Premenopausal Asian Breast 
Cancers) and comparison to 43 premenopausal breast cancer patients who had 
relapsed from both TCGA and ICGC studies. (A) Comparison of all 63 samples in the 
cohort against 43 premenopausal breast cancer patients (all subtypes) who had 
relapsed from both TCGA and ICGC studies (25 non-Asian premenopausal from 
TCGA and 18 premenopausal from ICGC-EU). (B) Comparison of 21 HER2-positive 
samples against 9 TCGA + ICGC samples. (C) Comparison of 27 hormone receptor-
positive samples against 17 TCGA + ICGC samples. (D) Comparison of 15 triple 






While large scale sequencing projects have unraveled the complex architecture of 
breast cancers in the West 19-22, data on the genomic landscape of Asian breast 
cancers, including premenopausal tumours, remains limited 23,24. Given that studies 
on next generation sequencing of Asian breast cancers that are currently published 
focus on special subsets, it is not possible to compare the mutation frequency from 
our cohort with an Asian premenopausal breast cancer cohort that has not relapsed. 
For example, in the study by Kim et al from Korea, whole exome sequencing was 
performed on 34 metastatic breast cancer specimens, with patient age ranging from 
26.5 to 75.7 years 23. In another study by Lee et al, also from Korea, a total of 78 
normal-paired breast cancers were subjected to whole exome and RNA sequencing, 
but only 35 were from patients under the age of 50 years 24. As illustrated in figures 
2 and 3, the numbers of premenopausal non-Asian tumours profiled in large 
sequencing projects such as TCGA and ICGC are also limited. In this study, we have 
focused on characterizing the genomic profile of premenopausal Asian breast 
cancers which ultimately relapse, given that this is an area of unmet need. Similar to 
reports from other sequencing studies 19-21, there is a large number of genes where 
the frequency of alterations is <10%, reflecting the heterogeneity of the genomic 
landscape in breast cancer. Each tumour was also distinct with its own unique set of 
alterations. 
 
The prevalence of TP53 mutations is higher among the hormone receptor positive 
and HER2-positive subtypes in our cohort compared to non-Asian premenopausal 
cancers in TCGA, along with elevated frequencies of TET2 and CDK12 mutations 
among hormone receptor positive patients. The finding that TP53 is more frequently 
mutated overall in our series may be related to the pre-selection of poor-prognosis 
tumours. However, this is also consistent with the findings from a recent study on 
unselected breast cancers from Chinese women. It reported no significant difference 
in the frequency of hormone receptor positive and HER2 negative tumours compared 
to the Caucasian series, but the prevalence of PAM50 luminal A subtype was lower 
and the prevalence of luminal B subtype was higher 25. The frequency of HER2-
overexpressing and basal-like breast cancers was similar between Chinese and 
Caucasian breast cancers. Luminal B subtypes are associated with more aggressive 
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biology and higher risk of relapse, and often harbour TP53 mutations which have 
been implicated in resistance to endocrine and cytotoxic therapies 20,21,26,27. In 
addition, the frequency of TP53 mutations appears higher in our cohort compared to 
non-Asian premenopausal tumours in TCGA and ICGC that had relapsed, though 
this finding will require further validation in a larger study. These differences may 
possibly be related to differences in germline variants or polymorphisms, or 
environmental factors such as exposure to pollutants with oestrogenic effects 4. While 
targeting the loss of function of tumour suppressor genes remains a major challenge, 
there may be opportunities in the near future with the advent of immune-based and 
epigenetic strategies, as well as compounds targeting downstream effectors in the 
affected pathways.  
 
Although the presence of inactivating mutations in NF1 was associated with inferior 
breast cancer-specific survival among ER negative tumours in the METABRIC study 
(hazard ratio 2.7; CI: 1.3-5.5) 28, with a different study reporting similar inferior 
outcomes more recently in ER positive tumours with NF1 nonsense or frameshift 
mutations 29, only 1 of the 63 specimens in our series of poor prognosis was found to 
harbor mutation in NF1 (2%).  This is similar to frequencies reported in the large-
scale sequencing projects of primary breast cancers which reported mutation 
frequency in NF1 of 1% to 3.6% 28,30,31. A study on the genomic evolution of breast 
cancer metastases also reported that NF1 mutations were significantly enriched in 
the metastatic specimens 32, in keeping with the important role that NF1 plays in 
breast cancer pathogenesis and progression. Our study focused on breast primary 
specimens, and amplification of NF1, with ploidy ranging from 2.1 to 3.4, was 
observed. The functional significance of gains in copy number of NF1 is not known, 
though amplification of NF1 has also been reported in breast cancers in other 
sequencing studies at frequencies of 1.6% to 2.5% 20,28 , with the frequency as high 
as 17% in 5 out of 29 breast cancer xenografts in another study 33 
(http://www.cbioportal.org). Due to the nature of DNA from FFPE specimens, we 
could not reliably identify loss of NF1 in the copy number analyses. 
 
Other alterations present at higher frequencies in our series of poor-prognosis 
tumours include CDK12 and TET2. CDK12 (cyclin-dependent kinase 12) is a 
regulatory kinase which protects cells from genomic instability. Recurrent CDK12 
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mutations in breast and ovarian cancers are associated with defects in DNA repair 34.  
Silencing of CDK12 has been shown to activate the mitogen-activated protein kinase 
(MAPK) signaling pathway, leading to endocrine therapy resistance through loss of 
ER dependence 35.  TET2 (tet-eleven translocation 2) from the TET family of DNA 
dioxygenases functions as DNA demethylases, antagonizing DNA 
methyltransferases-mediated DNA methylation and gene repression. Knockdown of 
TET2 in breast cancer cells decreases epithelial cell adhesion molecule (EpCAM) 
and E-cadherin, increasing cell invasiveness 36.  
 
MCL1 (myeloid cell leukaemia-1), a member of the anti-apoptotic pro-survival Bcl-2 
family, can be amplified in all subtypes of breast cancer. In our cohort, MCL1 
amplification was predictive of inferior OS, likely related to the resistance to endocrine, 
cytotoxic and anti-HER2 therapies reported in preclinical studies 37,38. The in vitro 
activity of MCL-1 inhibitors alone or in combination with other anti-cancer drugs 
provide a strong rationale for their clinical development 39,40. 
 
Limitations of our study include the relatively small sample size, and the limited 
number of premenopausal breast cancers in TCGA and ICGC databases for 
comparison. Information on ethnicity was not documented for the ICGC cohort, 
although most of the patients were non-Asian. The suboptimal quality of DNA from 
older FFPE specimens also led to greater representation of more recent aggressive 
cases such as HER2-positive and triple negative cases which relapsed soon after 
initial diagnosis. This bias may partly explain why there were no significant survival 
differences among the different immunohistochemical subtypes, without association 
of younger age with worse survival. Conversely, increasing age was associated with 
worse OS in this selected premenopausal cohort, unlike studies which reported 
higher risk of relapse among younger women in non-metastatic cancers 7. The 
retrospective nature of our study may also create some bias and heterogeneity, as it 
was not performed as a prospective cohort study or clinical trial. However, the data 
from this, and from similar studies4,25, is sufficiently compelling to suggest that a 





While it is possible to identify increased copy number with the targeted gene panel, 
the low tumour purity of FFPE samples makes it difficult to distinguish between lack 
of tumour content and a true copy number loss. Hence the computational loss of 
heterozygosity calls in this cohort may not be reliable and are not reported. Germline 
DNA was not available for this study as a matched control. However our 
computational pipelines have been optimized to exclude germline and false positive 
sites, including for tumor suppressor genes. Lastly, we did not profile the recurrent 
specimens to interrogate the genomic evolution in the metastatic process. However, 
a recent study has demonstrated that new driver mutations private to the metastatic 
lesions are acquired later in the metastatic lineage 32. Hence the primary tumour 
genome can still serve as a good proxy for the cells that seed the distant sites, and 
remains relevant in the development of therapeutic strategies in the adjuvant setting 
to prevent relapse. 
 
5.6  Conclusions 
In conclusion, our study has provided insights into the molecular profiles of Asian 
premenopausal breast cancer associated with relapse. The heterogeneity of breast 
cancers highlights the need to explore ethnic diversity in the genomic landscape. 
Standard systemic adjuvant therapies may be ineffective in these patients, and novel 
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5.8 Supplementary data 
 
Supplementary Table S5.1: List of genes in NGDx PanCancer versión 2 panel 
 
Gene Gene.Name Entrez_ID Rationale 
ABL1 c-abl oncogene 1, receptor tyrosine 
kinase 
25 Known Cancer Gene 
ABL2 v-abl Abelson murine leukemia viral 
oncogene homolog 2 (arg, Abelson-
related gene) 
27 Copy Number Gene 
ACTL6A actin-like 6A 86 Exploratory Gene 
ACTL6B actin-like 6B 51412 Exploratory Gene 
ACVR1B activin A receptor, type IB 91 Known Cancer Gene 
ACVR2A activin A receptor type 2A 92 Exploratory Gene 
AFF2 AF4/FMR2 family, member 2 2334 Known Cancer Gene 
AKT1 v-akt murine thymoma viral oncogene 
homolog 1 
207 Known Cancer Gene 
AKT2 v-akt murine thymoma viral oncogene 
homolog 2 
208 Known Cancer Gene 
AKT3 v-akt murine thymoma viral oncogene 
homolog 3 (protein kinase B, gamma) 
10000 Known Cancer Gene 
ALK anaplastic lymphoma receptor tyrosine 
kinase 
238 Known Cancer Gene 
ALOX12B arachidonate 12-lipoxygenase, 12R type 242 Exploratory Gene 
AMER1 APC membrane recruitment protein 1 139285 Exploratory Gene 
ANAPC1 anaphase promoting complex subunit 1 64682 Exploratory Gene 
ANO1 anoctamin 1, calcium activated chloride 
channel 
55107 Exploratory Gene 
APC adenomatous polyposis coli 324 Known Cancer Gene 
AR androgen receptor 367 Copy Number Gene 
ARAF v-raf murine sarcoma 3611 viral 
oncogene homolog 
369 Exploratory Gene 
ARFRP1 ADP-ribosylation factor related protein 
1 
10139 Exploratory Gene 
ARHGEF39   84904 Known Cancer Gene 
ARID1A AT rich interactive domain 1A (SWI-like) 8289 Known Cancer Gene 
ARID1B AT rich interactive domain 1B (SWI1-
like) 
57492 Exploratory Gene 
ARID2 AT rich interactive domain 2 (ARID, RFX-
like) 
196528 Known Cancer Gene 
ARID5B AT-rich interaction domain 5B 84159 Exploratory Gene 
ATAD2 ATPase family, AAA domain containing 2 29028 Exploratory Gene 
ATM similar to Serine-protein kinase ATM 
(Ataxia telangiectasia mutated) (A-T, 
mutated); ataxia telangiectasia mutated 
651610 Known Cancer Gene 
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ATR ataxia telangiectasia and Rad3 related; 
similar to ataxia telangiectasia and Rad3 
related protein 
651921 Exploratory Gene 
ATRX alpha thalassemia/mental retardation 
syndrome X-linked (RAD54 homolog, S. 
cerevisiae) 
546 Known Cancer Gene 
AURKA aurora kinase A; aurora kinase A 
pseudogene 1 
6791 Exploratory Gene 
AURKB aurora kinase B 9212 Exploratory Gene 
AXIN1 axin 1 8312 Known Cancer Gene 
AXL AXL receptor tyrosine kinase 558 Known Cancer Gene 
B3GAT1 beta-1,3-glucuronyltransferase 1 
(glucuronosyltransferase P) 
27087 Copy Number Gene 
BACH1 BTB and CNC homology 1, basic leucine 
zipper transcription factor 1 
571 Known Cancer Gene 
BACH2 BTB and CNC homology 1, basic leucine 
zipper transcription factor 2 
60468 Copy Number Gene 
BAP1 BRCA1 associated protein-1 (ubiquitin 
carboxy-terminal hydrolase) 
8314 Known Cancer Gene 
BARD1 BRCA1 associated RING domain 1 580 Known Cancer Gene 
BCL11A B-cell CLL/lymphoma 11A 53335 Exploratory Gene 
BCL11B B-cell CLL/lymphoma 11B 64919 Exploratory Gene 
BCL2A1 BCL2-related protein A1 597 Exploratory Gene 
BCL2L1 BCL2-like 1 598 Copy Number Gene 
BCL2L11 BCL2-like 11 (apoptosis facilitator) 10018 Known Cancer Gene 
BCL3 B-cell CLL/lymphoma 3 602 Copy Number Gene 
BCL6 B-cell CLL/lymphoma 6 604 Exploratory Gene 
BCL7A BCL tumor suppressor 7A 605 Exploratory Gene 
BCL7B BCL tumor suppressor 7B 9275 Exploratory Gene 
BCL7C BCL tumor suppressor 7C 9274 Exploratory Gene 
BCOR BCL6 co-repressor 54880 Known Cancer Gene 
BDH1 3-hydroxybutyrate dehydrogenase, 
type 1 
622 Known Cancer Gene 
BIRC2 baculoviral IAP repeat-containing 2 329 Copy Number Gene 
BIRC3 baculoviral IAP repeat-containing 3 330 Exploratory Gene 
BIRC7 baculoviral IAP repeat-containing 7 79444 Copy Number Gene 
BLM Bloom syndrome, RecQ helicase-like 641 Known Cancer Gene 
BOK BCL2-related ovarian killer 666 Copy Number Gene 
BRAF v-raf murine sarcoma viral oncogene 
homolog B1 
673 Known Cancer Gene 
BRCA1 breast cancer 1, early onset 672 Known Cancer Gene 
BRCA2 breast cancer 2, early onset 675 Known Cancer Gene 
BRD4 bromodomain containing 4 23476 Exploratory Gene 
BRD7 bromodomain containing 7; 
bromodomain containing 7 pseudogene 
2 
29117 Exploratory Gene 
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BRD9 bromodomain containing 9 65980 Exploratory Gene 
BRIP1 BRCA1 interacting protein C-terminal 
helicase 1 
83990 Exploratory Gene 
BTG1 B-cell translocation gene 1, anti-
proliferative 
694 Exploratory Gene 
BTK Bruton agammaglobulinemia tyrosine 
kinase 
695 Exploratory Gene 
C11orf30 chromosome 11 open reading frame 30 56946 Exploratory Gene 
CABLES1 Cdk5 and Abl enzyme substrate 1 91768 Known Cancer Gene 
CARD11 caspase recruitment domain family, 
member 11 
84433 Exploratory Gene 
CASP8 caspase 8, apoptosis-related cysteine 
peptidase 
841 Exploratory Gene 
CBFB core-binding factor, beta subunit 865 Known Cancer Gene 
CBL Cas-Br-M (murine) ecotropic retroviral 
transforming sequence 
867 Known Cancer Gene 
CCND1 cyclin D1 595 Copy Number Gene 
CCND2 cyclin D2 894 Exploratory Gene 
CCND3 cyclin D3 896 Exploratory Gene 
CCNE1 cyclin E1 898 Copy Number Gene 
CCSER1 coiled-coil serine rich protein 1 401145 Exploratory Gene 
CD19 CD19 molecule 930 Exploratory Gene 
CD274 CD274 molecule 29126 Exploratory Gene 
CD79A CD79a molecule, immunoglobulin-
associated alpha 
973 Exploratory Gene 
CD79B CD79b molecule, immunoglobulin-
associated beta 
974 Exploratory Gene 
CDA cytidine deaminase 978 Known Cancer Gene 
CDC73 cell division cycle 73, Paf1/RNA 
polymerase II complex component, 
homolog (S. cerevisiae) 
79577 Exploratory Gene 
CDH1 cadherin 1, type 1, E-cadherin 
(epithelial) 
999 Known Cancer Gene 
CDH13 cadherin 13, H-cadherin (heart) 1012 Copy Number Gene 
CDH20 cadherin 20, type 2 28316 Copy Number Gene 
CDH3 cadherin 3 1001 Exploratory Gene 
CDH5 cadherin 5, type 2 (vascular 
endothelium) 
1003 Copy Number Gene 
CDH6 cadherin 6 1004 Exploratory Gene 
CDK12 Cdc2-related kinase, arginine/serine-
rich 
51755 Exploratory Gene 
CDK17 PCTAIRE protein kinase 2 5128 Known Cancer Gene 
CDK2 cyclin dependent kinase 2 1017 Exploratory Gene 
CDK4 cyclin-dependent kinase 4 1019 Exploratory Gene 
CDK6 cyclin-dependent kinase 6 1021 Exploratory Gene 
CDKN1A cyclin dependent kinase inhibitor 1A 1026 Exploratory Gene 
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CDKN1B cyclin-dependent kinase inhibitor 1B 
(p27, Kip1) 
1027 Known Cancer Gene 
CDKN2A cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4) 
1029 Known Cancer Gene 
CDKN2B cyclin-dependent kinase inhibitor 2B 
(p15, inhibits CDK4) 
1030 Copy Number Gene 
CDKN2C cyclin-dependent kinase inhibitor 2C 
(p18, inhibits CDK4) 
1031 Exploratory Gene 
CEBPA CCAAT/enhancer binding protein 
(C/EBP), alpha 
1050 Exploratory Gene 
CHD1 chromodomain helicase DNA binding 
protein 1 
1105 Known Cancer Gene 
CHD3 chromodomain helicase DNA binding 
protein 3 
1107 Known Cancer Gene 
CHD4 chromodomain helicase DNA binding 
protein 4 
1108 Known Cancer Gene 
CHD5 chromodomain helicase DNA binding 
protein 5 
26038 Exploratory Gene 
CHEK1 CHK1 checkpoint homolog (S. pombe) 1111 Known Cancer Gene 
CHEK2 protein kinase CHK2-like; CHK2 
checkpoint homolog (S. pombe); similar 
to hCG1983233 
11200 Exploratory Gene 
CHFR checkpoint with forkhead and ring 
finger domains 
55743 Copy Number Gene 
CHSY3 chondroitin sulfate synthase 3 337876 Known Cancer Gene 
CHUK conserved helix-loop-helix ubiquitous 
kinase 
1147 Exploratory Gene 
CIC capicua homolog (Drosophila) 23152 Known Cancer Gene 
COPS5 COP9 constitutive photomorphogenic 
homolog subunit 5 (Arabidopsis) 
10987 Exploratory Gene 
COX18 COX18 cytochrome c oxidase assembly 
homolog (S. cerevisiae) 
285521 Known Cancer Gene 
CPSF3 cleavage and polyadenylation specific 
factor 3 
51692 Exploratory Gene 
CREBBP CREB binding protein 1387 Known Cancer Gene 
CRKL v-crk sarcoma virus CT10 oncogene 
homolog (avian)-like 
1399 Copy Number Gene 
CSF1 colony stimulating factor 1 1435 Exploratory Gene 
CSF1R colony stimulating factor 1 receptor 1436 Exploratory Gene 
CTCF CCCTC-binding factor (zinc finger 
protein) 
10664 Known Cancer Gene 
CTLA4 cytotoxic T-lymphocyte-associated 
protein 4 
1493 Copy Number Gene 
CTNNB1 catenin (cadherin-associated protein), 
beta 1, 88kDa 
1499 Known Cancer Gene 
CUL1 cullin 1 8454 Known Cancer Gene 
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CUL4A cullin 4A 8451 Exploratory Gene 
CUL4B cullin 4B 8450 Exploratory Gene 
CUX1 cut like homeobox 1 1523 Exploratory Gene 
CYP17A1 cytochrome P450, family 17, subfamily 
A, polypeptide 1 
1586 Known Cancer Gene 
DAXX death-domain associated protein 1616 Known Cancer Gene 
DCC deleted in colorectal carcinoma 1630 Known Cancer Gene 
DDR2 discoidin domain receptor tyrosine 
kinase 2 
4921 Known Cancer Gene 
DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 11 (CHL1-like helicase 
homolog, S. cerevisiae) 
1663 Copy Number Gene 
DEPDC5 DEP domain containing 5 9681 Exploratory Gene 
DICER1 dicer 1, ribonuclease type III 23405 Known Cancer Gene 
DIS3 DIS3 mitotic control homolog (S. 
cerevisiae) 
22894 Exploratory Gene 
DKK1 dickkopf homolog 1 (Xenopus laevis) 22943 Exploratory Gene 
DLGAP2 discs, large (Drosophila) homolog-
associated protein 2 
9228 Copy Number Gene 
DNMT3A DNA (cytosine-5-)-methyltransferase 3 
alpha 
1788 Known Cancer Gene 
DOT1L DOT1-like, histone H3 
methyltransferase (S. cerevisiae) 
84444 Exploratory Gene 
DPF1 D4, zinc and double PHD fingers family 1 8193 Exploratory Gene 
DPF2 D4, zinc and double PHD fingers family 2 5977 Exploratory Gene 
DPF3 D4, zinc and double PHD fingers, family 
3 
8110 Exploratory Gene 
DSG3 desmoglein 3 (pemphigus vulgaris 
antigen) 
1830 Known Cancer Gene 
DTX2 deltex homolog 2 (Drosophila) 113878 Copy Number Gene 
DUSP4 dual specificity phosphatase 4 1846 Copy Number Gene 
EED embryonic ectoderm development 8726 Exploratory Gene 
EGFR epidermal growth factor receptor 
(erythroblastic leukemia viral (v-erb-b) 
oncogene homolog, avian) 
1956 Known Cancer Gene 
EIF1AX eukaryotic translation initiation factor 
1A, X-linked 
1964 Exploratory Gene 
ELK3 ELK3, ETS-domain protein (SRF 
accessory protein 2) 
2004 Copy Number Gene 
ELK4 ELK4, ETS-domain protein (SRF 
accessory protein 1) 
2005 Known Cancer Gene 
ELMO1 engulfment and cell motility 1 9844 Exploratory Gene 
EML4 echinoderm microtubule associated 
protein like 4 
27436 Known Cancer Gene 
EP300 E1A binding protein p300 2033 Known Cancer Gene 
EPAS1 endothelial PAS domain protein 1 2034 Exploratory Gene 
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EPHA2 EPH receptor A2 1969 Known Cancer Gene 
EPHA3 EPH receptor A3 2042 Known Cancer Gene 
EPHA6 EPH receptor A6 285220 Known Cancer Gene 
EPHA7 EPH receptor A7 2045 Known Cancer Gene 
ERBB2 v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, 
neuro/glioblastoma derived oncogene 
homolog (avian) 
2064 Known Cancer Gene 
ERBB3 v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 3 (avian) 
2065 Exploratory Gene 
ERBB4 v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) 
2066 Known Cancer Gene 
ERCC1 excision repair cross-complementing 
rodent repair deficiency, 
complementation group 1 (includes 
overlapping antisense sequence) 
2067 Known Cancer Gene 
ERCC2 excision repair cross-complementing 
rodent repair deficiency, 
complementation group 2 
2068 Known Cancer Gene 
ERG v-ets erythroblastosis virus E26 
oncogene homolog (avian) 
2078 Known Cancer Gene 
ESR1 estrogen receptor 1 2099 Exploratory Gene 
ESR2 estrogen receptor 2 (ER beta) 2100 Exploratory Gene 
ETV1 ets variant 1 2115 Known Cancer Gene 
ETV4 ets variant 4 2118 Known Cancer Gene 
ETV5 ets variant 5 2119 Known Cancer Gene 
ETV6 ets variant 6 2120 Known Cancer Gene 
EWSR1 similar to Ewing sarcoma breakpoint 
region 1; Ewing sarcoma breakpoint 
region 1 
2130 Known Cancer Gene 
EZH2 enhancer of zeste homolog 2 
(Drosophila) 
2146 Known Cancer Gene 
FANCA Fanconi anemia, complementation 
group A 
2175 Exploratory Gene 
FANCC Fanconi anemia, complementation 
group C 
2176 Exploratory Gene 
FANCD2 Fanconi anemia, complementation 
group D2 
2177 Exploratory Gene 
FANCE Fanconi anemia, complementation 
group E 
2178 Exploratory Gene 
FANCG Fanconi anemia, complementation 
group G 
2189 Exploratory Gene 
FANCI Fanconi anemia, complementation 
group I 
55215 Exploratory Gene 
FANCL Fanconi anemia, complementation 
group L 
55120 Exploratory Gene 
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FANCM Fanconi anemia, complementation 
group M 
57697 Exploratory Gene 
FAT1 FAT tumor suppressor homolog 1 
(Drosophila) 
2195 Known Cancer Gene 
FAT3 FAT tumor suppressor homolog 3 
(Drosophila) 
120114 Exploratory Gene 
FBXW7 F-box and WD repeat domain 
containing 7 
55294 Known Cancer Gene 
FCGR2A Fc fragment of IgG, low affinity IIa, 
receptor (CD32) 
2212 Known Cancer Gene 
FCGR3A Fc fragment of IgG, low affinity IIIa, 
receptor (CD16a) 
2214 Known Cancer Gene 
FGF10 fibroblast growth factor 10 2255 Exploratory Gene 
FGF12 fibroblast growth factor 12 2257 Exploratory Gene 
FGF14 fibroblast growth factor 14 2259 Exploratory Gene 
FGF19 fibroblast growth factor 19 9965 Exploratory Gene 
FGF23 fibroblast growth factor 23 8074 Exploratory Gene 
FGF3 fibroblast growth factor 3 (murine 
mammary tumor virus integration site 
(v-int-2) oncogene homolog) 
2248 Exploratory Gene 
FGF4 fibroblast growth factor 4 2249 Exploratory Gene 
FGF6 fibroblast growth factor 6 2251 Exploratory Gene 
FGFR1 fibroblast growth factor receptor 1 2260 Known Cancer Gene 
FGFR2 fibroblast growth factor receptor 2 2263 Known Cancer Gene 
FGFR3 fibroblast growth factor receptor 3 2261 Known Cancer Gene 
FGFR4 fibroblast growth factor receptor 4 2264 Known Cancer Gene 
FH fumarate hydratase 2271 Copy Number Gene 
FLG filaggrin 2312 Copy Number Gene 
FLG2 filaggrin family member 2 388698 Known Cancer Gene 
FLI1 Friend leukemia virus integration 1 2313 Known Cancer Gene 
FLT1 fms-related tyrosine kinase 1 (vascular 
endothelial growth factor/vascular 
permeability factor receptor) 
2321 Known Cancer Gene 
FLT3 fms-related tyrosine kinase 3 2322 Known Cancer Gene 
FLT4 fms-related tyrosine kinase 4 2324 Copy Number Gene 
FOXA1 forkhead box A1 3169 Known Cancer Gene 
FOXC1 forkhead box C1 2296 Copy Number Gene 
FOXL2 forkhead box L2 668 Known Cancer Gene 
FOXM1 forkhead box M1 2305 Copy Number Gene 
FOXP1 forkhead box P1 27086 Exploratory Gene 
FRK fyn related Src family tyrosine kinase 2444 Exploratory Gene 
FRS2 fibroblast growth factor receptor 
substrate 2 
10818 Known Cancer Gene 
GAB2 GRB2-associated binding protein 2 9846 Copy Number Gene 
GATA1 GATA binding protein 1 (globin 
transcription factor 1) 
2623 Known Cancer Gene 
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GATA3 GATA binding protein 3 2625 Known Cancer Gene 
GLI1   2735 Exploratory Gene 
GMDS GDP-mannose 4,6-dehydratase 2762 Known Cancer Gene 
GNA11 guanine nucleotide binding protein (G 
protein), alpha 11 (Gq class) 
2767 Known Cancer Gene 
GNAQ guanine nucleotide binding protein (G 
protein), q polypeptide 
2776 Known Cancer Gene 
GNAS GNAS complex locus 2778 Known Cancer Gene 
GPC6 glypican 6 10082 Copy Number Gene 
GPR124 G protein-coupled receptor 124 25960 Exploratory Gene 
GPS2 G protein pathway suppressor 2 2874 Known Cancer Gene 
GRB2 growth factor receptor-bound protein 2 2885 Copy Number Gene 
GRIN2A glutamate receptor, ionotropic, N-
methyl D-aspartate 2A 
2903 Exploratory Gene 
GSK3B glycogen synthase kinase 3 beta 2932 Copy Number Gene 
H3F3A H3 histone, family 3B (H3.3B); H3 
histone, family 3A pseudogene; H3 
histone, family 3A; similar to H3 histone, 
family 3B; similar to histone H3.3B 
3021 Known Cancer Gene 
HAVCR2 hepatitis A virus cellular receptor 2 84868 Exploratory Gene 
HAX1 HCLS1 associated protein X-1 10456 Known Cancer Gene 
HDAC10 histone deacetylase 10 83933 Known Cancer Gene 
HGF hepatocyte growth factor (hepapoietin 
A; scatter factor) 
3082 Exploratory Gene 
HIF1A hypoxia inducible factor 1 alpha subunit 3091 Exploratory Gene 
HLA-A major histocompatibility complex, class 
I, A 
3105 Exploratory Gene 
HLA-B major histocompatibility complex, class 
I, B 
3106 Exploratory Gene 
HLA-C major histocompatibility complex, class 
I, C 
3107 Exploratory Gene 
HNF4A hepatocyte nuclear factor 4 alpha 3172 Exploratory Gene 
HOXA13 homeobox A13 3209 Known Cancer Gene 
HRAS v-Ha-ras Harvey rat sarcoma viral 
oncogene homolog 
3265 Known Cancer Gene 
HRNR hornerin 388697 Known Cancer Gene 
HSP90AA1 heat shock protein 90kDa alpha 
(cytosolic), class A member 2; heat 
shock protein 90kDa alpha (cytosolic), 
class A member 1 
3320 Exploratory Gene 
HSP90AB1 heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
3326 Exploratory Gene 
HSP90B1 heat shock protein 90kDa beta (Grp94), 
member 1 
7184 Exploratory Gene 
IDH1 isocitrate dehydrogenase 1 (NADP+), 
soluble 
3417 Known Cancer Gene 
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IDH2 isocitrate dehydrogenase 2 (NADP+), 
mitochondrial 
3418 Known Cancer Gene 
IFNG interferon, gamma 3458 Known Cancer Gene 
IGF1 insulin-like growth factor 1 
(somatomedin C) 
3479 Exploratory Gene 
IGF1R insulin-like growth factor 1 receptor 3480 Copy Number Gene 
IGF2 insulin-like growth factor 2 
(somatomedin A); insulin; INS-IGF2 
readthrough transcript 
3481 Copy Number Gene 
IGF2R insulin-like growth factor 2 receptor 3482 Exploratory Gene 
IKBKE inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase epsilon 
9641 Copy Number Gene 
IL7R interleukin 7 receptor 3575 Known Cancer Gene 
ING1 inhibitor of growth family, member 1 3621 Known Cancer Gene 
INPP4B inositol polyphosphate-4-phosphatase 
type II B 
8821 Exploratory Gene 
INSR insulin receptor 3643 Exploratory Gene 
INTS4 integrator complex subunit 4 92105 Known Cancer Gene 
IRAK1 interleukin-1 receptor-associated 
kinase 1 
3654 Copy Number Gene 
IRF2 interferon regulatory factor 2 3660 Exploratory Gene 
IRF4 interferon regulatory factor 4 3662 Exploratory Gene 
IRS2 insulin receptor substrate 2 8660 Copy Number Gene 
JAK1 Janus kinase 1 3716 Exploratory Gene 
JAK2 Janus kinase 2 3717 Exploratory Gene 
JAK3 Janus kinase 3 3718 Known Cancer Gene 
JUB jub, ajuba homolog (Xenopus laevis) 84962 Known Cancer Gene 
KAT6A   7994 Exploratory Gene 
KAT6B   23522 Copy Number Gene 
KDM1A lysine (K)-specific demethylase 1 23028 Exploratory Gene 
KDM2A lysine (K)-specific demethylase 2A 22992 Exploratory Gene 
KDM2B lysine (K)-specific demethylase 2B 84678 Exploratory Gene 
KDM3B lysine (K)-specific demethylase 3B 51780 Exploratory Gene 
KDM4A lysine (K)-specific demethylase 4A 9682 Exploratory Gene 
KDM4B lysine (K)-specific demethylase 4B 23030 Exploratory Gene 
KDM4C lysine (K)-specific demethylase 4C 23081 Exploratory Gene 
KDM5A lysine (K)-specific demethylase 5A 5927 Known Cancer Gene 
KDM5C lysine (K)-specific demethylase 5C 8242 Known Cancer Gene 
KDM6A lysine (K)-specific demethylase 6A 7403 Known Cancer Gene 
KDR kinase insert domain receptor (a type III 
receptor tyrosine kinase) 
3791 Known Cancer Gene 
KEAP1 kelch-like ECH-associated protein 1 9817 Known Cancer Gene 
KIF5B kinesin family member 5B 3799 Known Cancer Gene 
KIT similar to Mast/stem cell growth factor 
receptor precursor(SCFR) (Proto-
oncogene tyrosine-protein kinase Kit) 
652799 Known Cancer Gene 
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(c-kit) (CD117 antigen); v-kit Hardy-
Zuckerman 4 feline sarcoma viral 
oncogene homolog 
KLF4 Kruppel-like factor 4 (gut) 9314 Exploratory Gene 
KLHL6 kelch-like 6 (Drosophila) 89857 Exploratory Gene 
KMT2A myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, 
Drosophila) 
4297 Known Cancer Gene 
KMT2B myeloid/lymphoid or mixed-lineage 
leukemia 4 
9757 Known Cancer Gene 
KMT2C myeloid/lymphoid or mixed-lineage 
leukemia 3 
58508 Known Cancer Gene 
KMT2D myeloid/lymphoid or mixed-lineage 
leukemia 2 
8085 Known Cancer Gene 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
3845 Known Cancer Gene 
KYNU kynureninase (L-kynurenine hydrolase) 8942 Copy Number Gene 
LAG3 lymphocyte activating 3 3902 Exploratory Gene 
LATS1 LATS, large tumor suppressor, homolog 
1 (Drosophila) 
9113 Exploratory Gene 
LATS2 LATS, large tumor suppressor, homolog 
2 (Drosophila) 
26524 Exploratory Gene 
LMO1 LIM domain only 1 (rhombotin 1) 4004 Known Cancer Gene 
LONRF1 LON peptidase N-terminal domain and 
ring finger 1 
91694 Known Cancer Gene 
LTK leukocyte receptor tyrosine kinase 4058 Known Cancer Gene 
MACROD2 MACRO domain containing 2 140733 Known Cancer Gene 
MAP2K1 mitogen-activated protein kinase kinase 
1 
5604 Known Cancer Gene 
MAP2K2 mitogen-activated protein kinase kinase 
2 pseudogene; mitogen-activated 
protein kinase kinase 2 
5605 Known Cancer Gene 
MAP2K4 mitogen-activated protein kinase kinase 
4 
6416 Known Cancer Gene 
MAP3K1 mitogen-activated protein kinase kinase 
kinase 1 
4214 Known Cancer Gene 
MAP3K13 mitogen-activated protein kinase kinase 
kinase 13 
9175 Known Cancer Gene 
MAP3K7 mitogen-activated protein kinase kinase 
kinase 7 
6885 Known Cancer Gene 
MAPK1 mitogen-activated protein kinase 1 5594 Exploratory Gene 
MAPK3 hypothetical LOC100271831; mitogen-
activated protein kinase 3 
5595 Exploratory Gene 
MAPK7 mitogen-activated protein kinase 7 5598 Copy Number Gene 
MAPKBP1 mitogen-activated protein kinase 
binding protein 1 
23005 Known Cancer Gene 
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MAX MYC associated factor X 4149 Copy Number Gene 
MCL1 myeloid cell leukemia sequence 1 
(BCL2-related) 
4170 Copy Number Gene 
MDM2 Mdm2 p53 binding protein homolog 
(mouse) 
4193 Copy Number Gene 
MDM4 Mdm4 p53 binding protein homolog 
(mouse) 
4194 Copy Number Gene 
MECOM ecotropic viral integration site 1 2122 Copy Number Gene 
MED12 mediator complex subunit 12 9968 Known Cancer Gene 
MELK maternal embryonic leucine zipper 
kinase 
9833 Copy Number Gene 
MEN1 multiple endocrine neoplasia I 4221 Known Cancer Gene 
MET met proto-oncogene (hepatocyte 
growth factor receptor) 
4233 Known Cancer Gene 
MGMT O-6-methylguanine-DNA 
methyltransferase 
4255 Copy Number Gene 
MITF microphthalmia-associated 
transcription factor 
4286 Copy Number Gene 
MLH1 mutL homolog 1, colon cancer, 
nonpolyposis type 2 (E. coli) 
4292 Known Cancer Gene 
MLH3 mutL homolog 3 (E. coli) 27030 Known Cancer Gene 
MOB1A   55233 Exploratory Gene 
MOB1B   92597 Exploratory Gene 
MORC1 MORC family CW-type zinc finger 1 27136 Known Cancer Gene 
MPL myeloproliferative leukemia virus 
oncogene 
4352 Known Cancer Gene 
MSH2 mutS homolog 2, colon cancer, 
nonpolyposis type 1 (E. coli) 
4436 Known Cancer Gene 
MSH3 mutS homolog 3 (E. coli) 4437 Known Cancer Gene 
MSH6 mutS homolog 6 (E. coli) 2956 Known Cancer Gene 
MST1 macrophage stimulating 1 (hepatocyte 
growth factor-like) 
4485 Exploratory Gene 
MST1R macrophage stimulating 1 receptor (c-
met-related tyrosine kinase) 
4486 Exploratory Gene 
MTAP methylthioadenosine phosphorylase 4507 Exploratory Gene 
MTOR mechanistic target of rapamycin 
(serine/threonine kinase) 
2475 Exploratory Gene 
MYB v-myb myeloblastosis viral oncogene 
homolog (avian) 
4602 Copy Number Gene 
MYC v-myc myelocytomatosis viral oncogene 
homolog (avian) 
4609 Copy Number Gene 
MYCL MYCL proto-oncogene, bHLH 
transcription factor 
4610 Exploratory Gene 
MYCN v-myc myelocytomatosis viral related 
oncogene, neuroblastoma derived 
(avian) 
4613 Copy Number Gene 
175 
 
MYH9 myosin, heavy chain 9, non-muscle 4627 Known Cancer Gene 
NAALADL2 N-acetylated alpha-linked acidic 
dipeptidase-like 2 
254827 Copy Number Gene 
NCOR1 nuclear receptor co-repressor 1 9611 Known Cancer Gene 
NEGR1 neuronal growth regulator 1 257194 Copy Number Gene 
NF1 neurofibromin 1 4763 Known Cancer Gene 
NF2 neurofibromin 2 (merlin) 4771 Known Cancer Gene 
NFE2L2 nuclear factor (erythroid-derived 2)-like 
2 
4780 Known Cancer Gene 
NFKBIA nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
inhibitor, alpha 
4792 Copy Number Gene 
NKX2-1 NK2 homeobox 1 7080 Copy Number Gene 
NOTCH1 Notch homolog 1, translocation-
associated (Drosophila) 
4851 Known Cancer Gene 
NOTCH2 Notch homolog 2 (Drosophila) 4853 Known Cancer Gene 
NOTCH3 Notch homolog 3 (Drosophila) 4854 Copy Number Gene 
NOTCH4 Notch homolog 4 (Drosophila) 4855 Known Cancer Gene 
NPM1 nucleophosmin 1 (nucleolar 
phosphoprotein B23, numatrin) 
pseudogene 21; hypothetical 
LOC100131044; similar to 
nucleophosmin 1; nucleophosmin 
(nucleolar phosphoprotein B23, 
numatrin) 
729686 Known Cancer Gene 
NRAS neuroblastoma RAS viral (v-ras) 
oncogene homolog 
4893 Known Cancer Gene 
NSD1 nuclear receptor binding SET domain 
protein 1 
64324 Known Cancer Gene 
NT5C2 5'-nucleotidase, cytosolic II 22978 Known Cancer Gene 
NTNG1 netrin G1 22854 Known Cancer Gene 
NTRK1 neurotrophic tyrosine kinase, receptor, 
type 1 
4914 Exploratory Gene 
NTRK2 neurotrophic tyrosine kinase, receptor, 
type 2 
4915 Exploratory Gene 
NTRK3 neurotrophic tyrosine kinase, receptor, 
type 3 
4916 Known Cancer Gene 
PAF1 Paf1, RNA polymerase II associated 
factor, homolog (S. cerevisiae) 
54623 Known Cancer Gene 
PAK7 p21 protein (Cdc42/Rac)-activated 
kinase 7 
57144 Known Cancer Gene 
PALB2 partner and localizer of BRCA2 79728 Exploratory Gene 
PARD6G par-6 partitioning defective 6 homolog 
gamma (C. elegans) 
84552 Copy Number Gene 
PARK2 Parkinson disease (autosomal recessive, 
juvenile) 2, parkin 
5071 Copy Number Gene 
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PARP1 poly (ADP-ribose) polymerase 1 142 Known Cancer Gene 
PARP10 poly (ADP-ribose) polymerase family, 
member 10 
84875 Known Cancer Gene 
PARP2 poly (ADP-ribose) polymerase 2 10038 Known Cancer Gene 
PARP3 poly (ADP-ribose) polymerase family, 
member 3 
10039 Known Cancer Gene 
PARP4 poly (ADP-ribose) polymerase family, 
member 4 
143 Known Cancer Gene 
PAX3 paired box 3 5077 Exploratory Gene 
PAX8 paired box 8 7849 Known Cancer Gene 
PBRM1 polybromo 1 55193 Known Cancer Gene 
PCDH15 protocadherin 15 65217 Known Cancer Gene 
PDCD1 programmed cell death 1 5133 Exploratory Gene 
PDCD1LG2 programmed cell death 1 ligand 2 80380 Exploratory Gene 
PDE4D phosphodiesterase 4D, cAMP-specific 
(phosphodiesterase E3 dunce homolog, 
Drosophila) 
5144 Known Cancer Gene 
PDGFRA platelet-derived growth factor receptor, 
alpha polypeptide 
5156 Known Cancer Gene 
PDGFRB platelet-derived growth factor receptor, 
beta polypeptide 
5159 Known Cancer Gene 
PDK1 pyruvate dehydrogenase kinase, 
isozyme 1 
5163 Exploratory Gene 
PDPK1 3-phosphoinositide dependent protein 
kinase-1 
5170 Exploratory Gene 
PEA15 phosphoprotein enriched in astrocytes 
15 
8682 Copy Number Gene 
PEG10 paternally expressed 10 23089 Known Cancer Gene 
PGM5 phosphoglucomutase 5 5239 Exploratory Gene 
PHF10 PHD finger protein 10 55274 Exploratory Gene 
PHF12 PHD finger protein 12 57649 Known Cancer Gene 
PHF6 PHD finger protein 6 84295 Known Cancer Gene 
PHLPP2 PH domain and leucine rich repeat 
protein phosphatase 2 
23035 Exploratory Gene 
PHOX2B paired-like homeobox 2b 8929 Known Cancer Gene 
PIK3C2G phosphoinositide-3-kinase, class 2, 
gamma polypeptide 
5288 Known Cancer Gene 
PIK3C3 phosphoinositide-3-kinase, class 3 5289 Exploratory Gene 
PIK3CA phosphoinositide-3-kinase, catalytic, 
alpha polypeptide 
5290 Known Cancer Gene 
PIK3CB phosphoinositide-3-kinase, catalytic, 
beta polypeptide 
5291 Exploratory Gene 
PIK3CG phosphoinositide-3-kinase, catalytic, 
gamma polypeptide 
5294 Exploratory Gene 
PIK3R1 phosphoinositide-3-kinase, regulatory 
subunit 1 (alpha) 
5295 Known Cancer Gene 
177 
 
PIK3R2 phosphoinositide-3-kinase, regulatory 
subunit 2 (beta) 
5296 Known Cancer Gene 
PIK3R3 phosphoinositide-3-kinase, regulatory 
subunit 3 (gamma) 
8503 Exploratory Gene 
PIK3R4 phosphoinositide-3-kinase, regulatory 
subunit 4 
30849 Exploratory Gene 
PIK3R5 phosphoinositide-3-kinase, regulatory 
subunit 5 
23533 Exploratory Gene 
PIK3R6 phosphoinositide-3-kinase, regulatory 
subunit 6 
146850 Exploratory Gene 
PIM1 pim-1 oncogene 5292 Exploratory Gene 
PIM2 pim-2 oncogene 11040 Exploratory Gene 
PIM3 pim-3 oncogene 415116 Exploratory Gene 
PKHD1 polycystic kidney and hepatic disease 1 
(autosomal recessive) 
5314 Exploratory Gene 
PLAT plasminogen activator, tissue 5327 Copy Number Gene 
PLK2 polo-like kinase 2 (Drosophila) 10769 Copy Number Gene 
PMS2 PMS2 postmeiotic segregation 
increased 2 (S. cerevisiae) 
5395 Exploratory Gene 
POLD1 polymerase (DNA directed), delta 1, 
catalytic subunit 125kDa 
5424 Exploratory Gene 
POLE polymerase (DNA directed), epsilon 5426 Known Cancer Gene 
PORCN porcupine homolog (Drosophila) 64840 Exploratory Gene 
PPARA peroxisome proliferator-activated 
receptor alpha 
5465 Copy Number Gene 
PPARG peroxisome proliferator-activated 
receptor gamma 
5468 Known Cancer Gene 
PPM1E protein phosphatase 1E (PP2C domain 
containing) 
22843 Known Cancer Gene 
PPP1R3A protein phosphatase 1, regulatory 
(inhibitor) subunit 3A 
5506 Known Cancer Gene 
PPP2R1A protein phosphatase 2 (formerly 2A), 
regulatory subunit A, alpha isoform 
5518 Known Cancer Gene 
PPP6C protein phosphatase 6, catalytic subunit 5537 Exploratory Gene 
PRDM1 PR domain containing 1, with ZNF 
domain 
639 Known Cancer Gene 
PREX2 phosphatidylinositol-3,4,5-
trisphosphate-dependent Rac exchange 
factor 2 
80243 Known Cancer Gene 
PRKAR1A protein kinase, cAMP-dependent, 
regulatory, type I, alpha (tissue specific 
extinguisher 1) 
5573 Exploratory Gene 
PRKCA protein kinase C, alpha 5578 Exploratory Gene 
PRKCB protein kinase C, beta 5579 Exploratory Gene 
PRKCG protein kinase C, gamma 5582 Exploratory Gene 
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PRKDC similar to protein kinase, DNA-
activated, catalytic polypeptide; protein 
kinase, DNA-activated, catalytic 
polypeptide 
731751 Exploratory Gene 
PRLR prolactin receptor 5618 Exploratory Gene 
PRMT5 protein arginine methyltransferase 5 10419 Exploratory Gene 
PROZ protein Z, vitamin K-dependent plasma 
glycoprotein 
8858 Copy Number Gene 
PRRX1 paired related homeobox 1 5396 Known Cancer Gene 
PRSS1 protease, serine, 1 (trypsin 1); 
trypsinogen C 
154754 Copy Number Gene 
PRX periaxin 57716 Known Cancer Gene 
PTCH1 patched homolog 1 (Drosophila) 5727 Known Cancer Gene 
PTCH2 patched homolog 2 (Drosophila) 8643 Exploratory Gene 
PTEN phosphatase and tensin homolog; 
phosphatase and tensin homolog 
pseudogene 1 
5728 Known Cancer Gene 
PTP4A1 protein tyrosine phosphatase type IVA, 
member 1 
7803 Copy Number Gene 
PTPN11 protein tyrosine phosphatase, non-
receptor type 11; similar to protein 
tyrosine phosphatase, non-receptor 
type 11 
442113 Known Cancer Gene 
PTPN22 protein tyrosine phosphatase, non-
receptor type 22 (lymphoid) 
26191 Known Cancer Gene 
PTPRD protein tyrosine phosphatase, receptor 
type, D 
5789 Copy Number Gene 
PTPRN2 protein tyrosine phosphatase, receptor 
type, N polypeptide 2 
5799 Known Cancer Gene 
RABGEF1 RAB guanine nucleotide exchange 
factor (GEF) 1 
27342 Copy Number Gene 
RAC1 ras-related C3 botulinum toxin 
substrate 1 (rho family, small GTP 
binding protein Rac1) 
5879 Known Cancer Gene 
RAD21 RAD21 homolog (S. pombe) 5885 Copy Number Gene 
RAD50 RAD50 homolog (S. cerevisiae) 10111 Exploratory Gene 
RAD51 RAD51 homolog (RecA homolog, E. coli) 
(S. cerevisiae) 
5888 Exploratory Gene 
RAD51B   5890 Exploratory Gene 
RAD51C RAD51 homolog C (S. cerevisiae) 5889 Exploratory Gene 
RAD51D   5892 Exploratory Gene 
RAD52 RAD52 homolog (S. cerevisiae) 5893 Exploratory Gene 
RAF1 v-raf-1 murine leukemia viral oncogene 
homolog 1 
5894 Known Cancer Gene 
RALA RAS like proto-oncogene A 5898 Exploratory Gene 
RALB RAS like proto-oncogene B 5899 Exploratory Gene 
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RB1 retinoblastoma 1 5925 Known Cancer Gene 
RBFOX1   54715 Copy Number Gene 
RBM10 RNA binding motif protein 10 8241 Known Cancer Gene 
REG4 regenerating islet-derived family, 
member 4 
83998 Copy Number Gene 
REL v-rel reticuloendotheliosis viral 
oncogene homolog (avian) 
5966 Exploratory Gene 
RET ret proto-oncogene 5979 Known Cancer Gene 
RHEB Ras homolog enriched in brain 6009 Known Cancer Gene 
RHOA ras homolog family member A 387 Exploratory Gene 
RICTOR RPTOR independent companion of 
MTOR, complex 2 
253260 Exploratory Gene 
RIOK3 RIO kinase 3 (yeast) 8780 Copy Number Gene 
RIT1 Ras like without CAAX 1 6016 Exploratory Gene 
RNF19A ring finger protein 19A 25897 Copy Number Gene 
RNF32 ring finger protein 32 140545 Copy Number Gene 
RNF43 ring finger protein 43 54894 Known Cancer Gene 
ROBO1 roundabout, axon guidance receptor, 
homolog 1 (Drosophila); similar to 
roundabout 1 isoform b 
642132 Known Cancer Gene 
ROBO2 roundabout, axon guidance receptor, 
homolog 2 (Drosophila) 
6092 Known Cancer Gene 
ROS1 c-ros oncogene 1 , receptor tyrosine 
kinase 
6098 Known Cancer Gene 
RPS6KA5 ribosomal protein S6 kinase, 90kDa, 
polypeptide 5 
9252 Copy Number Gene 
RPS6KB1 ribosomal protein S6 kinase, 70kDa, 
polypeptide 1 
6198 Copy Number Gene 
RPS6KC1 ribosomal protein S6 kinase, 52kDa, 
polypeptide 1 
26750 Known Cancer Gene 
RPTN repetin 126638 Known Cancer Gene 
RPTOR regulatory associated protein of MTOR, 
complex 1 
57521 Exploratory Gene 
RSPO1 R-spondin homolog (Xenopus laevis) 284654 Known Cancer Gene 
RSPO2 R-spondin 2 homolog (Xenopus laevis) 340419 Known Cancer Gene 
RSPO3 R-spondin 3 homolog (Xenopus laevis) 84870 Known Cancer Gene 
RSPO4 R-spondin family, member 4 343637 Exploratory Gene 
RUNX1 runt-related transcription factor 1 861 Known Cancer Gene 
SAV1 salvador homolog 1 (Drosophila) 60485 Exploratory Gene 
SDK1 sidekick homolog 1, cell adhesion 
molecule (chicken); hypothetical 
LOC730351 
730351 Known Cancer Gene 
SELL selectin L 6402 Copy Number Gene 
SETD2 SET domain containing 2 29072 Known Cancer Gene 
SF3B1 splicing factor 3b, subunit 1, 155kDa 23451 Known Cancer Gene 
SFRP1 secreted frizzled-related protein 1 6422 Copy Number Gene 
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SGK1 serum/glucocorticoid regulated kinase 
1 
6446 Exploratory Gene 
SH2B3 SH2B adaptor protein 3 10019 Exploratory Gene 
SIM1 single-minded homolog 1 (Drosophila) 6492 Copy Number Gene 
SKP2 S-phase kinase associated protein 2 6502 Exploratory Gene 
SLIT2 slit homolog 2 (Drosophila) 9353 Known Cancer Gene 
SMAD2 SMAD family member 2 4087 Known Cancer Gene 
SMAD3 SMAD family member 3 4088 Known Cancer Gene 
SMAD4 SMAD family member 4 4089 Known Cancer Gene 
SMARCA1 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 1 
6594 Exploratory Gene 
SMARCA2 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 2 
6595 Exploratory Gene 
SMARCA4 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 4 
6597 Known Cancer Gene 
SMARCA5 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 5 




actin-dependent regulator of 
chromatin, subfamily a, containing 
DEAD/H box 1 
56916 Exploratory Gene 
SMARCAL
1 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a-like 1 
50485 Exploratory Gene 
SMARCB1 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily b, member 1 
6598 Known Cancer Gene 
SMARCC1 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily c, member 1 
6599 Exploratory Gene 
SMARCC2 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily c, member 2 
6601 Exploratory Gene 
SMARCD1 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily d, member 1 
6602 Exploratory Gene 
SMARCD2 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily d, member 2 
6603 Exploratory Gene 
SMARCD3 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily d, member 3 
6604 Exploratory Gene 
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SMARCE1 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily e, member 1 
6605 Exploratory Gene 
SMO smoothened homolog (Drosophila) 6608 Known Cancer Gene 
SNTG2 syntrophin, gamma 2 54221 Known Cancer Gene 
SNX31 sorting nexin 31 169166 Known Cancer Gene 
SOCS1 suppressor of cytokine signaling 1 8651 Known Cancer Gene 
SOX17 SRY (sex determining region Y)-box 17 64321 Known Cancer Gene 
SOX2 SRY (sex determining region Y)-box 2 6657 Copy Number Gene 
SOX9 SRY-box 9 6662 Exploratory Gene 
SPEN spen homolog, transcriptional regulator 
(Drosophila) 
23013 Exploratory Gene 
SPOP speckle-type POZ protein 8405 Known Cancer Gene 
SS18 synovial sarcoma translocation, 
chromosome 18 
6760 Exploratory Gene 
STAG2 stromal antigen 2 10735 Exploratory Gene 
STAT3 signal transducer and activator of 
transcription 3 (acute-phase response 
factor) 
6774 Known Cancer Gene 
STK11 serine/threonine kinase 11 6794 Known Cancer Gene 
STK19 serine/threonine kinase 19 8859 Exploratory Gene 
STK3 serine/threonine kinase 3 (STE20 
homolog, yeast) 
6788 Exploratory Gene 
STRADA STE20-related kinase adaptor alpha 92335 Exploratory Gene 
STXBP5L syntaxin binding protein 5-like 9515 Known Cancer Gene 
SUFU suppressor of fused homolog 
(Drosophila) 
51684 Known Cancer Gene 
SUZ12 suppressor of zeste 12 homolog 
(Drosophila) 
23512 Known Cancer Gene 
TAB3 mitogen-activated protein kinase kinase 
kinase 7 interacting protein 3 
257397 Copy Number Gene 
TACC1 transforming, acidic coiled-coil 
containing protein 1 
6867 Known Cancer Gene 
TACC3 transforming, acidic coiled-coil 
containing protein 3 
10460 Known Cancer Gene 
TBC1D7 TBC1 domain family, member 7 51256 Copy Number Gene 
TBX3 T-box 3 6926 Known Cancer Gene 
TCF7 transcription factor 7 (T-cell specific, 
HMG-box) 
6932 Known Cancer Gene 
TCF7L1 transcription factor 7-like 1 (T-cell 
specific, HMG-box) 
83439 Known Cancer Gene 
TCF7L2 transcription factor 7-like 2 (T-cell 
specific, HMG-box) 
6934 Known Cancer Gene 
TEAD4 TEA domain transcription factor 4 7004 Exploratory Gene 
TERT telomerase reverse transcriptase 7015 Copy Number Gene 
TET2 tet oncogene family member 2 54790 Known Cancer Gene 
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TEX15 testis expressed 15 56154 Known Cancer Gene 
TFE3 transcription factor binding to IGHM 
enhancer 3 
7030 Known Cancer Gene 
TGFBR2 transforming growth factor, beta 
receptor II (70/80kDa) 
7048 Known Cancer Gene 
TLR3 toll-like receptor 3 7098 Copy Number Gene 
TMEM173 transmembrane protein 173 340061 Exploratory Gene 
TMPRSS2 transmembrane protease, serine 2 7113 Known Cancer Gene 
TNFSF10 tumor necrosis factor (ligand) 
superfamily, member 10 
8743 Copy Number Gene 
TNKS tankyrase, TRF1-interacting ankyrin-
related ADP-ribose polymerase 
8658 Exploratory Gene 
TNKS2 tankyrase, TRF1-interacting ankyrin-
related ADP-ribose polymerase 2 
80351 Exploratory Gene 
TOP1 topoisomerase (DNA) I 7150 Copy Number Gene 
TP53 tumor protein p53 7157 Known Cancer Gene 
TP63 tumor protein p63 8626 Exploratory Gene 
TP73 tumor protein p73 7161 Copy Number Gene 
TPK1 thiamin pyrophosphokinase 1 27010 Copy Number Gene 
TPR translocated promoter region (to 
activated MET oncogene) 
7175 Known Cancer Gene 
TRAF2 TNF receptor-associated factor 2 7186 Exploratory Gene 
TRAF3 TNF receptor-associated factor 3 7187 Exploratory Gene 
TRAF7 TNF receptor-associated factor 7 84231 Exploratory Gene 
TRRAP transformation/transcription domain-
associated protein 
8295 Exploratory Gene 
TSC1 tuberous sclerosis 1 7248 Exploratory Gene 
TSC2 tuberous sclerosis 2 7249 Exploratory Gene 
TSHR thyroid stimulating hormone receptor 7253 Known Cancer Gene 




Known Cancer Gene 
TTK TTK protein kinase 7272 Copy Number Gene 
TUBD1 tubulin, delta 1 51174 Known Cancer Gene 
U2AF1 U2 small nuclear RNA auxiliary factor 1 7307 Known Cancer Gene 
VEGFA vascular endothelial growth factor A 7422 Copy Number Gene 
VHL von Hippel-Lindau tumor suppressor 7428 Known Cancer Gene 
VTI1A vesicle transport through interaction 
with t-SNAREs homolog 1A (yeast) 
143187 Known Cancer Gene 
WDFY4 WDFY family member 4 57705 Known Cancer Gene 
WDR5 WD repeat domain 5 11091 Exploratory Gene 
WHSC1 Wolf-Hirschhorn syndrome candidate 1 7468 Exploratory Gene 
WHSC1L1 Wolf-Hirschhorn syndrome candidate 1-
like 1 
54904 Exploratory Gene 
WRN Werner syndrome RecQ like helicase 7486 Exploratory Gene 
WSB1 WD repeat and SOCS box-containing 1 26118 Copy Number Gene 
WT1 Wilms tumor 1 7490 Known Cancer Gene 
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WWOX WW domain containing oxidoreductase 51741 Copy Number Gene 
XRCC1 X-ray repair complementing defective 
repair in Chinese hamster cells 1 
7515 Known Cancer Gene 
YAF2 YY1 associated factor 2 10138 Copy Number Gene 
YAP1 Yes-associated protein 1, 65kDa 10413 Exploratory Gene 
ZC3H13 zinc finger CCCH-type containing 13 23091 Known Cancer Gene 
ZEB2 zinc finger E-box binding homeobox 2 9839 Known Cancer Gene 
ZNF132 zinc finger protein 132 7691 Known Cancer Gene 
ZNF217 zinc finger protein 217 7764 Copy Number Gene 
ZNF324 zinc finger protein 324 25799 Copy Number Gene 
ZNF639 zinc finger protein 639 51193 Known Cancer Gene 
ZNF703 zinc finger protein 703 80139 Exploratory Gene 







Supplementary Table S5.2: Pathway names and member genes; pathway level 



















Conclusion and Future Directions 
 
6.1 Summary of Findings 
 
As mentioned in the Introduction, this collection of studies with the theme 
“Neurofibromatosis Type 1 (NF1) and Breast Cancer (BC)” was initiated after seeing 
a series of women with NF1 and breast cancer at National Cancer Centre Singapore 
(NCCS) from 2006 to 2009. These patients under my care had aggressive HER2-
positive disease that did not seem to respond to standard systemic therapies as well 
as in individuals without NF1 syndrome. This clinical observation triggered a literature 
search, which revealed limited data at the time of commencement of my candidature 
in 2011. The studies included in this thesis were conceived to address clinically 
relevant questions around the topic of neurofibromatosis type 1, the NF1 gene and 
breast cancer. 
Since 2007, the higher risk of breast cancer in women with NF1 has been 
increasingly recognized, especially for the younger women under 50 years 1,2. Data 
on the characteristics of BC in NF1 patients is still relatively sparse. Our group was 
the first to discover the higher frequency of HER2-positive, hormone receptor 
negative and grade 3 breast cancers in women with NF1, and also the first to 
genomically profile these NF1-associated breast cancers. 
Over the course of my candidature, data from large-scale exome or genome 
sequencing studies led by TCGA, ICGC and METABRIC, have unravelled the 
heterogeneity and complexity of cancer genomes. Somatic NF1 aberrations were 
detected in different sporadic tumours from individuals without NF1 syndrome 
(Source: The cBio Cancer genomics Portal; http://www.cbioportal.org). In my projects, 
we also aimed to explore the potential role of NF1 and neurofibromin in sporadic 
breast cancers from patients without NF1. This included immunohistochemical 
staining of tissue micrroarrays, and targeted gene sequencing (with NF1 in the gene 
panel) of poor prognosis breast cancers in premenopausal women. This study group 
was selected as there is a higher proportion of premenopausal breast cancers in Asia 
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compared to the West populations. It was proposed that NF1 mutations may 
contribute to themore aggressive disease and poor prognosis of this younger aged 
group. 
In this thesis, we started with a systematic overview in Chapter 1, “The NF1 gene 
revisited – from bench to bedside”. This comprehensive review of the literature 
focused on the oncological aspects of the germline NF1 disorder, the biology of the 
NF1 gene and neurofibromin, tumours associated with NF1 as well as sporadic 
tumours harbouring somatic NF1 aberrations in individuals without NF1 disorder. 
NF1, a tumour suppressor gene, plays a critical role in carcinogenesis. The gene 
product neurofibromin is a negative regulator of the Ras cellular proliferation pathway 
3,4, and also exerts tumour suppression via other mechanisms5. During the course of 
the candidature, with the data that emerged from the large scale tumour sequencing 
projects, somatic NF1 aberrations have been increasingly reported in various 
sporadic tumours, including brain, lung, breast, ovarian tumours as well melanomas 
and leukemias. NF1 alterations appear to be associated with resistance to therapy 
and adverse outcomes in several tumour types 5. Identification of a patient's germline 
or somatic NF1 aberrations can be challenging, as NF1 is one of the largest genes 
in the human genome (60 exons spanning over 350kb of genomic DNA), and in the 
absence of any mutation hotspots, has a myriad of possible mutations. Epigenetic 
factors may also contribute to inadequate levels of neurofibromin in cancer cells. To 
our knowledge, the efficacy of NF1-based therapeutic approaches has not been 
established. Clinical trials using various agents, including mTOR inhibitors, for mainly 
the plexiform neurofibromas in individuals with NF1, have to date not yielded any 
impressive results 5. It is hoped that the emerging recognition of the role of NF1 in 
sporadic cancers will lead to additional clinical trials exploring NF1-based treatments, 
such as MEK inhibitors, for various tumour types. Improved understanding of the 
implications of NF1 aberrations is critical for the development of novel therapeutic 
strategies. 
 
In Chapter 2, titled “Whole exome sequencing of multiple tumours from an NF1 
patient”, apart from the germline NF1 mutation (L847P), we demonstrated 
independent somatic NF1 mutations in the 3 tumors from this patient (frameshift 
insertion in breast cancer (p.A985fs), missense mutation in malignant peripheral 
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nerve sheath tumour (p.G23R), and inframe deletion in dermal neurofibroma 
(p.L1876del-Inf)), indicating that a second hit in NF1 gene resulting in its loss of 
function is likely to be critical for tumor formation 6. This is the classic scenario of a 
tumour suppressor as first demonstrated in the retinoblastoma gene by Knudson. 
Each of the three tumours had a distinct genomic profile with mutually exclusive 
mutations in different genes. Copy number analysis revealed multiple copy number 
alterations in the breast cancer and the MPNST, but not the benign neurofibroma. 
Germline loss of chromosome 6q22.33, which harbors 2 potential tumor suppressor 
genes, PTPRK and LAMA2, was also identified; this may increase tumour 
predisposition further. In the background of NF1 syndrome, although second-hit NF1 
mutation is critical in tumorigenesis, different additional mutations are required to 
further drive the formation of different tumors.  
 
The aim of Chapter 3, “Comprehensive case series of BCs in women with NF1 with 
molecular insights into its aggressive phenotype” was to improve the understanding 
of NF1-associated breast cancer, given the increased risk of breast cancer in this 
tumour predisposition syndrome and the limited available data. We identified 18 
women with NF1 and breast cancer at our institution, and performed next generation 
sequencing on DNA from the available blood and breast cancer specimens. 
Expression of neurofibromin in the NF1-associated breast cancers was evaluated 
using immunohistochemistry. Compared with 7132 breast cancers in patients without 
NF1 from our institutional database, there was a higher frequency of grade 3 (83.3% 
vs 45.4%, p=0.005), oestrogen receptor (ER) negative (66.7% vs 26.3%, p<0.001) 
and human epidermal growth factor receptor 2 (HER2) positive (66.7% vs 23.4%, 
p<0.001) tumours among NF1 patients. Overall survival was inferior in NF1 patients 
compared with the non-NF1 breast cancers in multivariable analysis (HR 2.25, 95% 
CI, 1.11 to 4.60; p = 0.025).  Apart from germline NF1 mutations (11/16 detected; 
69%), somatic mutations in TP53 (8/10; 80%), second-hit NF1 (2/10; 20%), somatic 
mutations in KMT2C (4/10; 40%), KMT2D (2/10; 20%), and PIK3CA (2/10; 20%) were 
observed. Immunohistochemical expression of neurofibromin was seen in the nuclei 
and/or cytoplasm of all specimens, but without any consistent pattern in its intensity 
or extent. This comprehensive series of NF1-associated breast cancers suggests 
that their aggressive features are related to germline NF1 mutations in cooperation 
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with somatic mutations in TP53, KMT2C and other genes. The high frequency of 
TP53 mutations in BC of NF1 syndrome patients was particularly striking. 
 
Chapter 4, “Immunohistochemical expression of neurofibromin in sporadic breast 
cancers” explores the potential role of NF1 and neurofibromin in sporadic breast 
cancers from patients without NF1. There is limited data on expression of 
neurofibromin in breast cancer, and the clinical relevance of neurofibromin deficiency 
in sporadic breast cancer is unclear. We hypothesised that loss of expression of 
neurofibromin, a tumour suppressor, will be associated with overexpression of pAkt 
and pMAPK, both downstream in the PI3K-MAPK pathway, and this contributes tp 
the resulting worse outcomes. The expression of neurofibromin was initially 
evaluated through immunohistochemistry on microarrayed cores obtained from 314 
stage 1-3 breast cancer specimens diagnosed between 2000 and 2002. “Positive” 
expression of neurofibromin was defined as nuclear and cytoplasmic staining in 10% 
or more of tumour cells. Positive expression of neurofibromin, as defined above, was 
seen in 44.6% (140/314) of tumours. “Negative” expression of neurofibromin was 
associated with high tumour grade (p<0.001), hormone receptor negativity (p<0.001), 
lymph node positivity (p=0.041) and larger tumour size (p=0.031). On multivariate 
analysis, lack of neurofibromin as defined above, was an independent predictor of 
relapse and death for triple negative cancers (hazard ratios 3.33, p=0.011 and 2.94, 
p=0.026 respectively), but not in the luminal and HER2 positive 
immunohistochemical subtypes. To validate this finding, the expression of 
neurofibromin was subsequently evaluated in tissue microarrays with a total of 594 
triple negative breast cancers diagnosed from 1993 to 2011. No association between 
neurofibromin expression survival outcomes was found in the validation set. 
Immunohistochemistry with currently available antibodies may be suboptimal for 
assessing deficiency or dysfunction of neurofibromin. The epitope for these 
antibodies is restricted to a limited region of the large neurofibromin protein, and 
cannot detect abnormal neurofibromin from mutations outside their specific epitopes. 
Novel methods such as mass-spectrometry-based proteomic analyses may 
potentially be superior for this purpose. 
 
In Chapter 5, “Elucidating therapeutic molecular targets in premenopausal Asian 
women with recurrent breast cancers”, targeted sequencing was performed using 
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FFPE specimens of the breast primary from a separate cohort of premenopausal 
patients who subsequently relapsed after initial diagnosis of non-metastatic disease. 
The most prevalent alterations included TP53 (65%). PIK3CA (32%), GATA3 (29%), 
ERBB2 (27%), MYC (25%) and KMT2C (21%). The frequency of NF1 mutation was 
2%, somewhat similar to the large scale breast cancer sequencing studies. Detecting 
changes in copy number of the NF1 gene in formalin-fixed paraffin-embedded 
specimens was not feasible.  
 
 
6.2 Suggestions for Future Work  
 
The important role of NF1 in various tumours is increasingly recognized, but 
challenges remain in the detection of NF1 aberrations as well as deficiency and 
dysfunction of neurofibromin 5. A multi-omics approach incorporating the DNA, RNA 
and proteins from each tumour can help to provide better insights, as epigenetic 
factors can influence the expression of key molecules in the complex cancer 
pathways. Analysis of copy number changes and more complex rearrangements in 
addition to mutations alone will also provide more comprehensive information on the 
tumour profile. Novel methods such as mass spectrometry-based proteomic 
analyses may potentially be promising, given the limitations of immunohistochemistry 
from our experience.  
 
Future studies should ideally aim to capture serial specimens using a longitudinal 
study, since the tumour genome is constantly evolving. While the frequency of NF1 
mutations in primary breast cancers is generally less than 5%, recent data suggest 
they are enriched in the metastatic specimens, highlighting the role of NF1 in the 
metastatic process 7. Consideration should also be given to the epigenetic and 
tumour microenvironment (including the immune ecosystem and the microbiome) in 
future studies, in addition to functional work to investigate the biological significance 
of alterations in NF1. 
 
Last but not least, we hope that these new findings can be translated to better 
treatment outcomes for both patients with germline NF1 syndrome, as well as 
patients with sporadic tumours harbouring NF1 alterations. Although targeting the 
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Ras pathway with a number of trials testing MEK inhibitors is the current focus, 
inhibiting a single checkpoint may lead to activation of compensatory negative 
feedback pathways. Blockade of multiple targets may not be feasible in clinical 
practice due to the additive toxicities. The role of immunotherapy in these tumours 
may be worth exploring, given the impressive breakthroughs with immune checkpoint 
blockade in several tumour types, including the recent report of impressive response 
rates in desmoplastic melanomas with NF1 mutations and high mutation load 8. 
 
6.3 Concluding Remarks 
 
In conclusion, NF1, a tumour suppressor gene, plays a key role in various sporadic 
tumours including breast cancers, beyond the germline NF1 tumour predisposition 
disorder. NF1 is one of the significantly mutated genes in various sporadic tumours 
from patients without NF1. In spite of recent progress with next generation 
sequencing technology, challenges remain with the detection of NF1 alterations and 
the interpretation of the functional significance. Improved understanding of the 
biology will hopefully lead to better treatments and outcomes not only for patients 
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